RICHARD ECHAMPLINRICHARD E CHAMPLIN8508CHAMPLIN, RICHARD EProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25405922Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK, Champlin RE, Chemaly RFTransplant infectious disease : an official journal of the Transplantation SocietyVaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis. 2014 Dec; 16(6):878-86.Transpl Infect Dis2014-11-18T00:00:002014Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.25263628Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSimilar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.Biol Blood Marrow Transplant2014-09-28T00:00:002014Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.1400 Holcombe BlvdHouston77030-4008TXAuthorship 16325010Authorship 1634205Authorship 1635531Authorship 1637093Authorship 1637422Authorship 1637471Authorship 1637831Authorship 1637911Authorship 1637961Authorship 1639941Authorship 1640761Authorship 1641905Authorship 1642173Authorship 1642317Authorship 1642881Authorship 1643012Authorship 1643365Authorship 1644121Authorship 1644321Authorship 1645315Authorship 1645333Authorship 1646544Authorship 1647262Authorship 1647271Authorship 16495711Authorship 1649611Authorship 164970Authorship 1650544Authorship 16528310Authorship 1654349Authorship 1654617Authorship 1657491Authorship 165756Authorship 1658579Authorship 1658822Authorship 16602113Authorship 1661886Authorship 1662618Authorship 1662681Authorship 1663665Authorship 16637518Authorship 1664113Authorship 16642116Authorship 1664348Authorship 16649512Authorship 1665416Authorship 16654712Authorship 1665622Authorship 16664010Authorship 1666853Authorship 1667664Authorship 1668323Authorship 1669656Authorship 1670982Authorship 1672462Authorship 16727310Authorship 1673299Authorship 16741015Authorship 16753712Authorship 1675637Authorship 16758318Authorship 1678477Authorship 1679052Authorship 1682944Authorship 1683434Authorship 16842220Authorship 1689005Authorship 1690072Authorship 1691002Authorship 1691172Authorship 1693735Authorship 16948412Authorship 1695952Authorship 1701688Authorship 17028910Authorship 1703449Authorship 1704224Authorship 1704727Authorship 1705655Authorship 1705902Authorship 1707324Authorship 17076113Authorship 1709563Authorship 1710987Authorship 17119515Authorship 1712807Authorship 1713781Authorship 1714232Authorship 1714889Authorship 17149814Authorship 17153012Authorship 17154912Authorship 1716392Authorship 1716628Authorship 17221516Authorship 17244513Authorship 1726152Authorship 1728009Authorship 1730717Authorship 1731377Authorship 17317714Authorship 17328416Authorship 1734151Authorship 1741782Authorship 17424511Authorship 1745096Authorship 17467418Authorship 1748529Authorship 17495615Authorship 1750665Authorship 1754105Authorship 1754927Authorship 17563610Authorship 1758967Authorship 17592219Authorship 1763286Authorship 17648310Authorship 17649510Authorship 17650213Authorship 1765069Authorship 1769079Authorship 17718914Authorship 1774029Authorship 1774073Authorship 17757112Authorship 1776038Authorship 1776426Authorship 1777394Authorship 1781375Authorship 1786449Authorship 17885814Authorship 17905320Authorship 1790844Authorship 17918510Authorship 17926111Authorship 1800099Authorship 18013113Authorship 1807664Authorship 18079012Authorship 1812222Authorship 1815829Authorship 18182110Authorship 1821937Authorship 18220512Authorship 18245011Authorship 18245817Authorship 18277414Authorship 1830574Authorship 1830915Authorship 1831535Authorship 18367410Authorship 18372221Authorship 1837246Authorship 1837258Authorship 18381116Authorship 1838952Authorship 1839139Authorship 1841208Authorship 18441517Authorship 18453916Authorship 1845549Authorship 18476511Authorship 18479113Authorship 18499613Authorship 18522111Authorship 18524611Authorship 1854694Authorship 1857949Authorship 1858089Authorship 1859489Authorship 18600612Authorship 1864059Authorship 18646113Authorship 18651815Authorship 1865879Authorship 1866298Authorship 18692519Authorship 1872431Authorship 18734511Authorship 1876965Authorship 18770417Authorship 18772212Authorship 18775711Authorship 18796015Authorship 1883206Authorship 1885249Authorship 18875813Authorship 18889717Authorship 1891776Authorship 1895323Authorship 1896296Authorship 1898405Authorship 18996211Authorship 1900628Authorship 19035411Authorship 19041315Authorship 19052313Authorship 19055810Authorship 1905676Authorship 1905833Authorship 19072212Authorship 19169210Authorship 1919477Authorship 19202717Authorship 19227823Authorship 19230516Authorship 19234019Authorship 19236212Authorship 19237127Authorship 19244515Authorship 1925082Authorship 19269517Authorship 19346219Authorship 19354121Authorship 1937115Authorship 19409910Authorship 19449321Authorship 19451415Authorship 19456810Authorship 19479213Authorship 19493919Authorship 19547111Authorship 19551123Authorship 19564012Authorship 19567814Authorship 19570110Authorship 19590410Authorship 1963311Authorship 19633861509294Champlin RSeminars in hematologyGraft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation. Semin Hematol. 1992 Jul; 29(3 Suppl 2):46-52.Semin Hematol1992-07-01T00:00:001992Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.1521091Gluckman E, Auerbach A, Ash RC, Biggs JC, Bortin MM, Camitta BM, Champlin RE, Friedrich W, Gale RP, Good RABone marrow transplantationAllogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1992; 10 Suppl 1:53-7.Bone Marrow Transplant1992-01-01T00:00:001992Allogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry.1586749Gajewski JL, Petz LD, Calhoun L, O'Rourke S, Landaw EM, Lyddane NR, Hunt LA, Schiller GJ, Ho WG, Champlin REBloodHemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate. Blood. 1992 Jun 01; 79(11):3076-85.Blood1992-06-01T00:00:001992Hemolysis of transfused group O red blood cells in minor ABO-incompatible unrelated-donor bone marrow transplants in patients receiving cyclosporine without posttransplant methotrexate.2153006Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin REThe American journal of medicineOfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1990 Jan; 88(1):36-42.Am J Med1990-01-01T00:00:001990Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.2438775Champlin R, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holly FE, Gale RPSeminars in oncologyTreatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. Semin Oncol. 1987 Jun; 14(2 Suppl 1):1-6.Semin Oncol1987-06-01T00:00:001987Treatment of adults with acute myelogenous leukemia: prospective evaluation of high-dose cytarabine in consolidation chemotherapy and with bone marrow transplantation.2571318Cain GR, Champlin REAmerican journal of veterinary researchLong-term complete chimerism and stable hematopoiesis in beagles after fetal liver hematopoietic stem cell transplantation. Am J Vet Res. 1989 Aug; 50(8):1282-4.Am J Vet Res1989-08-01T00:00:001989Long-term complete chimerism and stable hematopoiesis in beagles after fetal liver hematopoietic stem cell transplantation.2581632Champlin RE, Golde DWBloodChronic myelogenous leukemia: recent advances. Blood. 1985 May; 65(5):1039-47.Blood1985-05-01T00:00:001985Chronic myelogenous leukemia: recent advances.2659098Champlin R, Gale RPBloodAcute lymphoblastic leukemia: recent advances in biology and therapy. Blood. 1989 Jun; 73(8):2051-66.Blood1989-06-01T00:00:001989Acute lymphoblastic leukemia: recent advances in biology and therapy.2693107Winston DJ, Ho WG, Champlin REEuropean journal of cancer & clinical oncologyCurrent approaches to management of infections in bone marrow transplants. Eur J Cancer Clin Oncol. 1989; 25 Suppl 2:S25-35.Eur J Cancer Clin Oncol1989-01-01T00:00:001989Current approaches to management of infections in bone marrow transplants.2896298Kedar E, Rezai AR, Giorgi JV, Gale RP, Champlin RE, Mitsuyasu RT, Fahey JLNatural immunity and cell growth regulationImmunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells. Nat Immun Cell Growth Regul. 1988; 7(1):13-30.Nat Immun Cell Growth Regul1988-01-01T00:00:001988Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on human blood and bone marrow mononuclear cells.2902126Champlin RE, Ho WG, Winston DJThe Journal of hospital infectionAcute graft-vs.-host disease and interstitial pneumonitis interrelated problems following allogeneic bone marrow transplantation: effects of intravenous immune globulin and other interventions. J Hosp Infect. 1988 Aug; 12 Suppl D:29-33.J Hosp Infect1988-08-01T00:00:001988Acute graft-vs.-host disease and interstitial pneumonitis interrelated problems following allogeneic bone marrow transplantation: effects of intravenous immune globulin and other interventions.2981496Winston DJ, Huang ES, Miller MJ, Lin CH, Ho WG, Gale RP, Champlin REAnnals of internal medicineMolecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. Ann Intern Med. 1985 Jan; 102(1):16-20.Ann Intern Med1985-01-01T00:00:001985Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation.3008618Champlin R, Gale RP, Foon KA, Golde DWAnnals of internal medicineChronic leukemias: oncogenes, chromosomes, and advances in therapy. Ann Intern Med. 1986 May; 104(5):671-88.Ann Intern Med1986-05-01T00:00:001986Chronic leukemias: oncogenes, chromosomes, and advances in therapy.3010716Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin REThe American journal of medicineNorfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986 May; 80(5):884-90.Am J Med1986-05-01T00:00:001986Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.3018101Ho WG, Winston DJ, Champlin RE, Gale RPInternational journal of cell cloningProphylactic use of immunoglobulin in bone marrow transplantation. Int J Cell Cloning. 1986; 4 Suppl 1:174-80.Int J Cell Cloning1986-01-01T00:00:001986Prophylactic use of immunoglobulin in bone marrow transplantation.3054191Nimer SD, Champlin RE, Golde DWJAMASerum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA. 1988 Dec 09; 260(22):3297-300.JAMA1988-12-09T00:00:001988Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor.3165197Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FPProceedings of the National Academy of Sciences of the United States of AmericaDiagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A. 1988 Aug; 85(15):5698-702.Proc Natl Acad Sci U S A1988-08-01T00:00:001988Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.3274769Champlin RTransplantation proceedingsBone marrow transplantation for leukemia: effects of T lymphocyte depletion of donor bone marrow. Transplant Proc. 1987 Feb; 19(1 Pt 1):157-9.Transplant Proc1987-02-01T00:00:001987Bone marrow transplantation for leukemia: effects of T lymphocyte depletion of donor bone marrow.3277219Champlin RRadiation researchTreatment for victims of nuclear accidents: the role of bone marrow transplantation. Radiat Res. 1988 Feb; 113(2):205-10.Radiat Res1988-02-01T00:00:001988Treatment for victims of nuclear accidents: the role of bone marrow transplantation.3310243Champlin RSeminars in hematologyThe role of bone marrow transplantation for nuclear accidents: implications of the Chernobyl disaster. Semin Hematol. 1987 Jul; 24(3 Suppl 2):1-4.Semin Hematol1987-07-01T00:00:001987The role of bone marrow transplantation for nuclear accidents: implications of the Chernobyl disaster.3324401Champlin RE, Cain G, Stitzel K, Gale RPThymusSustained recovery of hematopoiesis and immunity following transplantation of fetal liver cells in dogs. Thymus. 1987; 10(1-2):13-8.Thymus1987-01-01T00:00:001987Sustained recovery of hematopoiesis and immunity following transplantation of fetal liver cells in dogs.3541203Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ONScience (New York, N.Y.)Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science. 1987 Jan 02; 235(4784):85-8.Science1987-01-02T00:00:001987Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.3903598Seto BG, Kim M, Wolinsky L, Mito RS, Champlin ROral surgery, oral medicine, and oral pathologyOral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol. 1985 Nov; 60(5):493-7.Oral Surg Oral Med Oral Pathol1985-11-01T00:00:001985Oral mucositis in patients undergoing bone marrow transplantation.3911215Champlin RE, Mitsuyasu RT, Gale RPProgress in clinical and biological researchTransplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation. Prog Clin Biol Res. 1985; 193:315-25.Prog Clin Biol Res1985-01-01T00:00:001985Transplantation of T lymphocyte depleted bone marrow to prevent graft-versus-host disease: its implications for fetal liver transplantation.6347239Feig SA, Champlin R, Arenson E, Yale C, Ho W, Tesler A, Gale RPBritish journal of haematologyImproved survival following bone marrow transplantation for aplastic anaemia. Br J Haematol. 1983 Aug; 54(4):509-17.Br J Haematol1983-08-01T00:00:001983Improved survival following bone marrow transplantation for aplastic anaemia.6365155Champlin RE, Feig SA, Sparkes RS, Galen RPBritish journal of haematologyBone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease. Br J Haematol. 1984 Mar; 56(3):455-63.Br J Haematol1984-03-01T00:00:001984Bone marrow transplantation from identical twins in the treatment of aplastic anaemia: implication for the pathogenesis of the disease.7052161Champlin R, Ho W, Arenson E, Gale RPBloodAllogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood. 1982 Oct; 60(4):1038-41.Blood1982-10-01T00:00:001982Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase.7545476K?rbling M, Huh YO, Durett A, Mirza N, Miller P, Engel H, Anderlini P, van Besien K, Andreeff M, Przepiorka D, Deisseroth AB, Champlin REBloodAllogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.Blood1995-10-01T00:00:001995Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.7556522Champlin RExperimental hematologySeparation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia. Exp Hematol. 1995 Oct; 23(11):1148-51.Exp Hematol1995-10-01T00:00:001995Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia.7888684K?rbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth ABBloodAllogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.Blood1995-03-15T00:00:001995Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts.8220156Schiller G, Nimer S, Gajewski J, Lee M, Ho W, Territo M, Champlin RLeukemia & lymphomaEffect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study. Leuk Lymphoma. 1993 Sep; 11(1-2):69-77.Leuk Lymphoma1993-09-01T00:00:001993Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: results of a randomized, controlled study.8241988Winston DJ, Ho WG, Bartoni K, Champlin REBone marrow transplantationIntravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant. 1993 Sep; 12(3):283-8.Bone Marrow Transplant1993-09-01T00:00:001993Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.8291119Nimer SD, Giorgi J, Gajewski JL, Ku N, Schiller GJ, Lee K, Territo M, Ho W, Feig S, Selch MTransplantationSelective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial. Transplantation. 1994 Jan; 57(1):82-7.Transplantation1994-01-01T00:00:001994Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.8422454Champlin RBloodPreparative regimens for autologous bone marrow transplantation. Blood. 1993 Jan 15; 81(2):277-80.Blood1993-01-15T00:00:001993Preparative regimens for autologous bone marrow transplantation.8453592Seong DC, Liu P, Siciliano J, Zhao Y, Cork A, Henske E, Warburton D, Yu MT, Champlin R, Trujillo JMCancer genetics and cytogeneticsDetection of variant Ph-positive chronic myelogenous leukemia involving chromosomes 1, 9, and 22 by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1993 Feb; 65(2):100-3.Cancer Genet Cytogenet1993-02-01T00:00:001993Detection of variant Ph-positive chronic myelogenous leukemia involving chromosomes 1, 9, and 22 by fluorescence in situ hybridization.8673059Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MMBone marrow transplantationRisk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996 Jan; 17(1):75-80.Bone Marrow Transplant1996-01-01T00:00:001996Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.8677736Champlin R, Giralt S, Gajewski JActa haematologicaT cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation. Acta Haematol. 1996; 95(3-4):157-63.Acta Haematol1996-01-01T00:00:001996T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation.8733697Khouri IF, Kantarjian HM, Talpaz M, Giralt S, Rios MO, Hester JP, Champlin RE, Deisseroth ABBone marrow transplantationResults with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience. Bone Marrow Transplant. 1996 May; 17(5):775-9.Bone Marrow Transplant1996-05-01T00:00:001996Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.8750262Przepiorka D, Chan KW, Champlin RE, Culbert SJ, Petropoulos D, Ippoliti C, Khouri I, Huh YO, Vreisendorp H, Deisseroth ABBone marrow transplantationPrevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients. Bone Marrow Transplant. 1995 Dec; 16(6):737-41.Bone Marrow Transplant1995-12-01T00:00:001995Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.8757527Anderlini P, Przepiorka D, Seong D, Champlin R, K?rbling MBritish journal of haematologyTransient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol. 1996 Jul; 94(1):155-8.Br J Haematol1996-07-01T00:00:001996Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis.8842290Seong D, Bruner JM, Lee KH, Mirza N, Kwon BD, Lee JH, Lee YY, Ro J, Talpaz M, Champlin R, Deisseroth ABClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaProgressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis. 1996 Aug; 23(2):402-3.Clin Infect Dis1996-08-01T00:00:001996Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia.8879640Rond?n G, Giralt S, Huh Y, Khouri I, Andersson B, Andreeff M, Champlin RBone marrow transplantationGraft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. 1996 Sep; 18(3):669-72.Bone Marrow Transplant1996-09-01T00:00:001996Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia.8971375K?rbling M, Anderlini P, Durett A, Maadani F, Bojko P, Seong D, Giralt S, Khouri I, Andersson B, Mehra R, vanBesien K, Mirza N, Przepiorka D, Champlin RBone marrow transplantationDelayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1073-9.Bone Marrow Transplant1996-12-01T00:00:001996Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.9085736Seong D, Giralt S, Fischer H, Hayes K, Glassman A, Arlinghaus R, Xu J, Kantarjian H, Siciliano M, Champlin RBone marrow transplantationUsefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant. 1997 Mar; 19(6):565-70.Bone Marrow Transplant1997-03-01T00:00:001997Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia.9192777Giralt S, Estey E, Albitar M, van Besien K, Rond?n G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, K?rbling M, Keating M, Kantarjian H, Champlin RBloodEngraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.Blood1997-06-15T00:00:001997Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.9193344Johansen MJ, Madden T, Mehra RC, Wood JG, Rondon G, Browne V, Newman RA, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol. 1997 Apr; 15(4):1481-91.J Clin Oncol1997-04-01T00:00:001997Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.9242518Anderlini P, K?rbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin RBloodAllogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 01; 90(3):903-8.Blood1997-08-01T00:00:001997Allogeneic blood stem cell transplantation: considerations for donors.9261519van Besien K, Forman A, Champlin RAnnals of oncology : official journal of the European Society for Medical OncologyCentral nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. Ann Oncol. 1997 Jun; 8(6):515-24.Ann Oncol1997-06-01T00:00:001997Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy.9310192van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka DBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.Biol Blood Marrow Transplant1997-08-01T00:00:001997Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.9336352Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GNJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997 Oct; 15(10):3171-7.J Clin Oncol1997-10-01T00:00:001997Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.9576200Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian RBritish journal of haematologyPrognostic value of cytogenetics in multiple myeloma. Br J Haematol. 1998 Apr; 101(1):189-94.Br J Haematol1998-04-01T00:00:001998Prognostic value of cytogenetics in multiple myeloma.9758346Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger BBone marrow transplantationTransfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients. Bone Marrow Transplant. 1998 Sep; 22(6):575-7.Bone Marrow Transplant1998-09-01T00:00:001998Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.10168556Hester J, Bojko P, Rondon G, Champlin RTransfusion scienceIntegration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs. Transfus Sci. 1996 Dec; 17(4):585-90.Transfus Sci1996-12-01T00:00:001996Integration of biological, procedural, apheresis principles of peripheral blood stem cell transplantation programs.10373061Przepiorka D, Khouri I, Thall P, Mehra R, Lee MS, Ippoliti C, Giralt S, Gajewski J, van Besien K, Andersson B, K?rbling M, Deisseroth AB, Champlin RBone marrow transplantationThiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.Bone Marrow Transplant1999-05-01T00:00:001999Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.10416001Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, K?rbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin RAnnals of oncology : official journal of the European Society for Medical OncologyCarmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.Ann Oncol1999-05-01T00:00:001999Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma.10655439Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin REJournal of the National Cancer InstituteRandomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.J Natl Cancer Inst2000-02-02T00:00:002000Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.10949384Donato ML, Champlin RE, Wharton JT, Bodurka-Bevers D, Gershenson DEuropean journal of gynaecological oncologyIntensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer. Eur J Gynaecol Oncol. 2000; 21(3):241-4.Eur J Gynaecol Oncol2000-01-01T00:00:002000Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer.11012192Jones DV, Ashby M, Vadhan-Raj S, Somlo G, Champlin R, Gajewski J, Hellmann S, Fyfe GStem cells (Dayton, Ohio)Recombinant human thrombopoietin clinical development. Stem Cells. 1998; 16 Suppl 2:199-206.Stem Cells1998-01-01T00:00:001998Recombinant human thrombopoietin clinical development.11054078Rodriguez J, Keating MJ, O'Brien S, Champlin RE, Khouri IFBritish journal of haematologyAllogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol. 2000 Sep; 110(4):897-9.Br J Haematol2000-09-01T00:00:002000Allogeneic haematopoietic transplantation for Richter's syndrome.11223976Shimoni A, K?rbling M, Champlin R, Molldrem JBone marrow transplantationCryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2000 Dec; 26(12):1343-5.Bone Marrow Transplant2000-12-01T00:00:002000Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.11369630Przepiorka D, Smith TL, Folloder J, Anderlini P, Chan KW, K?rbling M, Lichtiger B, Norfleet F, Champlin RBloodControlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001 Jun 01; 97(11):3405-10.Blood2001-06-01T00:00:002001Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors.11548839Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, Andersson B, Claxton D, Donato M, Gajewski J, Khouri I, Korbling M, Ueno N, deVos D, Champlin R, Giralt SBone marrow transplantationDecitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.Bone Marrow Transplant2001-06-01T00:00:002001Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study.11642601Claxton DF, McMannis J, Champlin R, Choudhury ACritical reviews in immunologyTherapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress. Crit Rev Immunol. 2001; 21(1-3):147-55.Crit Rev Immunol2001-01-01T00:00:002001Therapeutic potential of leukemia-derived dendritic cells: preclinical and clinical progress.11939604Andersson BS, Kashyap A, Gian V, Wingard JR, Fernandez H, Cagnoni PJ, Jones RB, Tarantolo S, Hu WW, Blume KG, Forman SJ, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationConditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002; 8(3):145-54.Biol Blood Marrow Transplant2002-01-01T00:00:002002Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study.11996478Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, K?rbling M, Martin T, Ueno NT, Champlin RE, Khouri IFAnnals of oncology : official journal of the European Society for Medical OncologyRisk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.Ann Oncol2002-03-01T00:00:002002Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma.12139741Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff MBritish journal of haematologyThe anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol. 2002 Aug; 118(2):521-34.Br J Haematol2002-08-01T00:00:002002The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells.12235521Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno NT, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin RBone marrow transplantationFludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.Bone Marrow Transplant2002-09-01T00:00:002002Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.12599934Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt SOncology (Williston Park, N.Y.)Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park). 2003 Jan; 17(1):94-100; discussion 103-7.Oncology (Williston Park)2003-01-01T00:00:002003Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications.12802922Wong R, de Lima M, Couriel D, Giralt S, Hosing C, Shahjahan M, Cheng YC, Bruton J, Champlin R, Khouri ILeukemia & lymphomaTreatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab. Leuk Lymphoma. 2003 May; 44(5):829-32.Leuk Lymphoma2003-05-01T00:00:002003Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab.12823354Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel DBritish journal of haematologyTacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003 Jul; 122(1):128-34.Br J Haematol2003-07-01T00:00:002003Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.12907445Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KVBloodCD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood. 2004 Feb 01; 103(3):1140-6.Blood2003-08-07T00:00:002003CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.14645431Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu S, McLaughlin P, Katz RL, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyNonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003 Dec 01; 21(23):4407-12.J Clin Oncol2003-12-01T00:00:002003Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.14751187Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin REGynecologic oncologyMatched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol. 2004 Jan; 92(1):365-7.Gynecol Oncol2004-01-01T00:00:002004Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report.14755312Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, Champlin REBone marrow transplantationLow-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 2004 Apr; 33(8):833-7.Bone Marrow Transplant2004-04-01T00:00:002004Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.14993883Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAcute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant. 2004 Mar; 10(3):178-85.Biol Blood Marrow Transplant2004-03-01T00:00:002004Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.15122310Thall PF, Champlin RE, Andersson BSBone marrow transplantationComparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant. 2004 Jun; 33(12):1191-9.Bone Marrow Transplant2004-06-01T00:00:002004Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects.15361906Anderlini P, Valbuena JR, Champlin RE, Bueso-Ramos CEBone marrow transplantationEpstein-Barr virus-associated, CD20- polyclonal lymphoproliferative disorder after matched unrelated donor marrow transplantation. Bone Marrow Transplant. 2004 Nov; 34(10):919-21.Bone Marrow Transplant2004-11-01T00:00:002004Epstein-Barr virus-associated, CD20- polyclonal lymphoproliferative disorder after matched unrelated donor marrow transplantation.15682071Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPrognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005 Feb; 11(2):108-14.Biol Blood Marrow Transplant2005-02-01T00:00:002005Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.16179379Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, Duvic MBloodScleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood. 2006 Jan 15; 107(2):463-6.Blood2005-09-22T00:00:002005Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation.16368882Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato MBloodExtracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15; 107(8):3074-80.Blood2005-12-20T00:00:002005Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD.16681642Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, K?rbling M, Champlin REBritish journal of haematologyFixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006 Jun; 133(5):533-7.Br J Haematol2006-06-01T00:00:002006Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma.16946302Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE, International Bone Marrow Transplant Registry, European Group for Blood and Marrow TransplantationBloodLong-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006 Dec 15; 108(13):4288-90.Blood2006-08-31T00:00:002006Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.17038533Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt SBloodProspective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007 Feb 15; 109(4):1395-400.Blood2006-10-12T00:00:002006Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).17262062Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SABone marrow transplantationAutologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83.Bone Marrow Transplant2007-01-29T00:00:002007Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma.17382253Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationTransplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007 Apr; 13(4):469-77.Biol Blood Marrow Transplant2007-02-08T00:00:002007Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment.17560447Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, Horowitz MM, Wagner JELancet (London, England)Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007 Jun 09; 369(9577):1947-54.Lancet2007-06-09T00:00:002007Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study.17989720de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt SLeukemiaPhase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia. 2008 Feb; 22(2):258-64.Leukemia2007-11-08T00:00:002007Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.18272911Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri IAnnals of oncology : official journal of the European Society for Medical OncologyHigh-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol. 2008 Jun; 19(6):1166-71.Ann Oncol2008-02-13T00:00:002008High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age.18411419Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin REBloodEight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.Blood2008-04-14T00:00:002008Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.18664621Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RTBloodImpact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15; 112(8):3500-7.Blood2008-07-29T00:00:002008Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.19011667Saliba RM, Komanduri KV, Giralt S, de Souza J, Patah P, Oran B, Couriel D, Rondon G, Champlin RE, de Lima MBone marrow transplantationLeukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML. Bone Marrow Transplant. 2009 May; 43(9):685-92.Bone Marrow Transplant2008-11-17T00:00:002008Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.19168784Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IFBloodMature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.Blood2009-01-23T00:00:002009Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.19384931Hosing C, Saliba RM, Ahlawat S, K?rbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat UAmerican journal of hematologyPoor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009 Jun; 84(6):335-7.Am J Hematol2009-06-01T00:00:002009Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.19660722de Souza JA, Saliba RM, Patah P, Rondon G, Ribeiro R, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Efebera Y, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationModerate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1094-9.Biol Blood Marrow Transplant2009-09-01T00:00:002009Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.19896079Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B, Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, Alousi ABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1555-62.Biol Blood Marrow Transplant2009-09-25T00:00:002009A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.19998065Cheng YC, Rond?n G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NTInternational journal of hematologyInterleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Int J Hematol. 2009 Dec; 90(5):627-634.Int J Hematol2009-12-09T00:00:002009Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.20164852Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W, Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Vi?a M, Cooper LJLeukemiaIdentifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia. 2010 May; 24(5):1059-62.Leukemia2010-02-18T00:00:002010Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype.20426540Gajewski JL, Nimer S, Saliba RM, Thomas M, Przepiorka D, Giralt S, von Besien K, Mehra R, Andersson B, Chan KW, Ippoliti C, Warkinten D, Feigs S, Territo M, Schiller G, Lebkowski J, Moseley AM, Lloyd K, von Hoeff M, Okarma T, Champlin RCytotherapyLong-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients. Cytotherapy. 1999; 1(5):401-7.Cytotherapy1999-01-01T00:00:001999Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients.21455998Khouri IF, Bassett R, Poindexter N, O'Brien S, Bueso-Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina MCancerNonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011 Oct 15; 117(20):4679-88.Cancer2011-03-31T00:00:002011Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.21558388Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJCancer researchReprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011 May 15; 71(10):3516-27.Cancer Res2011-05-10T00:00:002011Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.21757626Champlin RBloodNow everyone has a donor for HSCT. Blood. 2011 Jul 14; 118(2):218.Blood2011-07-14T00:00:002011Now everyone has a donor for HSCT.21767516Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationTreatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1874-7.Biol Blood Marrow Transplant2011-07-20T00:00:002011Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.22081487Howell JE, Gulbis AM, Champlin RE, Qazilbash MHAmerican journal of hematologyRetrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. Am J Hematol. 2012 Feb; 87(2):172-4.Am J Hematol2011-11-12T00:00:002011Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients.22355761O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJScientific reportsAdoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012; 2:249.Sci Rep2012-02-13T00:00:002012Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.22496153Brunstein CG, Eapen M, Ahn KW, Appelbaum FR, Ballen KK, Champlin RE, Cutler C, Kan F, Laughlin MJ, Soiffer RJ, Weisdorf DJ, Woolfrey A, Wagner JEBloodReduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012 Jun 07; 119(23):5591-8.Blood2012-04-10T00:00:002012Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.22732703Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BSBone marrow transplantationIntravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant. 2013 Jan; 48(1):26-31.Bone Marrow Transplant2012-06-25T00:00:002012Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.22750645Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationClofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26.Biol Blood Marrow Transplant2012-06-29T00:00:002012Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.22892554Ciurea SO, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDonor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies. Biol Blood Marrow Transplant. 2013 Feb; 19(2):180-4.Biol Blood Marrow Transplant2012-08-11T00:00:002012Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.23220013Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study. Biol Blood Marrow Transplant. 2013 Mar; 19(3):474-80.Biol Blood Marrow Transplant2012-12-07T00:00:002012Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.23295945Deniger DC, Switzer K, Mi T, Maiti S, Hurton L, Singh H, Huls H, Olivares S, Lee DA, Champlin RE, Cooper LJMolecular therapy : the journal of the American Society of Gene TherapyBispecific T-cells expressing polyclonal repertoire of endogenous ?d T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther. 2013 Mar; 21(3):638-47.Mol Ther2013-01-08T00:00:002013Bispecific T-cells expressing polyclonal repertoire of endogenous ?d T-cell receptors and introduced CD19-specific chimeric antigen receptor.23377665Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJJournal of immunotherapy (Hagerstown, Md. : 1997)Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013 Feb; 36(2):112-23.J Immunother2013-02-01T00:00:002013Sleeping beauty system to redirect T-cell specificity for human applications.24779033Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi FAmerican journal of hematologyPhase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar; 89(3):282-7.Am J Hematol2014-03-01T00:00:002014Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.LeukemiaStem Cell TransplantationMD Anderson21.72070.001908161648research areas17.33940.0059247296coauthor of1522.84159.26260similar to111303selected publicationsELIZABETHSHPALLELIZABETH SHPALL9025SHPALL, ELIZABETHProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorPARTOWKEBRIAEIPARTOW KEBRIAEI8535KEBRIAEI, PARTOWProfessorUDAY RPOPATUDAY R POPAT8670POPAT, UDAY RProfessorMUZAFFAR HQAZILBASHMUZAFFAR H QAZILBASH9055QAZILBASH, MUZAFFAR HProfessorSTEFAN OCTAVIANCIUREASTEFAN OCTAVIAN CIUREA9422CIUREA, STEFAN OCTAVIANAssociate ProfessorAuthorship 2121037Authorship 2122454Authorship 2123833Authorship 2124161Authorship 2124273Authorship 2124391Authorship 2124582Authorship 2124703Authorship 2124893Authorship 2125374Authorship 2125923Authorship 2126176Authorship 2126331Authorship 2126341Authorship 2126725Authorship 2127244Authorship 2127382Authorship 2127911Authorship 2128005Authorship 2129311Authorship 2129641Authorship 2130007Authorship 2130075Authorship 21300810Authorship 2130132Authorship 2131032Authorship 2132253Authorship 2132963Authorship 2132972Authorship 2133441Authorship 2133753Authorship 2134901Authorship 2136021Authorship 2136243Authorship 2136371Authorship 2136482Authorship 2138191Authorship 2138492Authorship 2138524Authorship 2139245Authorship 2141705Authorship 2141793Authorship 2141812Authorship 2142425Authorship 2142932Authorship 2143195Authorship 2144495Authorship 214492Authorship 2145411Authorship 2145767Authorship 2146656Authorship 2146685Authorship 2146746Authorship 2147216Authorship 2147659Authorship 2148474Authorship 2148494Authorship 2148982Authorship 2149251Authorship 215030Authorship 2150477Authorship 2150675Authorship 2150873Authorship 2150885Authorship 2151278Authorship 2152892Authorship 2152966Authorship 21533811Authorship 215373Authorship 2153849Authorship 2154331Authorship 2155338Authorship 2155365Authorship 2156335Authorship 21577116Authorship 2158208Authorship 2158289Authorship 2158686Authorship 2158838Authorship 215888Authorship 2159044Authorship 2159135Authorship 2159766Authorship 2159894Authorship 2160111Authorship 21603910Authorship 2160597Authorship 2161126Authorship 2161685Authorship 2162175Authorship 21622218Authorship 2162278Authorship 2162745Authorship 2163924Authorship 2164458Authorship 2164507Authorship 2164805Authorship 2165093Authorship 2165253Authorship 21654610Authorship 2165689Authorship 2166246Authorship 2166523Authorship 21666212Authorship 21682610Authorship 2168952Authorship 2169311Authorship 2169973Authorship 2170497Authorship 21705912Authorship 2171681Authorship 2172173Authorship 21725715Authorship 21732915Authorship 2174251Authorship 21753117Authorship 2176139Authorship 2177836Authorship 2178163Authorship 2178276Authorship 2178715Authorship 2180011Authorship 2180194Authorship 2180664Authorship 2181022Authorship 2182907Authorship 2183351Authorship 2184271Authorship 2184529Authorship 2185771Authorship 2186712Authorship 2187727Authorship 2187804Authorship 21892821Authorship 2190286Authorship 2190307Authorship 2191473Authorship 2192255Authorship 2192343Authorship 2192807Authorship 21949615Authorship 21995912Authorship 22001712Authorship 2202402Authorship 22025918Authorship 22028711Authorship 2209313Authorship 2209343Authorship 2210337Authorship 2210763Authorship 2211788Authorship 2213436Authorship 2213487Authorship 2213729Authorship 2213891Authorship 2215269Authorship 22165813Authorship 2217263Authorship 2219673Authorship 2220289Authorship 22210110Authorship 2223073Authorship 2224086Authorship 2225268Authorship 2226062Authorship 2228568Authorship 2230077Authorship 2231846Authorship 2232688Authorship 22360412Authorship 2243828Authorship 22459515Authorship 2251836Authorship 22552210Authorship 2257298Authorship 2261869Authorship 2268317Authorship 22712219Authorship 2273769Authorship 2276941Authorship 2282397Authorship 2287913Authorship 2291242Authorship 22918313Authorship 22976611Authorship 2300262Authorship 23004310Authorship 2304134Authorship 23050814Authorship 23063913Authorship 23091013Authorship 23092911Authorship 23100711Authorship 2310864Authorship 23136216Authorship 2316256Authorship 23163314Authorship 2318973Authorship 2322354Authorship 2322624Authorship 2327282Authorship 23340717Authorship 2334617Authorship 2335364Authorship 2342131Authorship 2342711Authorship 2346601Authorship 23509910Authorship 2354758Authorship 23552711438435Champlin R, Giralt S, Przepiorka D, Ho W, Lee K, Gajewski J, Nimer S, Andersson B, Wallerstein R, Ippolito CProgress in clinical and biological researchSelective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia. Prog Clin Biol Res. 1992; 377:385-94; discussion 395-8.Prog Clin Biol Res1992-01-01T00:00:001992Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.1465994Przepiorka D, Giralt S, Huh YO, Andreeff M, Luna M, Reading C, Thomas M, Champlin RETransplantation proceedingsT-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma. Transplant Proc. 1992 Dec; 24(6):2906-7.Transplant Proc1992-12-01T00:00:001992T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.1600415Mrs?c M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Prentice HGBone marrow transplantationSecond HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992 Apr; 9(4):269-75.Bone Marrow Transplant1992-04-01T00:00:001992Second HLA-identical sibling transplants for leukemia recurrence.1643014Schiller G, Gajewski J, Nimer S, Territo M, Ho W, Lee M, Champlin RBritish journal of haematologyA randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia. Br J Haematol. 1992 Jun; 81(2):170-7.Br J Haematol1992-06-01T00:00:001992A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.1728315Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AMBloodBone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992 Jan 01; 79(1):269-75.Blood1992-01-01T00:00:001992Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.1878732Visani G, Gamberi B, Greenberg P, Advani R, Gulati S, Champlin R, Hoglund M, Karanes C, Williams S, Keating ABone marrow transplantationThe use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial. Bone Marrow Transplant. 1991; 7 Suppl 2:81.Bone Marrow Transplant1991-01-01T00:00:001991The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: a prospective randomized controlled trial.1952471Winston DJ, Ho WG, Bruckner DA, Champlin REAnnals of internal medicineBeta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991 Dec 01; 115(11):849-59.Ann Intern Med1991-12-01T00:00:001991Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone.1976346Winston DJ, Ho WG, Champlin RECancer treatment and researchCytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Cancer Treat Res. 1990; 50:113-28.Cancer Treat Res1990-01-01T00:00:001990Cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.1976350Champlin RECancer treatment and researchBone marrow transplantation for aplastic anemia: recent advances and comparisons with alternative therapies. Cancer Treat Res. 1990; 50:185-99.Cancer Treat Res1990-01-01T00:00:001990Bone marrow transplantation for aplastic anemia: recent advances and comparisons with alternative therapies.1976361Champlin RECancer treatment and researchT-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res. 1990; 50:99-111.Cancer Treat Res1990-01-01T00:00:001990T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival.2142440Champlin R, Ho W, Gajewski J, Feig S, Burnison M, Holley G, Greenberg P, Lee K, Schmid I, Giorgi JBloodSelective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood. 1990 Jul 15; 76(2):418-23.Blood1990-07-15T00:00:001990Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.2194597Gajewski J, Cecka M, Champlin RBlood reviewsBone marrow transplantation utilizing HLA-matched unrelated marrow donors. Blood Rev. 1990 Jun; 4(2):132-8.Blood Rev1990-06-01T00:00:001990Bone marrow transplantation utilizing HLA-matched unrelated marrow donors.2326866Champlin RE, Ho WG, Nimer SD, Gajewski JG, Selch M, Burnison M, Holley G, Yam P, Petz L, Winston DJTransplantationBone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy. Transplantation. 1990 Apr; 49(4):720-4.Transplantation1990-04-01T00:00:001990Bone marrow transplantation for severe aplastic anemia. Effect of a preparative regimen of cyclophosphamide-low-dose total-lymphoid irradiation and posttransplant cyclosporine-methotrexate therapy.2390632Hershman JM, Eriksen E, Kaufman N, Champlin REBone marrow transplantationThyroid function tests in patients undergoing bone marrow transplantation. Bone Marrow Transplant. 1990 Jul; 6(1):49-51.Bone Marrow Transplant1990-07-01T00:00:001990Thyroid function tests in patients undergoing bone marrow transplantation.2654255Macy E, Bulpitt K, Champlin RE, Saxon AThe Journal of allergy and clinical immunologyAnaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin. J Allergy Clin Immunol. 1989 May; 83(5):871-5.J Allergy Clin Immunol1989-05-01T00:00:001989Anaphylaxis to infusion of autologous bone marrow: an apparent reaction to self, mediated by IgE antibody to bovine serum albumin.2665854Kagan JM, Champlin RE, Saxon ABloodB-cell dysfunction following human bone marrow transplantation: functional-phenotypic dissociation in the early posttransplant period. Blood. 1989 Aug 01; 74(2):777-85.Blood1989-08-01T00:00:001989B-cell dysfunction following human bone marrow transplantation: functional-phenotypic dissociation in the early posttransplant period.2757012Schiller GJ, Naeim F, Champlin REAmerican journal of hematologyBone marrow aplasia associated with proliferation of large granular lymphocytes and subsequent transformation to acute lymphoblastic leukemia. Am J Hematol. 1989 Oct; 32(2):153-4.Am J Hematol1989-10-01T00:00:001989Bone marrow aplasia associated with proliferation of large granular lymphocytes and subsequent transformation to acute lymphoblastic leukemia.2830829Champlin R, Gale RPAnnals of the New York Academy of SciencesBone marrow transplantation: its biology and role as treatment for acute and chronic leukemias. Ann N Y Acad Sci. 1987; 511:447-58.Ann N Y Acad Sci1987-01-01T00:00:001987Bone marrow transplantation: its biology and role as treatment for acute and chronic leukemias.2867626Cain GR, Cardinet GH, Cuddon PA, Gale RP, Champlin RTransplantationMyasthenia gravis and polymyositis in a dog following fetal hematopoietic cell transplantation. Transplantation. 1986 Jan; 41(1):21-5.Transplantation1986-01-01T00:00:001986Myasthenia gravis and polymyositis in a dog following fetal hematopoietic cell transplantation.2868458Champlin R, Cain G, Stitzel KA, Gale RPProgress in clinical and biological researchFetal liver cell transplantation in dogs: results with DLA-compatible and incompatible grafts. Prog Clin Biol Res. 1985; 193:195-204.Prog Clin Biol Res1985-01-01T00:00:001985Fetal liver cell transplantation in dogs: results with DLA-compatible and incompatible grafts.3024542Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin REAnnals of internal medicineIntravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med. 1987 Jan; 106(1):12-8.Ann Intern Med1987-01-01T00:00:001987Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.3037899Winston DJ, Ho WG, Champlin RE, Karp J, Bartlett J, Finley RS, Joshi JH, Talbot G, Levitt L, Deresinski SThe American journal of medicineNorfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med. 1987 Jun 26; 82(6B):40-6.Am J Med1987-06-26T00:00:001987Norfloxacin for prevention of bacterial infections in granulocytopenic patients.3041815Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin REThe American journal of medicineControlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med. 1988 Jul 25; 85(1A):21-30.Am J Med1988-07-25T00:00:001988Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients.3041829Winston DJ, Eron LJ, Ho M, Pazin G, Kessler H, Pottage JC, Gallagher J, Sartiano G, Ho WG, Champlin REThe American journal of medicineRecombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer. Am J Med. 1988 Aug; 85(2):147-51.Am J Med1988-08-01T00:00:001988Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer.3079092Cain GR, Champlin RE, Gale RPTransplantation proceedingsSurvival and immune recovery in dogs following fetal liver transplantation. Transplant Proc. 1987 Feb; 19(1 Pt 3):2695-7.Transplant Proc1987-02-01T00:00:001987Survival and immune recovery in dogs following fetal liver transplantation.3086277Winston DJ, Ho WG, Champlin RE, Gale RP, Busuttil RWThe Journal of antimicrobial chemotherapyUreidopenicillins, aztreonam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:55-66.J Antimicrob Chemother1986-03-01T00:00:001986Ureidopenicillins, aztreonam, and thienamycin: efficacy as single-drug therapy of severe infections and potential as components of combined therapy.3260357Champlin RENeurologyTreating multiple sclerosis with monoclonal antibodies: the cons. Neurology. 1988 Jul; 38(7 Suppl 2):47-9.Neurology1988-07-01T00:00:001988Treating multiple sclerosis with monoclonal antibodies: the cons.3285744Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PBAnnals of internal medicineBone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun; 108(6):806-14.Ann Intern Med1988-06-01T00:00:001988Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.3311126Ho WG, Champlin RE, Winston DJ, Feig SA, Gale RPBritish journal of haematologyBone marrow transplantation in patients with leukaemia previously transfused with blood products from family members. Br J Haematol. 1987 Sep; 67(1):67-70.Br J Haematol1987-09-01T00:00:001987Bone marrow transplantation in patients with leukaemia previously transfused with blood products from family members.3521427Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells JAnnals of internal medicineTreatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986 Jul; 105(1):20-6.Ann Intern Med1986-07-01T00:00:001986Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.3531239Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RPThe Journal of clinical investigationDesigned transfer of specific immune responses with bone marrow transplantation. J Clin Invest. 1986 Oct; 78(4):959-67.J Clin Invest1986-10-01T00:00:001986Designed transfer of specific immune responses with bone marrow transplantation.3555647Champlin R, Gale RPBloodAcute myelogenous leukemia: recent advances in therapy. Blood. 1987 Jun; 69(6):1551-62.Blood1987-06-01T00:00:001987Acute myelogenous leukemia: recent advances in therapy.3880774Li S, Champlin R, Fitchen JH, Gale RPThe Journal of clinical investigationAbnormalities of myeloid progenitor cells after "successful" bone marrow transplantation. J Clin Invest. 1985 Jan; 75(1):234-41.J Clin Invest1985-01-01T00:00:001985Abnormalities of myeloid progenitor cells after "successful" bone marrow transplantation.3884059Jacobs AD, Champlin RE, Golde DWBloodRecombinant alpha-2-interferon for hairy cell leukemia. Blood. 1985 Apr; 65(4):1017-20.Blood1985-04-01T00:00:001985Recombinant alpha-2-interferon for hairy cell leukemia.3892702Champlin R, Jacobs A, Gale RP, Ho W, Selch M, Lenarsky C, Feig SASeminars in oncologyHigh-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results. Semin Oncol. 1985 Jun; 12(2 Suppl 3):190-5.Semin Oncol1985-06-01T00:00:001985High-dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with acute leukemia: preliminary results.3919580Jacobs AD, Champlin RE, Golde DWThe American journal of medicinePure red cell aplasia characterized by erythropoietic maturation arrest. Response to anti-thymocyte globulin. Am J Med. 1985 Mar; 78(3):515-7.Am J Med1985-03-01T00:00:001985Pure red cell aplasia characterized by erythropoietic maturation arrest. Response to anti-thymocyte globulin.3967099Jacobs AD, Naiem F, Champlin RE, Golde DWBlutToxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) alpha-2-interferon. Blut. 1985 Jan; 50(1):33-4.Blut1985-01-01T00:00:001985Toxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) alpha-2-interferon.4005428Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RPBloodDo androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood. 1985 Jul; 66(1):184-8.Blood1985-07-01T00:00:001985Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial.6132450Niskanen E, Champlin R, Oki A, Golde DW, Gale RP, Cline MJStem cellsHumoral stimulation of hemopoietic progenitors from human fetal liver. Stem Cells (1981). 1982; 2(4):246-52.Stem Cells (1981)1982-01-01T00:00:001982Humoral stimulation of hemopoietic progenitors from human fetal liver.6142357Speck B, Bortin MM, Champlin R, Goldman JM, Herzig RH, McGlave PB, Messner HA, Weiner RS, Rimm AALancet (London, England)Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984 Mar 24; 1(8378):665-8.Lancet1984-03-24T00:00:001984Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia.6200742Champlin R, Jacobs A, Gale RP, Boccia R, Elashoff R, Foon K, Zighelboim JLancet (London, England)Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy. Lancet. 1984 Apr 21; 1(8382):894-6.Lancet1984-04-21T00:00:001984Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.6324586Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RPThe American journal of medicineIntravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. Am J Med. 1984 Mar 30; 76(3A):128-33.Am J Med1984-03-30T00:00:001984Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial.6368256Winston DJ, Ho WG, Champlin RE, Gale RPExperimental hematologyInfectious complications of bone marrow transplantation. Exp Hematol. 1984 Mar; 12(3):205-15.Exp Hematol1984-03-01T00:00:001984Infectious complications of bone marrow transplantation.6372850Ho WG, Champlin RE, Feig SA, Gale RPBritish journal of haematologyTransplantation of ABH incompatible bone marrow: gravity sedimentation of donor marrow. Br J Haematol. 1984 May; 57(1):155-62.Br J Haematol1984-05-01T00:00:001984Transplantation of ABH incompatible bone marrow: gravity sedimentation of donor marrow.6386510Champlin RE, Feig SA, Gale RPExperimental hematologyCase problems in bone marrow transplantation. I. Graft failure in aplastic anemia: its biology and treatment. Exp Hematol. 1984 Oct; 12(9):728-33.Exp Hematol1984-10-01T00:00:001984Case problems in bone marrow transplantation. I. Graft failure in aplastic anemia: its biology and treatment.6475984Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RPThe American journal of medicineMoxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984 Sep; 77(3):442-50.Am J Med1984-09-01T00:00:001984Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.6608893Foon KA, Mitsuyasu RT, Schroff RW, McIntyre RE, Champlin R, Gale RPAnnals of internal medicineImmunologic defects in young male patients with hepatitis-associated aplastic anemia. Ann Intern Med. 1984 May; 100(5):657-62.Ann Intern Med1984-05-01T00:00:001984Immunologic defects in young male patients with hepatitis-associated aplastic anemia.7032290Douer D, Champlin RE, Ho WG, Sarna GP, Wells JH, Graze PR, Cline MJ, Gale RPThe American journal of medicineHigh-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer. Am J Med. 1981 Dec; 71(6):973-6.Am J Med1981-12-01T00:00:001981High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer.7483980Abu-Farsakh HA, Katz RL, Atkinson N, Champlin REActa cytologicaPrognostic factors in bronchoalveolar lavage in 77 patients with bone marrow transplants. Acta Cytol. 1995 Nov-Dec; 39(6):1081-8.Acta Cytol1995-11-01T00:00:001995Prognostic factors in bronchoalveolar lavage in 77 patients with bone marrow transplants.7485213Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth ABThe American journal of medicineRecent advances in the application of gene therapy to human disease. Am J Med. 1995 Nov; 99(5):537-52.Am J Med1995-11-01T00:00:001995Recent advances in the application of gene therapy to human disease.7489144Hester JP, Rond?n G, Huh YO, Lauppe MJ, Champlin RE, Deisseroth ABJournal of hematotherapyPrinciples of bone marrow processing and progenitor cell/mononuclear cell concentrate collection in a continuous flow blood cell separation system. J Hematother. 1995 Aug; 4(4):299-306.J Hematother1995-08-01T00:00:001995Principles of bone marrow processing and progenitor cell/mononuclear cell concentrate collection in a continuous flow blood cell separation system.7549833Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels BLeukemia & lymphomaA phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma. 1995 May; 17(5-6):427-33.Leuk Lymphoma1995-05-01T00:00:001995A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.7584486Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RETherapeutic immunologyEvaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation. Ther Immunol. 1994 Apr; 1(2):77-82.Ther Immunol1994-04-01T00:00:001994Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.7655380van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri IBone marrow transplantationHigh-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995 Apr; 15(4):549-55.Bone Marrow Transplant1995-04-01T00:00:001995High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.7662980Seong DC, Kantarjian HM, Ro JY, Talpaz M, Xu J, Robinson JR, Deisseroth AB, Champlin RE, Siciliano MJBloodHypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood. 1995 Sep 15; 86(6):2343-9.Blood1995-09-15T00:00:001995Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment.7670120Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RPBloodBone marrow transplantation for Fanconi anemia. Blood. 1995 Oct 01; 86(7):2856-62.Blood1995-10-01T00:00:001995Bone marrow transplantation for Fanconi anemia.7728124Vriesendorp HM, Chu H, Ochran TG, Besa PC, Champlin REBone marrow transplantationRadiobiology of total body radiation. Bone Marrow Transplant. 1994; 14 Suppl 4:S4-8.Bone Marrow Transplant1994-01-01T00:00:001994Radiobiology of total body radiation.7738615van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Bellare N, Nath RJournal of clinical oncology : official journal of the American Society of Clinical OncologyAllogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.J Clin Oncol1995-05-01T00:00:001995Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management.7757401Champlin RJournal of hematotherapyOptimizing the composition of bone marrow for allogenic transplantation. J Hematother. 1995 Feb; 4(1):53-60.J Hematother1995-02-01T00:00:001995Optimizing the composition of bone marrow for allogenic transplantation.7773225Shaffer L, Giralt S, Champlin R, Chan KWBone marrow transplantationTreatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2. Bone Marrow Transplant. 1995 Feb; 15(2):317-9.Bone Marrow Transplant1995-02-01T00:00:001995Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2.7773226van Besien K, Demuynck H, Lemaistre CF, Bogaerts MA, Champlin RBone marrow transplantationHigh-dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995 Feb; 15(2):321-3.Bone Marrow Transplant1995-02-01T00:00:001995High-dose melphalan allows durable engraftment of allogeneic bone marrow.7858506Schiller G, Gajewski J, Lee M, Ho W, Territo M, Champlin RLeukemia & lymphomaBenefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Leuk Lymphoma. 1994 Sep; 15(1-2):85-90.Leuk Lymphoma1994-09-01T00:00:001994Benefit of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.7904486Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin RBloodLimited value of myeloablative therapy for late multiple myeloma. Blood. 1994 Jan 15; 83(2):512-6.Blood1994-01-15T00:00:001994Limited value of myeloablative therapy for late multiple myeloma.7915163Dimopoulos MA, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian RLeukemia & lymphomaIntensive sequential therapy for VAD-resistant multiple myeloma. Leuk Lymphoma. 1994 May; 13(5-6):479-84.Leuk Lymphoma1994-05-01T00:00:001994Intensive sequential therapy for VAD-resistant multiple myeloma.7921964Champlin RJournal of hematotherapyT-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia. J Hematother. 1993; 2(1):27-42.J Hematother1993-01-01T00:00:001993T-cell depletion for allogeneic bone marrow transplantation: impact on graft-versus-host disease, engraftment, and graft-versus-leukemia.7921999Deisseroth AB, Hanania EG, Fu S, Claxton D, Andreeff M, Champlin R, Kavanagh J, Hortobagyi G, Holmes F, Reading CJournal of hematotherapyGenetic therapy of human neoplastic disease. J Hematother. 1993; 2(3):373-5.J Hematother1993-01-01T00:00:001993Genetic therapy of human neoplastic disease.7951120Kantarjian HM, Talpaz M, Andersson B, Khouri I, Giralt S, Rios MB, Champlin R, Hester J, Deisseroth ABBone marrow transplantationHigh doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1994 Jul; 14(1):57-61.Bone Marrow Transplant1994-07-01T00:00:001994High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.8019468Whimbey E, Elting LS, Couch RB, Lo W, Williams L, Champlin RE, Bodey GPBone marrow transplantationInfluenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant. 1994 Apr; 13(4):437-40.Bone Marrow Transplant1994-04-01T00:00:001994Influenza A virus infections among hospitalized adult bone marrow transplant recipients.8050196Storek J, Hultin LE, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon AClinical immunology and immunopathologyB cell dysfunction after bone marrow transplantation is associated with decreased Ca2+ flux upon membrane Ig crosslinking. Clin Immunol Immunopathol. 1994 Aug; 72(2):210-6.Clin Immunol Immunopathol1994-08-01T00:00:001994B cell dysfunction after bone marrow transplantation is associated with decreased Ca2+ flux upon membrane Ig crosslinking.8094309Ippoliti C, Przepiorka D, Giralt S, Andersson BS, Wallerstein RO, Gutterman J, Deisseroth AB, Champlin REBone marrow transplantationLow-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation. Bone Marrow Transplant. 1993 Jan; 11(1):55-9.Bone Marrow Transplant1993-01-01T00:00:001993Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.8104539Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading CBloodThiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood. 1993 Oct 15; 82(8):2324-8.Blood1993-10-15T00:00:001993Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma.8135448Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringd?n O, Stone JA, Bortin MMAnnals of internal medicineIdentical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994 Apr 15; 120(8):646-52.Ann Intern Med1994-04-15T00:00:001994Identical-twin bone marrow transplants for leukemia.8151324Meyers CA, Weitzner M, Byrne K, Valentine A, Champlin RE, Przepiorka DJournal of clinical oncology : official journal of the American Society of Clinical OncologyEvaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation. J Clin Oncol. 1994 Apr; 12(4):820-6.J Clin Oncol1994-04-01T00:00:001994Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation.8275039Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon ABone marrow transplantationB cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant. 1993 Oct; 12(4):387-98.Bone Marrow Transplant1993-10-01T00:00:001993B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny?8324232Parks NJ, Kawakami TG, Avila MJ, White R, Cain GR, Raaka SD, Hornoff W, Fisher P, Moore P, Seibert JABloodBone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP). Blood. 1993 Jul 01; 82(1):318-25.Blood1993-07-01T00:00:001993Bone marrow transplantation in dogs after radio-ablation with a new Ho-166 amino phosphonic acid bone-seeking agent (DOTMP).8354039Ippoliti C, Przepiorka D, Smith T, Maiese S, Giralt S, Andersson BS, Deisseroth AB, Champlin REClinical pharmacyAdverse effects of molgramostim in marrow transplant recipients. Clin Pharm. 1993 Jul; 12(7):520-5.Clin Pharm1993-07-01T00:00:001993Adverse effects of molgramostim in marrow transplant recipients.8380243Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin REAnnals of internal medicineGanciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993 Feb 01; 118(3):179-84.Ann Intern Med1993-02-01T00:00:001993Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial.8427991Ringd?n O, Horowitz MM, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RLBloodMethotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993 Feb 15; 81(4):1094-101.Blood1993-02-15T00:00:001993Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?8429851Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough JThe New England journal of medicineAnalysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993 Mar 04; 328(9):593-602.N Engl J Med1993-03-04T00:00:001993Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.8520499Alexanian R, Dimopoulos MA, Delasalle KB, Hester J, Champlin RStem cells (Dayton, Ohio)Myeloablative therapy for primary resistant multiple myeloma. Stem Cells. 1995 Aug; 13 Suppl 2:118-21.Stem Cells1995-08-01T00:00:001995Myeloablative therapy for primary resistant multiple myeloma.8558917Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee-Downey PS, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, Prentice HG, Reiffers J, Rimm AA, Bortin MMLeukemiaChemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996 Jan; 10(1):13-9.Leukemia1996-01-01T00:00:001996Chemotherapy versus transplants for acute myelogenous leukemia in second remission.8600543Champlin RESeminars in oncologyPeripheral blood progenitor cells: a replacement for marrow transplantation? Semin Oncol. 1996 Apr; 23(2 Suppl 4):15-21.Semin Oncol1996-04-01T00:00:001996Peripheral blood progenitor cells: a replacement for marrow transplantation?8701453Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B, Norfleet F, Chan KW, Champlin R, K?rbling MTransfusionClinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996 Jul; 36(7):590-5.Transfusion1996-07-01T00:00:001996Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.8830827McCarthy PL, Williams L, Harris-Bacile M, Yen J, Przepiorka D, Ippoliti C, Champlin R, Fay J, Blosch C, Jacobs C, Anasetti CTransplantationA clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. Transplantation. 1996 Sep 15; 62(5):626-31.Transplantation1996-09-15T00:00:001996A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease.8929023Khouri I, Champlin RAnnals of internal medicineAllogenic bone marrow transplantation in chronic lymphocytic leukemia. Ann Intern Med. 1996 Nov 01; 125(9):780.Ann Intern Med1996-11-01T00:00:001996Allogenic bone marrow transplantation in chronic lymphocytic leukemia.8932841K?rbling M, Chan KW, Anderlini P, Seong D, Durett A, Langlinais A, Przepiorka D, Gajewski J, Miller P, Sundberg J, Alilaen P, Bojko P, Mirza N, Claxton D, van Besien K, Khouri I, Andersson B, Mehra R, Champlin RBone marrow transplantationAllogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90.Bone Marrow Transplant1996-11-01T00:00:001996Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors.8938521Przepiorka D, Van Vlasselaer P, Huynh L, Durett A, Agbor P, Lauppe J, Valone F, Champlin R, K?rbling MJournal of hematotherapyRapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by semiautomated density gradient centrifugation in a closed system. J Hematother. 1996 Oct; 5(5):497-502.J Hematother1996-10-01T00:00:001996Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by semiautomated density gradient centrifugation in a closed system.8971373Greenberg P, Advani R, Keating A, Gulati SC, Nimer S, Champlin R, Karanes C, Gorin NC, Powles RL, Smith A, Lamborn K, Cuffie CBone marrow transplantationGM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1057-64.Bone Marrow Transplant1996-12-01T00:00:001996GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.8991538K?rbling M, Champlin RStem cells (Dayton, Ohio)Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. Stem Cells. 1996 Mar; 14(2):185-95.Stem Cells1996-03-01T00:00:001996Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts.9028934Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin REBloodUse of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997 Feb 15; 89(4):1133-42.Blood1997-02-15T00:00:001997Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.9029035Anderlini P, Lauppe J, Przepiorka D, Seong D, Champlin R, K?rbling MBritish journal of haematologyPeripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol. 1997 Feb; 96(2):415-7.Br J Haematol1997-02-01T00:00:001997Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections.9071338Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AUSeminars in oncologyThe University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 3):S30-3.Semin Oncol1997-02-01T00:00:001997The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.9116608de Lima M, van Besien KW, Giralt SA, Khouri IF, Mehra R, Andersson BS, Przepiorka D, Gajewski JL, Korbling M, Champlin REBone marrow transplantationBone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7.Bone Marrow Transplant1997-01-01T00:00:001997Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.9134180Woo MH, Ippoliti C, Bruton J, Mehra R, Champlin R, Przepiorka DBone marrow transplantationHeadache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion. Bone Marrow Transplant. 1997 Apr; 19(8):845-7.Bone Marrow Transplant1997-04-01T00:00:001997Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.9149776Anderlini P, Przepiorka D, Seong C, Smith TL, Huh YO, Lauppe J, Champlin R, K?rbling MTransfusionFactors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 1997 May; 37(5):507-12.Transfusion1997-05-01T00:00:001997Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim.9169641van Besien KW, de Lima M, Giralt SA, Moore DF, Khouri IF, Rond?n G, Mehra R, Andersson BS, Dyer C, Cleary K, Przepiorka D, Gajewski JL, Champlin REBone marrow transplantationManagement of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant. 1997 May; 19(10):977-82.Bone Marrow Transplant1997-05-01T00:00:001997Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.9313883Ippoliti C, Morgan A, Warkentin D, van Besien K, Mehra R, Khouri I, Giralt S, Gajewski J, Champlin R, Andersson B, Przepiorka DBone marrow transplantationFoscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant. 1997 Sep; 20(6):491-5.Bone Marrow Transplant1997-09-01T00:00:001997Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.9373242Shpall EJ, LeMaistre CF, Holland K, Ball E, Jones RB, Saral R, Jacobs C, Heimfeld S, Berenson R, Champlin RBloodA prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood. 1997 Dec 01; 90(11):4313-20.Blood1997-12-01T00:00:001997A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy.9374100Rahman Z, Champlin R, Rondon G, Frye D, Valero V, Mehra R, Hortobagyi GSeminars in oncologyPhase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol. 1997 Oct; 24(5 Suppl 17):S17-77-S17-80.Semin Oncol1997-10-01T00:00:001997Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.9377066Shpall EJJournal of hematotherapyFoundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors. J Hematother. 1997 Aug; 6(4):287-9.J Hematother1997-08-01T00:00:001997Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT) response to FDA (Docket no. 97N-0068). FAHCT Board of Directors.9423812Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos CAmerican journal of hematologyAllogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol. 1998 Jan; 57(1):24-8.Am J Hematol1998-01-01T00:00:001998Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases.9440724Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien KJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome. J Clin Oncol. 1998 Jan; 16(1):63-9.J Clin Oncol1998-01-01T00:00:001998High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.9457395van Besien K, Margolin K, Champlin R, Forman SThe cancer journal from Scientific AmericanActivity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells. Cancer J Sci Am. 1997 Dec; 3 Suppl 1:S54-8.Cancer J Sci Am1997-12-01T00:00:001997Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.9502301Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, Horowitz MM, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KMBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSafeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec; 3(6):331-40.Biol Blood Marrow Transplant1997-12-01T00:00:001997Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation.9508181Ueno NT, Rond?n G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, K?rbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyAllogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.J Clin Oncol1998-03-01T00:00:001998Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer.9558368Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, Kantarjian H, Deisseroth AB, Champlin RC, Feinberg APBloodLoss of imprinting in disease progression in chronic myelogenous leukemia. Blood. 1998 May 01; 91(9):3144-7.Blood1998-05-01T00:00:001998Loss of imprinting in disease progression in chronic myelogenous leukemia.9712491Anderlini P, Przepiorka D, K?rbling M, Champlin RBone marrow transplantationBlood stem cell procurement: donor safety issues. Bone Marrow Transplant. 1998 Jun; 21 Suppl 3:S35-9.Bone Marrow Transplant1998-06-01T00:00:001998Blood stem cell procurement: donor safety issues.9805506Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin RCancer treatment reviewsHigh-dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev. 1998 Aug; 24(4):249-63.Cancer Treat Rev1998-08-01T00:00:001998High-dose chemotherapy with autologous stem cell support in patients with breast cancer.9814655Khouri IF, Keating MJ, Champlin RCurrent opinion in hematologyHematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol. 1998 Nov; 5(6):454-9.Curr Opin Hematol1998-11-01T00:00:001998Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.9850025Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin RJournal of clinical oncology : official journal of the American Society of Clinical OncologyHyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.J Clin Oncol1998-12-01T00:00:001998Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.9920826Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DFBloodDendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999 Feb 01; 93(3):780-6.Blood1999-02-01T00:00:001999Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.9921808Garderet L, Snell V, Przepiorka D, Schenk T, Lu JG, Marini F, Gluckman E, Andreeff M, Champlin RETransplantationEffective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation. 1999 Jan 15; 67(1):124-30.Transplantation1999-01-15T00:00:001999Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations.10084258Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin RBone marrow transplantationAntiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant. 1999 Feb; 23(3):265-9.Bone Marrow Transplant1999-02-01T00:00:001999Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.10188072Champlin R, Khouri I, Kornblau S, Molldrem J, Giralt SCurrent opinion in oncologyReinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999 Mar; 11(2):87-95.Curr Opin Oncol1999-03-01T00:00:001999Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy.10355664Champlin R, Khouri I, Giralt SJournal of clinical apheresisUse of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases. J Clin Apher. 1999; 14(1):45-9.J Clin Apher1999-01-01T00:00:001999Use of nonmyeloablative preparative regimens for allogeneic blood stem cell transplantation: induction of graft-vs.-malignancy as treatment for malignant diseases.10363991Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MMCancer researchA PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999 Jun 01; 59(11):2675-81.Cancer Res1999-06-01T00:00:001999A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.10389945Marini FC, Snell V, Yu Q, Zhang X, Singletary SE, Champlin R, Andreeff MClinical cancer research : an official journal of the American Association for Cancer ResearchPurging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation. Clin Cancer Res. 1999 Jun; 5(6):1557-68.Clin Cancer Res1999-06-01T00:00:001999Purging of contaminating breast cancer cells from hematopoietic stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation.10438735Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R, K?rbling M, Huh YO, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin RBloodRisk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.Blood1999-08-15T00:00:001999Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.10444179Anderlini P, Riggs SA, K?rbling M, Champlin RBritish journal of haematologySyngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Br J Haematol. 1999 Jul; 106(1):159-61.Br J Haematol1999-07-01T00:00:001999Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia.10465104Deeg HJ, Seidel K, Casper J, Anasetti C, Davies S, Gajeweski JL, Territo M, Ramsay N, Harris RE, Catro-Malaspina H, Collins R, Champlin R, Schoch G, King R, Howe CBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationMarrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant. 1999; 5(4):243-52.Biol Blood Marrow Transplant1999-01-01T00:00:001999Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.10490734Maltezou H, Whimbey E, Abi-Said D, Przepiorka D, Champlin R, Goodrich J, Maltazou H, Champlain RBone marrow transplantationCytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study. Bone Marrow Transplant. 1999 Sep; 24(6):665-9.Bone Marrow Transplant1999-09-01T00:00:001999Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.10587972Champlin R, Khouri I, Giralt SPediatric transplantationGraft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality. Pediatr Transplant. 1999; 3 Suppl 1:52-8.Pediatr Transplant1999-01-01T00:00:001999Graft-vs.-malignancy with allogeneic blood stem cell transplantation: a potential primary treatment modality.10631455Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin RAnnals of oncology : official journal of the European Society for Medical OncologyAllogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9.Ann Oncol1999-11-01T00:00:001999Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.10733488McGlave PB, Shu XO, Wen W, Anasetti C, Nademanee A, Champlin R, Antin JH, Kernan NA, King R, Weisdorf DJBloodUnrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000 Apr 01; 95(7):2219-25.Blood2000-04-01T00:00:002000Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program.10800648Ueno NT, Hortobagyi GN, Champlin RECancer treatment and researchAllogeneic peripheral blood progenitor cell transplantation in solid tumors. Cancer Treat Res. 1999; 101:133-56.Cancer Treat Res1999-01-01T00:00:001999Allogeneic peripheral blood progenitor cell transplantation in solid tumors.10849525Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin REBone marrow transplantationHigh-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.Bone Marrow Transplant2000-06-01T00:00:002000High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer.10929027Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, K?rbling MBritish journal of haematologyA comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2.Br J Haematol2000-06-01T00:00:002000A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors.10967575de Lima M, van Besien K, Gajewski J, Khouri I, Andersson B, Korbling M, Champlin R, Giralt SBone marrow transplantationHigh-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.Bone Marrow Transplant2000-08-01T00:00:002000High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.11063377Nieto Y, Champlin RE, Wingard JR, Vredenburgh JF, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EFBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationStatus of high-dose chemotherapy for breast cancer: a review. Biol Blood Marrow Transplant. 2000; 6(5):476-95.Biol Blood Marrow Transplant2000-01-01T00:00:002000Status of high-dose chemotherapy for breast cancer: a review.11091179Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini PBritish journal of haematologyHarnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000 Oct; 111(1):18-29.Br J Haematol2000-10-01T00:00:002000Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.11309292Kornblau SM, Stiouf I, Snell V, Przepiorka D, Stephens LC, Champlin R, Marini FCCancer researchPreemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Cancer Res. 2001 Apr 15; 61(8):3355-60.Cancer Res2001-04-15T00:00:002001Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.11360107Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM, IBMTR Statistical Center of the International Bone Marrow Transplant Registry, Medical College of Wi, EBMT, Kiel, GermanyBone marrow transplantationPeripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001 Apr; 27(7):689-92.Bone Marrow Transplant2001-04-01T00:00:002001Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases.11436116Champlin R, Khouri I, Anderlini P, Gajewski J, Kornblau S, Molldrem J, Shimoni A, Ueno N, Giralt SBone marrow transplantationNonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2001 May; 27 Suppl 2:S13-22.Bone Marrow Transplant2001-05-01T00:00:002001Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.11438816Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, Giralt SBone marrow transplantationHigh-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant. 2001 May; 27(10):1027-9.Bone Marrow Transplant2001-05-01T00:00:002001High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia.11438818Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, Champlin RBone marrow transplantationImpact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant. 2001 May; 27(10):1037-43.Bone Marrow Transplant2001-05-01T00:00:002001Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.11722994Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EHHematology. American Society of Hematology. Education ProgramNon-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program. 2001; 375-91.Hematology Am Soc Hematol Educ Program2001-01-01T00:00:002001Non-myeloablative transplants for malignant disease.11760089Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75.Biol Blood Marrow Transplant2001-01-01T00:00:002001Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.11777103Champlin RE, Whimbey EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCommunity respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant. 2001; 7 Suppl:8S-10S.Biol Blood Marrow Transplant2001-01-01T00:00:002001Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience.11861270van Rood JJ, Loberiza FR, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringd?n O, Hows JM, Horowitz MHBloodEffect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002 Mar 01; 99(5):1572-7.Blood2002-03-01T00:00:002002Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.11899644Montemurro F, Ueno NT, Rond?n G, Aglietta M, Champlin REClinical breast cancerHigh-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer. 2000 Oct; 1(3):197-209; discussion 210.Clin Breast Cancer2000-10-01T00:00:002000High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends.12058236Montemurro F, Rond?n G, Ueno NT, Munsell M, Gajewski JL, Champlin REBone marrow transplantationFactors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy. Bone Marrow Transplant. 2002 May; 29(10):861-6.Bone Marrow Transplant2002-05-01T00:00:002002Factors affecting progression-free survival in hormone-dependent metastatic breast cancer patients receiving high-dose chemotherapy and hematopoietic progenitor cell transplantation: role of maintenance endocrine therapy.12097260Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff MCancer researchBone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002 Jul 01; 62(13):3603-8.Cancer Res2002-07-01T00:00:002002Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.12176876Kantarjian HM, O'Brien S, Cortes JE, Giralt SA, Rios MB, Shan J, Giles FJ, Thomas DA, Faderl S, De Lima M, Garcia-Manero G, Champlin R, Arlinghaus R, Talpaz MBloodImatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002 Sep 01; 100(5):1590-5.Blood2002-09-01T00:00:002002Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.12420204Anderlini P, Chan FA, Champlin RE, K?rbling M, Strom SSBone marrow transplantationLong-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002 Nov; 30(10):661-3.Bone Marrow Transplant2002-11-01T00:00:002002Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development.12702528Hosing C, Saliba RM, McLaughlin P, Andersson B, Rodriguez MA, Fayad L, Cabanillas F, Champlin RE, Khouri IFAnnals of oncology : official journal of the European Society for Medical OncologyLong-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol. 2003 May; 14(5):737-44.Ann Oncol2003-05-01T00:00:002003Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.12881308Ueno NT, Cheng YC, Rond?n G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin REBloodRapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003 Nov 15; 102(10):3829-36.Blood2003-07-24T00:00:002003Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors.14523458Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima MLeukemiaUnrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia. 2003 Dec; 17(12):2538-40.Leukemia2003-12-01T00:00:002003Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant.14635076Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock RCancerSequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses. Cancer. 2003 Dec 01; 98(11):2410-9.Cancer2003-12-01T00:00:002003Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.14725898Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin REExperimental hematologyNonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan; 32(1):28-35.Exp Hematol2004-01-01T00:00:002004Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.14970933Khouri IF, Champlin RESeminars in oncologyNonmyeloablative stem cell transplantation for lymphoma. Semin Oncol. 2004 Feb; 31(1):22-6.Semin Oncol2004-02-01T00:00:002004Nonmyeloablative stem cell transplantation for lymphoma.15048141Mittal P, Saliba RM, Giralt SA, Shahjahan M, Cohen AI, Karandish S, Onida F, Beran M, Champlin RE, de Lima MBone marrow transplantationAllogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone Marrow Transplant. 2004 May; 33(10):1005-9.Bone Marrow Transplant2004-05-01T00:00:002004Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.15048145Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D, Khouri IF, Gajewski J, Claxton D, Giralt S, Rodriguez M, Romaguera J, Hagemeister F, Ha C, Cox J, Cabanillas F, Andersson BS, Champlin REBone marrow transplantationPrognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant. 2004 May; 33(10):1015-23.Bone Marrow Transplant2004-05-01T00:00:002004Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.15090449de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt SBloodNonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 01; 104(3):865-72.Blood2004-04-15T00:00:002004Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.15197204Escal?n MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, Giralt S, Ueno NT, Maadani F, Pro B, Donato M, McLaughlin P, Khouri IFJournal of clinical oncology : official journal of the American Society of Clinical OncologyNonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004 Jun 15; 22(12):2419-23.J Clin Oncol2004-06-15T00:00:002004Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.15220957Jabbour E, Keating MJ, Champlin RE, Khouri IFBone marrow transplantationStem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant. 2004 Aug; 34(4):289-97.Bone Marrow Transplant2004-08-01T00:00:002004Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?15222001Patel SR, Papadopolous N, Raymond AK, Donato M, Seong CM, Yasko AW, Lewis VO, Lin PP, Champlin R, Benjamin RSCancerA phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer. 2004 Jul 01; 101(1):156-63.Cancer2004-07-01T00:00:002004A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.15271401Qazilbash MH, Giralt SA, Champlin REHematology/oncology clinics of North AmericaNonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004 Jun; 18(3):703-13, xi.Hematol Oncol Clin North Am2004-06-01T00:00:002004Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.15284108Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KVBloodFunctional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004 Dec 01; 104(12):3429-36.Blood2004-07-29T00:00:002004Functional assessment and specific depletion of alloreactive human T cells using flow cytometry.15314060Ueno NT, Shpall EJ, Champlin RE, Jones RBJournal of clinical oncology : official journal of the American Society of Clinical OncologyGraft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. J Clin Oncol. 2004 Oct 01; 22(19):3846-7.J Clin Oncol2004-08-16T00:00:002004Graft--versus--breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier.15505610Cheng YC, Rond?n G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NTBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationThe use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. Biol Blood Marrow Transplant. 2004 Nov; 10(11):794-804.Biol Blood Marrow Transplant2004-11-01T00:00:002004The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.15523088Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff MJournal of the National Cancer InstituteMesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004 Nov 03; 96(21):1593-603.J Natl Cancer Inst2004-11-03T00:00:002004Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.15564543Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MMThe New England journal of medicineOutcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004 Nov 25; 351(22):2265-75.N Engl J Med2004-11-25T00:00:002004Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.15570660Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, Champlin REThe Journal of rheumatologyNonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol. 2004 Dec; 31(12):2513-6.J Rheumatol2004-12-01T00:00:002004Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus.15937511Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima MBone marrow transplantationDisease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 2005 Jul; 36(2):157-62.Bone Marrow Transplant2005-07-01T00:00:002005Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.16081352K?rbling M, Robinson S, Estrov Z, Champlin R, Shpall ECytotherapyUmbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61.Cytotherapy2005-01-01T00:00:002005Umbilical cord blood-derived cells for tissue repair.16239431Khoury HJ, Loberiza FR, Ringd?n O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MMBloodImpact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1712-6.Blood2005-10-20T00:00:002005Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.16370093Wagner J, Champlin R, Petz LDBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSymposium summary. Biol Blood Marrow Transplant. 2005 Nov; 11(11):921-7.Biol Blood Marrow Transplant2005-11-01T00:00:002005Symposium summary.16399600Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U, Donato M, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationExtracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):37-40.Biol Blood Marrow Transplant2006-01-01T00:00:002006Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?16456814Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, Roden L, Champlin R, Giralt SACancerSecond autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer. 2006 Mar 01; 106(5):1084-9.Cancer2006-03-01T00:00:002006Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.16565737Ueno NT, Konoplev S, Buchholz TA, Smith T, Rond?n G, Anderlini P, Giralt SA, Gajewski JL, Donato ML, Cristofanilli M, Champlin REBone marrow transplantationHigh-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant. 2006 May; 37(10):929-35.Bone Marrow Transplant2006-05-01T00:00:002006High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.16710033Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyClinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20; 24(15):2343-51.J Clin Oncol2006-05-20T00:00:002006Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.16923569Qazilbash MH, Saliba RM, Aleman A, Lei X, Weber D, Carrasco A, Champlin RE, Giralt SALeukemia & lymphomaRisk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leuk Lymphoma. 2006 Jul; 47(7):1360-4.Leuk Lymphoma2006-07-01T00:00:002006Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.17138825Saliba RM, de Lima M, Giralt S, Andersson B, Khouri IF, Hosing C, Ghosh S, Neumann J, Hsu Y, De Jesus J, Qazilbash MH, Champlin RE, Couriel DRBloodHyperacute GVHD: risk factors, outcomes, and clinical implications. Blood. 2007 Apr 01; 109(7):2751-8.Blood2007-04-01T00:00:002007Hyperacute GVHD: risk factors, outcomes, and clinical implications.17222753Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D, Pierre B, Shpall EJ, Jones RB, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 Jan; 13(1):56-64.Biol Blood Marrow Transplant2007-01-01T00:00:002007Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.17475907Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, Camitta BM, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Schattenberg AV, Socie G, Eapen MBloodWorse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007 Aug 15; 110(4):1397-400.Blood2007-05-02T00:00:002007Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.17594720Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R, Wu X, Li DCancerElevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence. Cancer. 2007 Aug 01; 110(3):534-42.Cancer2007-08-01T00:00:002007Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence.17640602Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NTBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationNatural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Aug; 13(8):975-85.Biol Blood Marrow Transplant2007-08-01T00:00:002007Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.17671230Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, Bryan SG, Kaur I, Martin S, Wieder ED, Worth L, Cooper LJ, Petropoulos D, Molldrem JJ, Champlin RE, Shpall EJBloodDelayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007 Dec 15; 110(13):4543-51.Blood2007-08-01T00:00:002007Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing.18347568Lee HJ, Gulbis A, De Padua Silva L, Hosing C, Khouri I, de Lima M, Champlin RE, Ciurea SOBone marrow transplantationRituximab for passenger lymphocyte syndrome associated with allogeneic SCT. Bone Marrow Transplant. 2008 Jul; 42(1):67-9.Bone Marrow Transplant2008-03-17T00:00:002008Rituximab for passenger lymphocyte syndrome associated with allogeneic SCT.18640568Rond?n G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008 Aug; 14(8):859-66.Biol Blood Marrow Transplant2008-08-01T00:00:002008Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.19151791De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi FBone marrow transplantationFeasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant. 2009 Jun; 43(11):839-43.Bone Marrow Transplant2009-01-19T00:00:002009Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome.19450756Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, K?rbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.Biol Blood Marrow Transplant2009-04-08T00:00:002009Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.19778850Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cort?s JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt SClinical lymphoma & myelomaNonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.Clin Lymphoma Myeloma2009-01-01T00:00:002009Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.20005966Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat UBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9.Biol Blood Marrow Transplant2010-01-29T00:00:002010Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.20575022Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MHAmerican journal of hematologyThe outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol. 2010 Jul; 85(7):502-4.Am J Hematol2010-07-01T00:00:002010The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.21252098Komanduri KV, Champlin REBloodCan Treg therapy prevent GVHD? Blood. 2011 Jan 20; 117(3):751-2.Blood2011-01-20T00:00:002011Can Treg therapy prevent GVHD?21423123Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SABone marrow transplantationLong-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant. 2012 Feb; 47(2):212-6.Bone Marrow Transplant2011-03-21T00:00:002011Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR.21551006Hosing C, Champlin REAnnals of oncology : official journal of the European Society for Medical OncologyStem-cell transplantation in T-cell non-Hodgkin's lymphomas. Ann Oncol. 2011 Jul; 22(7):1471-1477.Ann Oncol2011-05-05T00:00:002011Stem-cell transplantation in T-cell non-Hodgkin's lymphomas.21575005Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, Khouri I, de Lima M, Balzer RJ, McMannis J, Champlin R, Giralt S, Popat UTransfusionAssessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. 2011 Jun; 51(6):1300-13.Transfusion2011-05-16T00:00:002011Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation.21677312Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JC, Deeg HJBloodEffect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011 Sep 01; 118(9):2618-21.Blood2011-06-15T00:00:002011Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.21859247Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RELeukemia & lymphomaGemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502.Leuk Lymphoma2011-10-24T00:00:002011Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.21887685Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MHCancerA randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.Cancer2011-09-01T00:00:002011A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.22023525Bashir Q, Munsell MF, Giralt S, de Padua Silva L, Sharma M, Couriel D, Chiattone A, Popat U, Qazilbash MH, Fernandez-Vina M, Champlin RE, de Lima MJLeukemia & lymphomaRandomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant. Leuk Lymphoma. 2012 May; 53(5):915-9.Leuk Lymphoma2011-12-05T00:00:002011Randomized phase II trial comparing two dose levels of thymoglobulin in patients undergoing unrelated donor hematopoietic cell transplant.22086552Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MHCancerDurable remission with salvage second autotransplants in patients with multiple myeloma. Cancer. 2012 Jul 15; 118(14):3549-55.Cancer2011-11-15T00:00:002011Durable remission with salvage second autotransplants in patients with multiple myeloma.22107246Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJHuman gene therapyInfusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012 May; 23(5):444-50.Hum Gene Ther2012-01-17T00:00:002012Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.22228624Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes JBloodImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012 Mar 01; 119(9):1981-7.Blood2012-01-06T00:00:002012Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.22282904Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NTThe oncologistPhase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist. 2012; 17(2):233-8.Oncologist2012-01-26T00:00:002012Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.22329587Farhan S, Lee DA, Champlin RE, Ciurea SOImmunotherapyNK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy. 2012 Mar; 4(3):305-13.Immunotherapy2012-02-13T00:00:002012NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation.22535661Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovich B, Rabinovitch B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJBloodA foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012 Jun 14; 119(24):5697-705.Blood2012-04-24T00:00:002012A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.22922522Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationFifty years of melphalan use in hematopoietic stem cell?transplantation. Biol Blood Marrow Transplant. 2013 Mar; 19(3):344-56.Biol Blood Marrow Transplant2012-08-24T00:00:002012Fifty years of melphalan use in hematopoietic stem cell?transplantation.23006952Khouri IF, Champlin RECancer journal (Sudbury, Mass.)Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma. Cancer J. 2012 Sep-Oct; 18(5):457-62.Cancer J2012-09-01T00:00:002012Nonmyeloablative allogeneic stem cell transplantation for non-hodgkin lymphoma.23075018Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJJournal of biopharmaceutical statisticsBayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat. 2012; 22(6):1206-19.J Biopharm Stat2012-01-01T00:00:002012Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.23085830Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei PBone marrow transplantationOutcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013 May; 48(5):666-70.Bone Marrow Transplant2012-10-22T00:00:002012Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.23345254Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima MAmerican journal of hematologyAllogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.Am J Hematol2013-01-24T00:00:002013Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.23361908Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin REBloodWho is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? Blood. 2013 Mar 28; 121(13):2567-73.Blood2013-01-29T00:00:002013Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?23407473Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJJournal of visualized experiments : JoVEClinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013 Feb 01; (72):e50070.J Vis Exp2013-02-01T00:00:002013Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood.24155780Cheng YC, Rond?n G, Anderlini P, Khouri IF, Champlin RE, Ueno NTJournal of CancerPaclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2013; 4(8):679-85.J Cancer2013-09-27T00:00:002013Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation.24309534Champlin RBest practice & research. Clinical haematologyReduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. Best Pract Res Clin Haematol. 2013 Sep; 26(3):297-300.Best Pract Res Clin Haematol2013-10-16T00:00:002013Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia.24311716Champlin REBloodBusulfan or TBI: answer to an age-old question. Blood. 2013 Dec 05; 122(24):3856-7.Blood2013-12-05T00:00:002013Busulfan or TBI: answer to an age-old question.24375125Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang MAnnals of hematologyAccelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014 Apr; 93(4):541-56.Ann Hematol2013-12-28T00:00:002013Accelerated therapeutic progress in diffuse large B cell lymphoma.25013162Champlin RBloodAcute graft-versus-host disease: more than just alloreactivity. Blood. 2014 Jul 10; 124(2):163-4.Blood2014-07-10T00:00:002014Acute graft-versus-host disease: more than just alloreactivity.Authorship 2355787Authorship 2356355Authorship 2356593Authorship 2356995Authorship 2357321Authorship 2357501Authorship 2359386Authorship 2360082Authorship 2361173Authorship 2362318Authorship 2362922Authorship 2363415Authorship 2363481Authorship 2364171Authorship 2364661Authorship 2367401Authorship 2367821Authorship 2369025Authorship 2369252Authorship 2369572Authorship 2369877Authorship 2370221Authorship 2370231Authorship 2371161Authorship 2371441Authorship 237147Authorship 2372364Authorship 2373851Authorship 2374012Authorship 2374172Authorship 2375831Authorship 2376762Authorship 2380594Authorship 238093Authorship 2382141Authorship 2382151Authorship 2383094Authorship 2383135Authorship 2383144Authorship 2383182Authorship 23890112Authorship 2389536Authorship 2389765Authorship 2389851Authorship 2390405Authorship 2391351Authorship 2391882Authorship 2391952Authorship 2392097Authorship 23923716Authorship 2392533Authorship 2392764Authorship 2393581Authorship 2393663Authorship 2393913Authorship 2393946Authorship 2394256Authorship 2395184Authorship 23964615Authorship 23977413Authorship 23981011Authorship 2398316Authorship 2398376Authorship 2398519Authorship 2399895Authorship 2400059Authorship 2401154Authorship 2401343Authorship 2402252Authorship 2402975Authorship 2405138Authorship 2405862Authorship 24069713Authorship 2409333Authorship 2409999Authorship 2410855Authorship 2411361Authorship 2412519Authorship 2414007Authorship 2415194Authorship 2415605Authorship 2415998Authorship 2416543Authorship 2416572Authorship 2416785Authorship 24169620Authorship 24174713Authorship 2417946Authorship 24206817Authorship 2421421Authorship 24221815Authorship 2423042Authorship 24233614Authorship 2423445Authorship 24258417Authorship 24268014Authorship 24284112Authorship 2428554Authorship 2429141Authorship 24296011Authorship 24323212Authorship 2436654Authorship 24368620Authorship 2438789Authorship 24391515Authorship 2439246Authorship 2440194Authorship 24419110Authorship 2443322Authorship 2448659Authorship 2449458Authorship 24510516Authorship 2452294Authorship 2456025Authorship 2456185Authorship 2457855Authorship 24583112Authorship 24614210Authorship 2461843Authorship 2463263Authorship 24648320Authorship 2466786Authorship 24692520Authorship 2469819Authorship 2470584Authorship 24715211Authorship 2472083Authorship 2472454Authorship 24727812Authorship 24769210Authorship 2478919Authorship 24805311Authorship 2481533Authorship 2486107Authorship 2489638Authorship 2490073Authorship 24903011Authorship 24931217Authorship 24965816Authorship 2502588Authorship 2503029Authorship 2503776Authorship 25051413Authorship 25071411Authorship 2511359Authorship 2513396Authorship 2519306Authorship 2522136Authorship 25250914Authorship 25313217Authorship 25363110Authorship 2537797Authorship 25384110Authorship 2539249Authorship 25394310Authorship 2540165Authorship 2541387Authorship 2543869Authorship 2543933Authorship 2545526Authorship 2546944Authorship 25474712Authorship 2550401Authorship 25516210Authorship 2554003Authorship 25597016Authorship 2561886Authorship 25620515Authorship 2562509Authorship 25637815Authorship 25640318Authorship 2564337Authorship 2565787Authorship 25699112Authorship 2570632Authorship 25712218Authorship 2574971Authorship 2576024Authorship 25760512Authorship 25816216Authorship 25823620Authorship 25845510Authorship 2588538Authorship 2589611Authorship 2589776Authorship 25914413Authorship 25916714Authorship 25921212Authorship 25959018Authorship 25960610Authorship 2598565Authorship 25992715Authorship 25999613Authorship 2600573Authorship 26018410Authorship 26029115Authorship 26051012Authorship 26054312Authorship 2607514Authorship 2610249Authorship 26132720Authorship 2614714Authorship 2617373Authorship 262100Authorship 2622661Authorship 2622981Authorship 2623521Authorship 2623546Authorship 2625542Authorship 2626085Authorship 2626133Authorship 2626154Authorship 26262891089714Champlin R, Hunter RLJournal of immunology (Baltimore, Md. : 1950)Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens. J Immunol. 1975 Jan; 114(1 Pt 1):76-80.J Immunol1975-01-01T00:00:001975Studies on the composition of adjuvants which selectively enhance delayed-type hypersensitivity to lipid conjugated protein antigens.1321298Bortin MM, Horowitz MM, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb HJ, Marmont AM, Mrsic MJAMAChanging trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA. 1992 Aug 05; 268(5):607-12.JAMA1992-08-05T00:00:001992Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s.1467513Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin RBloodLong-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood. 1992 Dec 15; 80(12):2977-82.Blood1992-12-15T00:00:001992Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.1586723Horowitz MM, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringd?n O, Bortin MMBloodShould HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood. 1992 May 15; 79(10):2771-4.Blood1992-05-15T00:00:001992Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers?1672615Ugozzoli L, Yam P, Petz LD, Ferrara GB, Champlin RE, Forman SJ, Koyal D, Wallace RBBloodAmplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood. 1991 Apr 01; 77(7):1607-15.Blood1991-04-01T00:00:001991Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation.1727924Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JLJournal of clinical oncology : official journal of the American Society of Clinical OncologyBone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol. 1992 Jan; 10(1):41-6.J Clin Oncol1992-01-01T00:00:001992Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.1899162Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert TTransplantation proceedingsRetention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc. 1991 Feb; 23(1 Pt 2):1695-6.Transplant Proc1991-02-01T00:00:001991Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia.1933061Storb R, Champlin REBone marrow transplantationBone marrow transplantation for severe aplastic anemia. Bone Marrow Transplant. 1991 Aug; 8(2):69-72.Bone Marrow Transplant1991-08-01T00:00:001991Bone marrow transplantation for severe aplastic anemia.1976345Champlin RECancer treatment and researchBone marrow transplantation: introduction and overview. Cancer Treat Res. 1990; 50:1-7.Cancer Treat Res1990-01-01T00:00:001990Bone marrow transplantation: introduction and overview.1976357Champlin RCancer treatment and researchRole of bone marrow transplantation as treatment for victims of nuclear accidents. Cancer Treat Res. 1990; 50:299-306.Cancer Treat Res1990-01-01T00:00:001990Role of bone marrow transplantation as treatment for victims of nuclear accidents.2143325Gajewski JL, Ho WG, Feig SA, Hunt L, Kaufman N, Champlin RETransplantationBone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation. 1990 Aug; 50(2):244-9.Transplantation1990-08-01T00:00:001990Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure.2170002Sun GX, Sparkes RS, Wormsley S, Naeim F, Champlin R, Gale RPCancer genetics and cytogeneticsAre some cases of acute leukemia with t(8;21) hybrid leukemias? Cancer Genet Cytogenet. 1990 Oct 15; 49(2):177-84.Cancer Genet Cytogenet1990-10-15T00:00:001990Are some cases of acute leukemia with t(8;21) hybrid leukemias?2189137Champlin RE, Nimer SD, Oette D, Golde DWProgress in clinical and biological researchEffects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis. Prog Clin Biol Res. 1990; 338:143-50.Prog Clin Biol Res1990-01-01T00:00:001990Effects of recombinant human granulocyte-macrophage colony-stimulating factor as treatment for aplastic anemia and agranulocytosis.2193019Champlin RHematology/oncology clinics of North AmericaT-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am. 1990 Jun; 4(3):687-98.Hematol Oncol Clin North Am1990-06-01T00:00:001990T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.2197266Naeim F, Champlin R, Nimer SHematologic pathologyBone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF. Hematol Pathol. 1990; 4(2):79-85.Hematol Pathol1990-01-01T00:00:001990Bone marrow changes in patients with refractory aplastic anemia treated by recombinant GM-CSF.2495694Champlin R, Gajewski J, Feig S, Giorgi J, Lyddane N, Lee K, Schmidt I, Winston D, Ho W, Reichert TTransplantation proceedingsSelective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc. 1989 Feb; 21(1 Pt 3):2947-8.Transplant Proc1989-02-01T00:00:001989Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.2563691Cain GR, Champlin R, Jain NExperimental hematologyImmune thrombocytopenia in dogs after fetal liver hematopoietic cell transplantation. Exp Hematol. 1989 Mar; 17(3):287-91.Exp Hematol1989-03-01T00:00:001989Immune thrombocytopenia in dogs after fetal liver hematopoietic cell transplantation.2644986Champlin RE, Nimer SD, Ireland P, Oette DH, Golde DWBloodTreatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. Blood. 1989 Feb 15; 73(3):694-9.Blood1989-02-15T00:00:001989Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor.2664512Baranov A, Gale RP, Guskova A, Piatkin E, Selidovkin G, Muravyova L, Champlin RE, Danilova N, Yevseeva L, Petrosyan LThe New England journal of medicineBone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989 Jul 27; 321(4):205-12.N Engl J Med1989-07-27T00:00:001989Bone marrow transplantation after the Chernobyl nuclear accident.2847292Winston DJ, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, Busuttil RW, Champlin REReviews of infectious diseasesGanciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis. 1988 Jul-Aug; 10 Suppl 3:S547-53.Rev Infect Dis1988-07-01T00:00:001988Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients.2866350Goldman JM, Bortin MM, Champlin RE, Herzig RH, McGlave PB, Messner HA, Rimm AA, Speck B, Weiner RSLancet (London, England)Bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1985 Dec 07; 2(8467):1295.Lancet1985-12-07T00:00:001985Bone-marrow transplantation for chronic myelogenous leukaemia.3056171Champlin RE, Kastenberg WE, Gale RPAnnals of internal medicineRadiation accidents and nuclear energy: medical consequences and therapy. Ann Intern Med. 1988 Nov 01; 109(9):730-44.Ann Intern Med1988-11-01T00:00:001988Radiation accidents and nuclear energy: medical consequences and therapy.3103427Hocking W, Champlin R, Mitsuyasu RAmerican journal of hematologyTransient response of pure red cell aplasia to anti-thymocyte globulin in a patient with T-cell chronic lymphocytic leukemia. Am J Hematol. 1987 Mar; 24(3):285-91.Am J Hematol1987-03-01T00:00:001987Transient response of pure red cell aplasia to anti-thymocyte globulin in a patient with T-cell chronic lymphocytic leukemia.3279516Champlin RE, Goldman JM, Gale RPSeminars in hematologyBone marrow transplantation in chronic myelogenous leukemia. Semin Hematol. 1988 Jan; 25(1):74-80.Semin Hematol1988-01-01T00:00:001988Bone marrow transplantation in chronic myelogenous leukemia.3291930Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle DBritish journal of haematologyBone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br J Haematol. 1988 Jun; 69(2):239-45.Br J Haematol1988-06-01T00:00:001988Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.3526560Golde DW, Jacobs AD, Glaspy JA, Champlin RESeminars in hematologyHairy-cell leukemia: biology and treatment. Semin Hematol. 1986 Jul; 23(3 Suppl 1):3-9.Semin Hematol1986-07-01T00:00:001986Hairy-cell leukemia: biology and treatment.3536244Gale RP, Champlin REClinics in haematologyBone marrow transplantation in acute leukaemia. Clin Haematol. 1986 Aug; 15(3):851-72.Clin Haematol1986-08-01T00:00:001986Bone marrow transplantation in acute leukaemia.3547673Champlin R, Gale RPSeminars in hematologyBone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies. Semin Hematol. 1987 Jan; 24(1):55-67.Semin Hematol1987-01-01T00:00:001987Bone marrow transplantation for acute leukemia: recent advances and comparison with alternative therapies.3547943Champlin RE, Ho WG, Mitsuyasu R, Burnison M, Greenberg P, Holly G, Winston DW, Feig SA, Gale RPTransplantation proceedingsGraft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning. Transplant Proc. 1987 Feb; 19(1 Pt 3):2616-9.Transplant Proc1987-02-01T00:00:001987Graft failure and leukemia relapse following T lymphocyte-depleted bone marrow transplants: effect of intensification of immunosuppressive conditioning.3882039Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, Lenarsky C, Elashoff R, Zighelboim J, Feig SAAnnals of internal medicineTreatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann Intern Med. 1985 Mar; 102(3):285-91.Ann Intern Med1985-03-01T00:00:001985Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy.6116472Gale RP, Champlin RE, Feig SA, Fitchen JHAnnals of internal medicineAplastic anemia: biology and treatment. Ann Intern Med. 1981 Oct; 95(4):477-94.Ann Intern Med1981-10-01T00:00:001981Aplastic anemia: biology and treatment.6311088Winston DJ, Ho WG, Schroff RW, Champlin RE, Gale RPAntimicrobial agents and chemotherapySafety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients. Antimicrob Agents Chemother. 1983 Jun; 23(6):846-51.Antimicrob Agents Chemother1983-06-01T00:00:001983Safety and tolerance of recombinant leukocyte A interferon in bone marrow transplant recipients.6349719Camitta B, O'Reilly RJ, Sensenbrenner L, Rappeport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan DBloodAntithoracic duct lymphocyte globulin therapy of severe aplastic anemia. Blood. 1983 Oct; 62(4):883-8.Blood1983-10-01T00:00:001983Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia.6351777Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RPArchives of internal medicinePneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med. 1983 Sep; 143(9):1735-7.Arch Intern Med1983-09-01T00:00:001983Pneumococcal vaccination of recipients of bone marrow transplants.6362862Champlin RE, Gale RPCancer treatment reportsRole of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants. Cancer Treat Rep. 1984 Jan; 68(1):145-61.Cancer Treat Rep1984-01-01T00:00:001984Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: critical review of syngeneic, autologous, and allogeneic transplants.6377500Champlin RE, Gale RPSeminars in hematologyThe early complications of bone marrow transplantation. Semin Hematol. 1984 Apr; 21(2):101-8.Semin Hematol1984-04-01T00:00:001984The early complications of bone marrow transplantation.6379661Champlin R, Ho W, Bayever E, Winston DJ, Lenarsky C, Feig SA, Gale RPProgress in clinical and biological researchTreatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody. Prog Clin Biol Res. 1984; 148:227-38.Prog Clin Biol Res1984-01-01T00:00:001984Treatment of aplastic anemia: results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T cell antibody.6389812Bayever E, Champlin R, Ho W, Lenarsky C, Storch S, Ladisch S, Gale RP, Feig SAThe Journal of pediatricsComparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr. 1984 Dec; 105(6):920-5.J Pediatr1984-12-01T00:00:001984Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia.7004532Gale RP, Ho W, Feig S, Champlin R, Tesler A, Arenson E, Ladish S, Young L, Winston D, Sparkes R, Fitchen J, Territo M, Sarna G, Wong L, Paik Y, Bryson Y, Golde D, Fahey J, Cline MBloodPrevention of graft rejection following bone marrow transplantation. Blood. 1981 Jan; 57(1):9-12.Blood1981-01-01T00:00:001981Prevention of graft rejection following bone marrow transplantation.7034933Sarna GP, Champlin R, Wells J, Gale RPCancer treatment reportsPhase I study of high-dose mitomycin with autologous bone marrow support. Cancer Treat Rep. 1982 Feb; 66(2):277-82.Cancer Treat Rep1982-02-01T00:00:001982Phase I study of high-dose mitomycin with autologous bone marrow support.7492795Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rond?n G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, K?rbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin RBloodCD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.Blood1995-12-01T00:00:001995CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.7514051Deisseroth AB, Zu Z, Claxton D, Hanania EG, Fu S, Ellerson D, Goldberg L, Thomas M, Janicek K, Anderson WFBloodGenetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76.Blood1994-05-15T00:00:001994Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.7519938K?rbling M, Drach J, Champlin RE, Engel H, Huynh L, Kleine HD, Berenson R, Deisseroth AB, Andreeff MBone marrow transplantationLarge-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant. 1994 May; 13(5):649-54.Bone Marrow Transplant1994-05-01T00:00:001994Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation.7685792Lotzov? E, Savary CA, Champlin REJournal of immunology (Baltimore, Md. : 1950)Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol. 1993 Jun 15; 150(12):5263-9.J Immunol1993-06-15T00:00:001993Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.7738641Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, Dimopoulos MA, Champlin REJournal of nuclear medicine : official publication, Society of Nuclear MedicinePharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med. 1995 May; 36(5):730-7.J Nucl Med1995-05-01T00:00:001995Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.7803259Schiller G, Feig SA, Territo M, Wolin M, Lill M, Belin T, Hunt L, Nimer S, Champlin R, Gajewski JBritish journal of haematologyTreatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol. 1994 Sep; 88(1):72-8.Br J Haematol1994-09-01T00:00:001994Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors.7803802Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Champlin RE, Nimer SDBloodLong-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood. 1995 Jan 01; 85(1):283-90.Blood1995-01-01T00:00:001995Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.7888562Scerpella EG, Whimbey EE, Champlin RE, Bodey GPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPericarditis associated with Legionnaires' disease in a bone marrow transplant recipient. Clin Infect Dis. 1994 Dec; 19(6):1168-70.Clin Infect Dis1994-12-01T00:00:001994Pericarditis associated with Legionnaires' disease in a bone marrow transplant recipient.7905320Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Hanania EG, Fu S, Randhawa GS, Cha Y, Fang XStem cells (Dayton, Ohio)Molecular approaches to the diagnosis and treatment of cancer. Stem Cells. 1993 Oct; 11 Suppl 3:129-30.Stem Cells1993-10-01T00:00:001993Molecular approaches to the diagnosis and treatment of cancer.7949117Giralt SA, Champlin REBloodLeukemia relapse after allogeneic bone marrow transplantation: a review. Blood. 1994 Dec 01; 84(11):3603-12.Blood1994-12-01T00:00:001994Leukemia relapse after allogeneic bone marrow transplantation: a review.7994043Alexanian R, Dimopoulos MA, Hester J, Delasalle K, Champlin RBloodEarly myeloablative therapy for multiple myeloma. Blood. 1994 Dec 15; 84(12):4278-82.Blood1994-12-15T00:00:001994Early myeloablative therapy for multiple myeloma.8003559Przepiorka D, Dimopoulos M, Smith T, Ippoliti C, Diener K, Luna M, Champlin REAnnals of hematologyThiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Ann Hematol. 1994 Apr; 68(4):183-8.Ann Hematol1994-04-01T00:00:001994Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity.8151318Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SAJournal of clinical oncology : official journal of the American Society of Clinical OncologyAutologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr; 12(4):748-58.J Clin Oncol1994-04-01T00:00:001994Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.8161793Seong DC, Song MY, Henske EP, Zimmerman SO, Champlin RE, Deisseroth AB, Siciliano MJBloodAnalysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid. Blood. 1994 Apr 15; 83(8):2268-73.Blood1994-04-15T00:00:001994Analysis of interphase cells for the Philadelphia translocation using painting probe made by inter-Alu-polymerase chain reaction from a radiation hybrid.8186294Human gene therapyUse of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients). Hum Gene Ther. 1993 Dec; 4(6):821-34.Hum Gene Ther1993-12-01T00:00:001993Use of retroviral markers to identify efficacy of purging and origin of relapse following autologous bone marrow and peripheral blood cell transplantation in indolent B cell neoplasms (follicular non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) patients).8257507Bleyer WA, Champlin RE, Chan KW, Deisseroth ABThe Journal of pediatricsBone marrow transplantation for leukemia. J Pediatr. 1993 Sep; 123(3):492-3.J Pediatr1993-09-01T00:00:001993Bone marrow transplantation for leukemia.8321030Champlin RLeukemiaAllogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia. Leukemia. 1993 Jul; 7(7):1084-6.Leukemia1993-07-01T00:00:001993Allogeneic, syngeneic and autologous bone marrow transplantation for chronic myelogenous leukemia.8431710Weyman C, Graham-Pole J, Emerson S, August C, Champlin R, Coccia P, Fay J, Harris R, Koch P, Johnson LBone marrow transplantationUse of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey. Bone Marrow Transplant. 1993 Jan; 11(1):43-50.Bone Marrow Transplant1993-01-01T00:00:001993Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey.8448555Champlin RBone marrow transplantationBone marrow transplantation for leukemia utilizing HLA-matched unrelated donors. Bone Marrow Transplant. 1993; 11 Suppl 1:74-7.Bone Marrow Transplant1993-01-01T00:00:001993Bone marrow transplantation for leukemia utilizing HLA-matched unrelated donors.8452099Seong DC, Przepiorka D, Bruner JM, Van Tassel P, Lo WK, Champlin REAmerican journal of clinical oncologyLeptomeningeal toxoplasmosis after allogeneic marrow transplantation. Case report and review of the literature. Am J Clin Oncol. 1993 Apr; 16(2):105-8.Am J Clin Oncol1993-04-01T00:00:001993Leptomeningeal toxoplasmosis after allogeneic marrow transplantation. Case report and review of the literature.8457473Dimopoulos MA, Delasalle KB, Champlin R, Alexanian RBritish journal of haematologyCyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol. 1993 Feb; 83(2):240-4.Br J Haematol1993-02-01T00:00:001993Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.8461383Deisseroth AB, Kantarjian H, Talpaz M, Champlin R, Reading C, Andersson B, Claxton DHuman gene therapyUse of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine. Hum Gene Ther. 1993 Feb; 4(1):71-85.Hum Gene Ther1993-02-01T00:00:001993Use of two retroviral markers to test relative contribution of marrow and peripheral blood autologous cells to recovery after preparative therapy. The University of Texas M.D. Anderson Cancer Center. Division of Medicine.8481659Champlin RLeukemia & lymphomaBone marrow transplantation for Hodgkin's disease--recent advances and current issues. Leuk Lymphoma. 1993; 10 Suppl:103-8.Leuk Lymphoma1993-01-01T00:00:001993Bone marrow transplantation for Hodgkin's disease--recent advances and current issues.8501491Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS, Przepiorka D, Deisseroth AB, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyEffect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol. 1993 Jun; 11(6):1055-61.J Clin Oncol1993-06-01T00:00:001993Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.8629675van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin RThe American journal of medicineAllogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996 Mar; 100(3):299-307.Am J Med1996-03-01T00:00:001996Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.8636773Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MMJournal of clinical oncology : official journal of the American Society of Clinical OncologyBone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996 Feb; 14(2):572-8.J Clin Oncol1996-02-01T00:00:001996Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.8701951Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin REAmerican journal of hematologyNeutropenias following allogeneic bone marrow transplantation: response to therapy with high-dose intravenous immunoglobulin. Am J Hematol. 1996 Aug; 52(4):313-5.Am J Hematol1996-08-01T00:00:001996Neutropenias following allogeneic bone marrow transplantation: response to therapy with high-dose intravenous immunoglobulin.8727298Champlin RCurrent opinion in oncologyPurging: elimination of malignant cells from autologous blood or marrow transplants. Curr Opin Oncol. 1996 Mar; 8(2):79-83.Curr Opin Oncol1996-03-01T00:00:001996Purging: elimination of malignant cells from autologous blood or marrow transplants.8835224Deisseroth AB, Holmes F, Hortobagyi G, Champlin RHuman gene therapyUse of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial. Hum Gene Ther. 1996 Feb 10; 7(3):401-16.Hum Gene Ther1996-02-10T00:00:001996Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: a pilot trial.8863780Champlin RTransfusionPurging: the separation of normal from malignant cells for autologous transplantation. Transfusion. 1996 Oct; 36(10):910-8.Transfusion1996-10-01T00:00:001996Purging: the separation of normal from malignant cells for autologous transplantation.8874177Anderlini P, Przepiorka D, Champlin R, K?rbling MBloodBiologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996 Oct 15; 88(8):2819-25.Blood1996-10-15T00:00:001996Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals.8892667Gale RP, B?chner T, Zhang MJ, Heinecke A, Champlin RE, Dicke KA, Gluckman E, Good RA, Gratwohl A, Herzig RH, Keating A, Klein JP, Marmont AM, Prentice HG, Rowlings PA, Sobocinski KA, Speck B, Weiner RS, Horowitz MMLeukemiaHLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia. 1996 Nov; 10(11):1687-91.Leukemia1996-11-01T00:00:001996HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission.8896438Anderlini P, Przepiorka D, Champlin R, K?rbling MBloodPeripheral blood stem cell apheresis in normal donors: the neglected side. Blood. 1996 Nov 01; 88(9):3663-4.Blood1996-11-01T00:00:001996Peripheral blood stem cell apheresis in normal donors: the neglected side.8943876Przepiorka D, Ippoliti C, Khouri I, Woo M, Mehra R, Le Bherz D, Giralt S, Gajewski J, Fischer H, Fritsche H, Deisseroth AB, Cleary K, Champlin R, Besien K, Andersson B, Maher R, Fitzsimmons WBloodTacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996 Dec 01; 88(11):4383-9.Blood1996-12-01T00:00:001996Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.8986814Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth ABProceedings of the National Academy of Sciences of the United States of AmericaResults of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51.Proc Natl Acad Sci U S A1996-12-24T00:00:001996Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.8990368Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, Korbling MTransplantationAllogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.Transplantation1996-12-27T00:00:001996Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus.9052911Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besien K, Andersson B, K?rbling MBone marrow transplantationAllogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.Bone Marrow Transplant1997-03-01T00:00:001997Allogeneic blood stem cell transplantation in advanced hematologic cancers.9111278Seong C, Durett A, Mirza N, Huh Y, Anderlini P, Champlin RTransfusionMobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors. Transfusion. 1997 Apr; 37(4):406-10.Transfusion1997-04-01T00:00:001997Mobilization kinetics of CD34+/Thy-1dim progenitor cells during recombinant human granulocyte-colony-stimulating factor administration in normal donors.9130690Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian HLeukemiaStudies of decitabine with allogeneic progenitor cell transplantation. Leukemia. 1997 Mar; 11 Suppl 1:S32-4.Leukemia1997-03-01T00:00:001997Studies of decitabine with allogeneic progenitor cell transplantation.9159354van Besien K, Verschraegen C, Mehra R, Giralt S, Kudelka AP, Edwards CL, Piamsonboom S, Termrungruanglert W, Champlin R, Kavanagh JJGynecologic oncologyComplete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue. Gynecol Oncol. 1997 May; 65(2):366-9.Gynecol Oncol1997-05-01T00:00:001997Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.9163620Anderlini P, Przepiorka D, Lauppe J, Seong D, Giralt S, Champlin R, K?rbling MBritish journal of haematologyCollection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol. 1997 May; 97(2):485-7.Br J Haematol1997-05-01T00:00:001997Collection of peripheral blood stem cells from normal donors 60 years of age or older.9384668Giralt S, O'Brien S, Talpaz M, Van Besien K, Chan KW, Rond?n G, Andersson B, Mehra R, Khouri I, Estey ECytokines and molecular therapyInterferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22.Cytokines Mol Ther1995-06-01T00:00:001995Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.9419454Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DFCritical reviews in immunologyHuman leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol. 1998; 18(1-2):121-31.Crit Rev Immunol1998-01-01T00:00:001998Human leukemia-derived dendritic cells: ex-vivo development of specific antileukemic cytotoxicity.9443008Piamsomboon S, Kudelka AP, Termrungruanglert W, Van Besien K, Edwards CL, Lifshitz S, Schomer DF, Champlin R, Mante RP, Kavanagh JJ, Verschraegen CFEuropean journal of gynaecological oncologyRemission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature. Eur J Gynaecol Oncol. 1997; 18(6):453-6.Eur J Gynaecol Oncol1997-01-01T00:00:001997Remission of refractory gestational trophoblastic disease in the brain with ifosfamide, carboplatin, and etoposide (ICE): first report and review of literature.9486846Wang MW, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M, Deisseroth ABCell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchRescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ. 1998 Feb; 9(2):105-12.Cell Growth Differ1998-02-01T00:00:001998Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells.9558412Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS, DiPersio J, Rondon G, Champlin R, Barnett MJ, Cornetta K, Herzig GP, Vaughan W, Geils G, Keating A, Messner H, Wolff SN, Miller KB, Linker C, Cairo M, Hellmann S, Ashby M, Stryker S, Nash RABloodA multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood. 1998 May 01; 91(9):3509-17.Blood1998-05-01T00:00:001998A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation.9590491Bojko P, Hester JP, Durett AG, Maadani F, K?rbling M, Champlin REJournal of clinical apheresisIdentification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. J Clin Apher. 1998; 13(1):7-15.J Clin Apher1998-01-01T00:00:001998Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors.9763111Shpall EJ, Champlin R, Glaspy JABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEffect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1998; 4(2):84-92.Biol Blood Marrow Transplant1998-01-01T00:00:001998Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery.9829734Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth AClinical cancer research : an official journal of the American Association for Cancer ResearchChemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2717-21.Clin Cancer Res1998-11-01T00:00:001998Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer.10037025Bachier CR, Giles RE, Ellerson D, Hanania EG, Garcia-Sanchez F, Andreeff M, Cabanillas F, Champlin R, Choudhury R, Berenson R, Heimfeld S, Deisseroth ABLeukemia & lymphomaHematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Jan; 32(3-4):279-88.Leuk Lymphoma1999-01-01T00:00:001999Hematopoietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma.10356683Champlin R, Khouri I, Komblau S, Molidrem J, Giralt SOncology (Williston Park, N.Y.)Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (Williston Park). 1999 May; 13(5):621-8; discussion 631, 635-8, 641.Oncology (Williston Park)1999-05-01T00:00:001999Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect.10435736Warkentin D, Ippoliti C, Bruton J, Van Besien K, Champlin RBone marrow transplantationToxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul; 24(1):57-61.Bone Marrow Transplant1999-07-01T00:00:001999Toxicity of single daily dose gentamicin in stem cell transplantation.10516680Przepiorka D, Khouri I, Ippoliti C, Ueno NT, Mehra R, K?rbling M, Giralt S, Gajewski J, Fischer H, Donato M, Cleary K, Claxton D, Chan KW, Braunschweig I, van Besien K, Andersson BS, Anderlini P, Champlin RBone marrow transplantationTacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.Bone Marrow Transplant1999-10-01T00:00:001999Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.10553260Champlin R, Khouri I, Kornblau S, Marini F, Anderlini P, Ueno NT, Molldrem J, Giralt SHematology/oncology clinics of North AmericaAllogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. Hematol Oncol Clin North Am. 1999 Oct; 13(5):1041-57, vii-viii.Hematol Oncol Clin North Am1999-10-01T00:00:001999Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy.10653889van Besien K, Champlin IK, McCarthy PJournal of clinical oncology : official journal of the American Society of Clinical OncologyAllogeneic transplantation for low-grade lymphoma: long-term follow-up. J Clin Oncol. 2000 Feb; 18(3):702-3.J Clin Oncol2000-02-01T00:00:002000Allogeneic transplantation for low-grade lymphoma: long-term follow-up.10661340Buchholz TA, Tucker SL, Moore RA, McNeese MD, Strom EA, Jhingrin A, Hortobagyi GN, Singletary SE, Champlin REInternational journal of radiation oncology, biology, physicsImportance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiat Oncol Biol Phys. 2000 Jan 15; 46(2):337-43.Int J Radiat Oncol Biol Phys2000-01-15T00:00:002000Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant.10699539Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler SJournal of pain and symptom managementManagement of cancer treatment-related diarrhea. Issues and therapeutic strategies. J Pain Symptom Manage. 2000 Feb; 19(2):118-29.J Pain Symptom Manage2000-02-01T00:00:002000Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.10707996Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2000; 6(1):25-34.Biol Blood Marrow Transplant2000-01-01T00:00:002000A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation.10723575Carella AM, Champlin R, Slavin S, McSweeney P, Storb RBone marrow transplantationMini-allografts: ongoing trials in humans. Bone Marrow Transplant. 2000 Feb; 25(4):345-50.Bone Marrow Transplant2000-02-01T00:00:002000Mini-allografts: ongoing trials in humans.10800646Giralt S, Khouri I, Champlin RCancer treatment and researchNon myeloablative "mini transplants". Cancer Treat Res. 1999; 101:97-108.Cancer Treat Res1999-01-01T00:00:001999Non myeloablative "mini transplants".10816027Przepiorka D, Saliba R, Cleary K, Fischer H, Tonai R, Fritsche H, Khouri IF, Folloder J, Ueno NT, Mehra R, Ippoliti C, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Anderlini P, Andersson BS, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationTacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1. Biol Blood Marrow Transplant. 2000; 6(2A):190-7.Biol Blood Marrow Transplant2000-01-01T00:00:002000Tacrolimus does not abrogate the increased risk of acute graft-versus-host disease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB1 and HLA-DQB1.10845940Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringd?n O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MMBloodT-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000 Jun 15; 95(12):3996-4003.Blood2000-06-15T00:00:002000T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities.10871733Abbott B, Ippoliti C, Hecth D, Bruton J, Whaley B, Champlin RBone marrow transplantationGranisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation. Bone Marrow Transplant. 2000 Jun; 25(12):1279-83.Bone Marrow Transplant2000-06-01T00:00:002000Granisetron (Kytril) plus dexamethasone for antiemetic control in bone marrow transplant patients receiving highly emetogenic chemotherapy with or without total body irradiation.10933185Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, Tarantolo S, Fernandez H, Hu WW, Blume K, Kashyap A, Forman SJ, Champlin REBone marrow transplantationAllogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant. 2000 May; 25 Suppl 2:S35-8.Bone Marrow Transplant2000-05-01T00:00:002000Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy).11041566Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, K?rbling MJ, Manning J, Romaguera J, Sarris A, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin REBone marrow transplantationAllogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.Bone Marrow Transplant2000-09-01T00:00:002000Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.11122834Shimoni A, Giralt S, Khouri I, Champlin RCurrent oncology reportsAllogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect. Curr Oncol Rep. 2000 Mar; 2(2):132-9.Curr Oncol Rep2000-03-01T00:00:002000Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect.11157478Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, Claxton D, Donato M, Bruton J, Cohen A, Davis M, Andersson BS, Anderlini P, Gajewski J, Kornblau S, Andreeff M, Przepiorka D, Ueno NT, Molldrem J, Champlin RBloodMelphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001 Feb 01; 97(3):631-7.Blood2001-02-01T00:00:002001Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.11196151Wang Y, Liu J, Wu Y, Luo W, Lin SH, Lin H, Hawk N, Sun T, Guo JQ, Estrov Z, Talpaz M, Champlin R, Arlinghaus RBCancer researchExpression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death. Cancer Res. 2001 Jan 01; 61(1):138-44.Cancer Res2001-01-01T00:00:002001Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.11231781Esmaeli B, Medeiros LJ, Myers J, Champlin R, Singh S, Ginsberg LArchives of ophthalmology (Chicago, Ill. : 1960)Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation. Arch Ophthalmol. 2001 Mar; 119(3):443-6.Arch Ophthalmol2001-03-01T00:00:002001Orbital mass secondary to precursor T-cell acute lymphoblastic leukemia: a rare presentation.11313669van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas FBone marrow transplantationPhase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. Bone Marrow Transplant. 2001 Feb; 27(4):397-404.Bone Marrow Transplant2001-02-01T00:00:002001Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.11443634Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka DAmerican journal of hematologyThiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol. 2001 Aug; 67(4):227-33.Am J Hematol2001-08-01T00:00:002001Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.11520135Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin REGynecologic oncologyHigh-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol. 2001 Sep; 82(3):420-6.Gynecol Oncol2001-09-01T00:00:002001High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.11739162Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB, Korbling M, Younes A, Ippoliti C, Gajewski JL, McLaughlin P, Anderlini P, Donato ML, Cabanillas FF, Champlin REBloodNonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9.Blood2001-12-15T00:00:002001Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.11745270Gopal R, Ha CS, Tucker SL, Khouri IF, Giralt SA, Gajewski JL, Andersson BS, Cox JD, Champlin RECancerComparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity. Cancer. 2001 Oct 01; 92(7):1949-58.Cancer2001-10-01T00:00:002001Comparison of two total body irradiation fractionation regimens with respect to acute and late pulmonary toxicity.11746533K?rbling M, Giralt S, Khouri I, Mirza N, Donato M, Anderlini P, Fischer H, Andreeff M, McMannis J, Champlin RJournal of clinical apheresisDonor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher. 2001; 16(2):82-7.J Clin Apher2001-01-01T00:00:002001Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis.11751494Kim YS, Konoplev SN, Montemurro F, Hoy E, Smith TL, Rond?n G, Champlin RE, Sahin AA, Ueno NTClinical cancer research : an official journal of the American Association for Cancer ResearchHER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12.Clin Cancer Res2001-12-01T00:00:002001HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.11799530Giralt S, Anagnostopoulos A, Shahjahan M, Champlin R, Anagnastopoulos A, Shahjahanan MSeminars in hematologyNonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol. 2002 Jan; 39(1):57-62.Semin Hematol2002-01-01T00:00:002002Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.12374454Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Blume K, Niland J, Palmer JM, Vaughan W, Fernandez H, Champlin R, Forman S, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIntravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002; 8(9):493-500.Biol Blood Marrow Transplant2002-01-01T00:00:002002Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.12599231de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian HCancerLong-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.Cancer2003-03-01T00:00:002003Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.12766883Montemurro F, Rond?n G, Munsell M, Smith TL, Donato ML, Gajewski JL, Rahman ZU, Buzdar AU, Champlin RE, Ueno NTBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPredicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. Biol Blood Marrow Transplant. 2003 May; 9(5):330-40.Biol Blood Marrow Transplant2003-05-01T00:00:002003Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.12931235K?rbling M, Estrov Z, Champlin RBone marrow transplantationAdult stem cells and tissue repair. Bone Marrow Transplant. 2003 Aug; 32 Suppl 1:S23-4.Bone Marrow Transplant2003-08-01T00:00:002003Adult stem cells and tissue repair.14551133Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian HBloodTreatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15; 103(12):4396-407.Blood2003-10-09T00:00:002003Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.14669282Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RECancerLong-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer. 2003 Dec 15; 98(12):2630-5.Cancer2003-12-15T00:00:002003Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score.14726405El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima MBloodHemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood. 2004 Jun 15; 103(12):4674-80.Blood2004-01-15T00:00:002004Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters.14730336Anagnostopoulos A, Aleman A, Yang Y, Donato M, Weber D, Champlin R, Smith T, Alexanian R, Giralt SBone marrow transplantationOutcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy. Bone Marrow Transplant. 2004 Mar; 33(6):623-8.Bone Marrow Transplant2004-03-01T00:00:002004Outcomes of autologous stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy.15122311Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DMBone marrow transplantationAnalysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004 Jun; 33(12):1219-24.Bone Marrow Transplant2004-06-01T00:00:002004Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation.15124402Pentz RD, Chan KW, Neumann JL, Champlin RE, Korbling MCambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committeesDesigning an ethical policy for bone marrow donation by minors and others lacking capacity. Camb Q Healthc Ethics. 2004; 13(2):149-55.Camb Q Healthc Ethics2004-01-01T00:00:002004Designing an ethical policy for bone marrow donation by minors and others lacking capacity.15160952Donato ML, Aleman A, Champlin RE, Weber D, Alexanian R, Ippoliti CM, de Lima M, Anagnostopoulos A, Giralt SLeukemia & lymphomaHigh-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma. Leuk Lymphoma. 2004 Apr; 45(4):755-9.Leuk Lymphoma2004-04-01T00:00:002004High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma.15170166Alexanian R, Weber D, Delasalle K, Handy B, Champlin R, Giralt SBone marrow transplantationClinical outcomes with intensive therapy for patients with primary resistant multiple myeloma. Bone Marrow Transplant. 2004 Aug; 34(3):229-34.Bone Marrow Transplant2004-08-01T00:00:002004Clinical outcomes with intensive therapy for patients with primary resistant multiple myeloma.15197803Anagnostopoulos A, Aleman A, Ayers G, Donato M, Champlin R, Weber D, Alexanian R, Giralt SCancerComparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer. 2004 Jun 15; 100(12):2607-12.Cancer2004-06-15T00:00:002004Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.15273710Anderlini P, Acholonu SA, Okoroji GJ, Andersson BS, Couriel DR, De Lima MJ, Donato ML, Khouri IF, Giralt SA, Ueno NT, Champlin REBone marrow transplantationDonor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant. 2004 Sep; 34(6):511-4.Bone Marrow Transplant2004-09-01T00:00:002004Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.15322568Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringd?n O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima MBone marrow transplantationSecond transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004 Oct; 34(8):721-7.Bone Marrow Transplant2004-10-01T00:00:002004Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.15372473Couriel D, Caldera H, Champlin R, Komanduri KCancerAcute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer. 2004 Nov 01; 101(9):1936-46.Cancer2004-11-01T00:00:002004Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management.15520055Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Ringd?n O, Wagner JEJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004 Dec 15; 22(24):4872-80.J Clin Oncol2004-11-01T00:00:002004Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.15800314Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyConcurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005 Apr 01; 23(10):2240-7.J Clin Oncol2005-04-01T00:00:002005Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.15806128Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S, Andersson B, Ueno NT, Khouri I, De Lima M, Hosing C, Cohen A, Ippoliti C, Romaguera J, Rodriguez MA, Pro B, Fayad L, Goy A, Younes A, Champlin REBone marrow transplantationReduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant. 2005 May; 35(10):943-51.Bone Marrow Transplant2005-05-01T00:00:002005Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.15830345Kantarjian H, Talpaz M, O'Brien S, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Shan J, Rios MB, Champlin R, de Lima M, Cortes JCancerSurvival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer. 2005 May 15; 103(10):2099-108.Cancer2005-05-15T00:00:002005Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.15993710Aviner S, Yao X, Krauthgamer R, Gan Y, Goren-Arbel R, Klein T, Tabilio A, McMannis JD, Champlin R, Martelli MF, Bachar-Lustig E, Reisner YHuman immunologyLarge-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Hum Immunol. 2005 Jun; 66(6):644-52.Hum Immunol2005-06-01T00:00:002005Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.16007107Lee SA, Diwan AH, Cohn M, Champlin R, Safdar ABone marrow transplantationCutaneous toxoplasmosis: a case of confounding diagnosis. Bone Marrow Transplant. 2005 Sep; 36(5):465-6.Bone Marrow Transplant2005-09-01T00:00:002005Cutaneous toxoplasmosis: a case of confounding diagnosis.16081350Robinson S, Niu T, de Lima M, Ng J, Yang H, McMannis J, Karandish S, Sadeghi T, Fu P, del Angel M, O'Connor S, Champlin R, Shpall ECytotherapyEx vivo expansion of umbilical cord blood. Cytotherapy. 2005; 7(3):243-50.Cytotherapy2005-01-01T00:00:002005Ex vivo expansion of umbilical cord blood.16330461Cheng YC, Saliba RM, Rond?n G, Giralt SA, Lu KH, Bodurka DC, Gershenson DM, Champlin RE, Ueno NTHaematologicaLow prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. Haematologica. 2005 Dec; 90(12):1725-6.Haematologica2005-12-01T00:00:002005Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation.16399595Komanduri KV, Couriel D, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGraft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):1-6.Biol Blood Marrow Transplant2006-01-01T00:00:002006Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis.16435013Petropoulos D, Worth LL, Mullen CA, Madden R, Mahajan A, Choroszy M, Ha CS, Champlin RC, Chan KWBone marrow transplantationTotal body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Bone Marrow Transplant. 2006 Mar; 37(5):463-7.Bone Marrow Transplant2006-03-01T00:00:002006Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.16639731Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GNCancerRandomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer. 2006 Jun 01; 106(11):2327-36.Cancer2006-06-01T00:00:002006Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.16799614Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IFBone marrow transplantationAllogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant. 2006 Aug; 38(3):203-9.Bone Marrow Transplant2006-06-26T00:00:002006Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.16819437Lee HJ, Oran B, Saliba RM, Couriel DM, Shin K, Massey P, Neumann J, de Lima M, Champlin R, Giralt SBone marrow transplantationSteroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy. Bone Marrow Transplant. 2006 Aug; 38(4):299-303.Bone Marrow Transplant2006-07-03T00:00:002006Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapy.17002637K?rbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov ZTransfusionRecombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Oct; 46(10):1795-802.Transfusion2006-10-01T00:00:002006Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.17085303Hymes SR, Turner ML, Champlin RE, Couriel DRBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1101-13.Biol Blood Marrow Transplant2006-11-01T00:00:002006Cutaneous manifestations of chronic graft-versus-host disease.17382251Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant. 2007 Apr; 13(4):454-62.Biol Blood Marrow Transplant2007-02-08T00:00:002007Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.17456058Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos CBritish journal of haematologyGraft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007 May; 137(4):355-63.Br J Haematol2007-05-01T00:00:002007Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia.17559140Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima MCancerNovel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007 Jul 15; 110(2):340-4.Cancer2007-07-15T00:00:002007Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.17572714Patah PA, Parmar S, McMannis J, Sadeghi T, Karandish S, Rondon G, Tarrand J, Champlin R, de Lima M, Shpall EJBone marrow transplantationMicrobial contamination of hematopoietic progenitor cell products: clinical outcome. Bone Marrow Transplant. 2007 Aug; 40(4):365-8.Bone Marrow Transplant2007-06-18T00:00:002007Microbial contamination of hematopoietic progenitor cell products: clinical outcome.17603511Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE, Khouri IFBone marrow transplantationTreatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2007 Sep; 40(5):431-5.Bone Marrow Transplant2007-07-02T00:00:002007Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.17697969Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDeletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72.Biol Blood Marrow Transplant2007-07-16T00:00:002007Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.18342791Anderlini P, Swanston N, Rashid A, Bueso-Ramos C, Macapinlac HA, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEvidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant. 2008 Apr; 14(4):478-80.Biol Blood Marrow Transplant2008-02-14T00:00:002008Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement.18413766Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJCancer researchRedirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008 Apr 15; 68(8):2961-71.Cancer Res2008-04-15T00:00:002008Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.18489993Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOnce daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.Biol Blood Marrow Transplant2008-06-01T00:00:002008Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.18940677Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R, Jagasia M, Kernan NA, Loberiza FR, Bevans M, Soiffer RJ, Joffe SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationVariation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1231-8.Biol Blood Marrow Transplant2008-11-01T00:00:002008Variation in supportive care practices in hematopoietic cell transplantation.19235255Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima MCancerLow-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.Cancer2009-05-01T00:00:002009Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia.19237479Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE, Hosing C, Verstovsek S, Pro BAnnals of oncology : official journal of the European Society for Medical OncologyHepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009 Jun; 20(6):1080-5.Ann Oncol2009-02-23T00:00:002009Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.19448681de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NTBone marrow transplantationProlonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant. 2009 Jul; 44(2):81-7.Bone Marrow Transplant2009-05-18T00:00:002009Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer.19539212Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Popat U, Alousi AM, Champlin RE, Giralt SA, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAutologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6.Biol Blood Marrow Transplant2009-07-01T00:00:002009Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.19767298Friedman MA, Fernandez M, Wefel JS, Myszka KA, Champlin RE, Meyers CAArchives of clinical neuropsychology : the official journal of the National Academy of NeuropsychologistsCourse of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol. 2009 Nov; 24(7):689-98.Arch Clin Neuropsychol2009-09-18T00:00:002009Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design.19822303Armistead PM, de Lima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R, Estey EBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationQuantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1431-8.Biol Blood Marrow Transplant2009-09-01T00:00:002009Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.19896074Wang Y, Li D, Jones D, Bassett R, Sale GE, Khalili J, Komanduri KV, Couriel DR, Champlin RE, Molldrem JJ, Ma QBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationBlocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1513-22.Biol Blood Marrow Transplant2009-10-07T00:00:002009Blocking LFA-1 activation with lovastatin prevents graft-versus-host disease in mouse bone marrow transplantation.19911448Murphy WJ, Artz AS, Champlin RE, Koreth J, Longo DL, van den Brink MRBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationBlood stem cell transplantation in older patients. Biol Blood Marrow Transplant. 2009 Dec; 15(12):1638-9.Biol Blood Marrow Transplant2009-12-01T00:00:002009Blood stem cell transplantation in older patients.20178853Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9.Biol Blood Marrow Transplant2010-02-21T00:00:002010Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.20424114Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJCancer researchCombining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res. 2010 May 15; 70(10):3915-24.Cancer Res2010-04-27T00:00:002010Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.20466853Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian HBloodFirst report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23; 116(12):2070-7.Blood2010-05-13T00:00:002010First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.20564073Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima MCancerStem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010 Aug 01; 116(15):3631-7.Cancer2010-08-01T00:00:002010Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.20574820Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJBiomedical microdevicesA high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices. 2010 Oct; 12(5):855-63.Biomed Microdevices2010-10-01T00:00:002010A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.20672358de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero GCancerMaintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer. 2010 Dec 01; 116(23):5420-31.Cancer2010-07-29T00:00:002010Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.20805315Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RECancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyEffect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52.Cancer Epidemiol Biomarkers Prev2010-08-30T00:00:002010Effect of long-term storage in TRIzol on microarray-based gene expression profiling.20939697Anderlini P, Acholonu SA, Okoroji GJ, Bassett RE, Shpall EJ, Qazilbash MH, Popat UR, Worth LL, Giralt SA, Champlin RELeukemia & lymphomaFludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia. Leuk Lymphoma. 2011 Jan; 52(1):137-41.Leuk Lymphoma2010-10-12T00:00:002010Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.21060030Bashir Q, Langford LA, Parmar S, Champlin RE, Qazilbash MHJournal of clinical oncology : official journal of the American Society of Clinical OncologyPrimary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol. 2011 Feb 01; 29(4):e79-80.J Clin Oncol2010-11-08T00:00:002010Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection.21156844Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima MBloodResults of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31; 117(13):3641-7.Blood2010-12-14T00:00:002010Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.21195312Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHematopoietic stem cell transplantation for treatment of myleodysplastic syndromes. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S6-8.Biol Blood Marrow Transplant2011-01-01T00:00:002011Hematopoietic stem cell transplantation for treatment of myleodysplastic syndromes.21338705Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationMyeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1490-6.Biol Blood Marrow Transplant2011-02-18T00:00:002011Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.21383686Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A, Champlin RE, Alousi AMBone marrow transplantationPrognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant. 2012 Jan; 47(1):125-31.Bone Marrow Transplant2011-03-07T00:00:002011Prognostic value of response after upfront therapy for acute GVHD.21464372Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, Horowitz MM, Eapen MBloodImpact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011 Jun 23; 117(25):6963-70.Blood2011-04-04T00:00:002011Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies.21684343Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPlatelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1841-5.Biol Blood Marrow Transplant2011-05-27T00:00:002011Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.21835146Bayraktar UD, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationProgress in haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2012 Mar; 18(3):372-80.Biol Blood Marrow Transplant2011-08-09T00:00:002011Progress in haploidentical stem cell transplantation.21867666Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Transplant. 2012 Apr; 18(4):584-92.Biol Blood Marrow Transplant2011-08-23T00:00:002011Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.21943676Parmar S, de Lima M, Deeg HJ, Champlin RSeminars in oncologyHematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Semin Oncol. 2011 Oct; 38(5):693-704.Semin Oncol2011-10-01T00:00:002011Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review.21948087Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat UAmerican journal of hematologyHigh incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol. 2011 Nov; 86(11):954-6.Am J Hematol2011-09-21T00:00:002011High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation.22005650Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1723-4.Biol Blood Marrow Transplant2011-10-17T00:00:002011Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia.22035758Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima MClinical lymphoma, myeloma & leukemiaAllogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S96-100.Clin Lymphoma Myeloma Leuk2011-04-28T00:00:002011Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.22110505Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, Khouri IF, Shpall EJ, Anderlini P, Rondon G, Andersson BS, Champlin R, Couriel DRAdvances in hematologySteroid-Refractory Acute GVHD: Predictors and Outcomes. Adv Hematol. 2011; 2011:601953.Adv Hematol2011-11-03T00:00:002011Steroid-Refractory Acute GVHD: Predictors and Outcomes.22132837Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RELeukemia & lymphomaDonor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. Leuk Lymphoma. 2012 Jun; 53(6):1239-41.Leuk Lymphoma2012-01-05T00:00:002012Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.22202074Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJFrontiers in bioscience (Scholar edition)Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed). 2012 01 01; 4(2):520-31.Front Biosci (Schol Ed)2012-01-01T00:00:002012Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.22357140Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien SThe Lancet. OncologyInotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11.Lancet Oncol2012-02-21T00:00:002012Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.22586182Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HABloodNonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8.Blood2012-05-14T00:00:002012Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.22761473Zhang M, Maiti S, Bernatchez C, Huls H, Rabinovich B, Champlin RE, Vence LM, Hwu P, Radvanyi L, Cooper LJClinical cancer research : an official journal of the American Association for Cancer ResearchA new approach to simultaneously quantify both TCR a- and ?-chain diversity after adoptive immunotherapy. Clin Cancer Res. 2012 Sep 01; 18(17):4733-42.Clin Cancer Res2012-07-03T00:00:002012A new approach to simultaneously quantify both TCR a- and ?-chain diversity after adoptive immunotherapy.22982533Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSignificance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission. Biol Blood Marrow Transplant. 2013 Feb; 19(2):214-20.Biol Blood Marrow Transplant2012-09-13T00:00:002012Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remission.22983587Keating A, DaSilva G, P?rez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, Camitta BM, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJHaematologicaAutologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. Haematologica. 2013 Feb; 98(2):185-92.Haematologica2012-09-14T00:00:002012Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research.23074378Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JMJournal of CancerPrognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer. 2012; 3:369-80.J Cancer2012-09-08T00:00:002012Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation.23313065Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian HClinical lymphoma, myeloma & leukemiaFeasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):296-301.Clin Lymphoma Myeloma Leuk2013-01-10T00:00:002013Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.23460378Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat UAmerican journal of hematologyTacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013 Apr; 88(4):301-5.Am J Hematol2013-03-05T00:00:002013Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation.23467126Bayraktar UD, de Lima M, Saliba RM, Maloy M, Castro-Malaspina HR, Chen J, Rondon G, Chiattone A, Jakubowski AA, Boulad F, Kernan NA, O'Reilly RJ, Champlin RE, Giralt S, Andersson BS, Papadopoulos EBBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEx vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013 Jun; 19(6):898-903.Biol Blood Marrow Transplant2013-03-01T00:00:002013Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.23507470Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat UBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHigh-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma. Biol Blood Marrow Transplant. 2013 Jun; 19(6):991-4.Biol Blood Marrow Transplant2013-03-16T00:00:002013High-dose chemotherapy and autologous stem cell transplantation for nodular lymphocyte-predominant Hodgkin lymphoma.23633004Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien SCancerResults of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36.Cancer2013-04-30T00:00:002013Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.23644077Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei PBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1059-64.Biol Blood Marrow Transplant2013-04-30T00:00:002013Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation.23733001Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1227-32.Biol Blood Marrow Transplant2013-05-31T00:00:002013Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.23741009Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJBloodToward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013 Aug 22; 122(8):1341-9.Blood2013-06-05T00:00:002013Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.23749720Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing CAmerican journal of hematologyJust-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol. 2013 Sep; 88(9):754-7.Am J Hematol2013-07-23T00:00:002013Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.23769669Pemmaraju N, Tanaka MF, Ravandi F, Lin H, Baladandayuthapani V, Rondon G, Giralt SA, Chen J, Pierce S, Cortes J, Kantarjian H, Champlin RE, De Lima M, Qazilbash MHClinical lymphoma, myeloma & leukemiaOutcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):485-92.Clin Lymphoma Myeloma Leuk2013-06-13T00:00:002013Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.23775587Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IFCancerCytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer. 2013 Sep 15; 119(18):3318-25.Cancer2013-06-17T00:00:002013Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.23872222Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationA randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.Biol Blood Marrow Transplant2013-07-17T00:00:002013A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.24091929Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman RHaematologicaAdvances in myelofibrosis: a clinical case approach. Haematologica. 2013 Oct; 98(10):1499-509.Haematologica2013-10-01T00:00:002013Advances in myelofibrosis: a clinical case approach.24122901Eckrich MJ, Ahn KW, Champlin RE, Coccia P, Godder K, Horan J, Margolis D, Deeg HJ, Eapen MAmerican journal of hematologyEffect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol. 2014 Feb; 89(2):125-9.Am J Hematol2013-11-15T00:00:002013Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.24127454Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JLJournal of clinical oncology : official journal of the American Society of Clinical OncologyHematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol. 2013 Nov 20; 31(33):4207-14.J Clin Oncol2013-10-14T00:00:002013Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit.24290213Oran B, Popat U, Andersson B, Champlin RClinical lymphoma, myeloma & leukemiaAllogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S282-8.Clin Lymphoma Myeloma Leuk2013-09-01T00:00:002013Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes.24375514Jabbour E, Daver N, Champlin R, Mathisen M, Oran B, Ciurea S, Khouri I, Cornelison AM, Ghanem H, Cardenas-Turanzas M, Popat U, Ravandi F, Giralt S, Garcia-Manero G, Cortes J, Kantarjian H, de Lima MAmerican journal of hematologyAllogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.Am J Hematol2014-03-07T00:00:002014Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.Authorship 2627206Authorship 2627341Authorship 2627713Authorship 2628434Authorship 2629866Authorship 2630963Authorship 2630983Authorship 2631671Authorship 26318010Authorship 2632683Authorship 2633806Authorship 2633811Authorship 2633877Authorship 2634563Authorship 2635461Authorship 2636211Authorship 2637321Authorship 2637851Authorship 2638271Authorship 263918Authorship 2639375Authorship 2639633Authorship 2639664Authorship 2639931Authorship 26403116Authorship 2640606Authorship 2641325Authorship 2642834Authorship 2644517Authorship 2645098Authorship 2645322Authorship 2645666Authorship 2646957Authorship 2647211Authorship 26487411Authorship 2649756Authorship 2649781Authorship 2653614Authorship 26543812Authorship 2655403Authorship 2655603Authorship 2658486Authorship 2658844Authorship 2659827Authorship 26601712Authorship 2661928Authorship 2662336Authorship 267016Authorship 26711813Authorship 2671412Authorship 2673292Authorship 2673862Authorship 26742914Authorship 26762118Authorship 2676841Authorship 2678584Authorship 2678854Authorship 26790918Authorship 2680525Authorship 26817412Authorship 2684389Authorship 26852215Authorship 2685487Authorship 2686249Authorship 26925521Authorship 2695409Authorship 2701372Authorship 2704592Authorship 27057212Authorship 27073119Authorship 2707788Authorship 27144717Authorship 2717258Authorship 27175012Authorship 27198512Authorship 2722344Authorship 2723123Authorship 2723483Authorship 2723631Authorship 2724787Authorship 27248131482658Lee M, Khouri I, Champlin R, Kantarjian H, Talpaz M, Trujillo J, Freireich E, Deisseroth A, Stass SBritish journal of haematologyDetection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation. Br J Haematol. 1992 Dec; 82(4):708-14.Br J Haematol1992-12-01T00:00:001992Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.1694236Champlin R, Gajewski J, Nimer S, Vollset S, Landaw E, Winston D, Schiller G, Ho WJournal of clinical oncology : official journal of the American Society of Clinical OncologyPostremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol. 1990 Jul; 8(7):1199-206.J Clin Oncol1990-07-01T00:00:001990Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.1871811Kato Y, Mitsuishi Y, Cecka M, Hopfield J, Hunt L, Champlin R, Terasaki PI, Gajewski JLTransplantationHLA-DP incompatibilities and severe graft-versus-host disease in unrelated bone marrow transplants. Transplantation. 1991 Aug; 52(2):374-6.Transplantation1991-08-01T00:00:001991HLA-DP incompatibilities and severe graft-versus-host disease in unrelated bone marrow transplants.1871828Champlin RTransplantation proceedingsImmunobiology of bone marrow transplantation as treatment for hematologic malignancies. Transplant Proc. 1991 Aug; 23(4):2123-7.Transplant Proc1991-08-01T00:00:001991Immunobiology of bone marrow transplantation as treatment for hematologic malignancies.1912589Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RABloodT-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15; 78(8):2120-30.Blood1991-10-15T00:00:001991T-cell depletion of HLA-identical transplants in leukemia.2070050Nimer SD, Golde DW, Kwan K, Lee K, Clark S, Champlin RBloodIn vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin. Blood. 1991 Jul 01; 78(1):163-8.Blood1991-07-01T00:00:001991In vitro production of granulocyte-macrophage colony-stimulating factor in aplastic anemia: possible mechanisms of action of antithymocyte globulin.2173107Winston DJ, Ho WG, Champlin REReviews of infectious diseasesCytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis. 1990 Sep-Oct; 12 Suppl 7:S776-92.Rev Infect Dis1990-09-01T00:00:001990Cytomegalovirus infections after allogeneic bone marrow transplantation.2207331Faisal M, Cumberland W, Champlin R, Fahey JLBloodEffect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood. 1990 Oct 15; 76(8):1580-5.Blood1990-10-15T00:00:001990Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia.2405384Sawyers CL, Timson L, Kawasaki ES, Clark SS, Witte ON, Champlin RProceedings of the National Academy of Sciences of the United States of AmericaMolecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci U S A. 1990 Jan; 87(2):563-7.Proc Natl Acad Sci U S A1990-01-01T00:00:001990Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.2539690Ho WG, Winston DJ, Champlin RETransplantation proceedingsTolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients. Transplant Proc. 1989 Feb; 21(1 Pt 3):3103-6.Transplant Proc1989-02-01T00:00:001989Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients.2645964Champlin RBailliere's clinical haematologyBone marrow aplasia due to radiation accidents: pathophysiology, assessment and treatment. Baillieres Clin Haematol. 1989 Jan; 2(1):69-82.Baillieres Clin Haematol1989-01-01T00:00:001989Bone marrow aplasia due to radiation accidents: pathophysiology, assessment and treatment.2821464Holland GN, Sidikaro Y, Kreiger AE, Hardy D, Sakamoto MJ, Frenkel LM, Winston DJ, Gottlieb MS, Bryson YJ, Champlin REOphthalmologyTreatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology. 1987 Jul; 94(7):815-23.Ophthalmology1987-07-01T00:00:001987Treatment of cytomegalovirus retinopathy with ganciclovir.3127217Winston DJ, Ho WG, Gale RP, Champlin REEuropean journal of cancer & clinical oncologyProphylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol. 1988; 24 Suppl 1:S15-23.Eur J Cancer Clin Oncol1988-01-01T00:00:001988Prophylaxis of infection in bone marrow transplants.3274570Champlin RTransplantation proceedingsBone marrow transplantation for acute leukemia: a preliminary report from the International Bone Marrow Transplant Registry. Transplant Proc. 1987 Feb; 19(1 Pt 3):2626-8.Transplant Proc1987-02-01T00:00:001987Bone marrow transplantation for acute leukemia: a preliminary report from the International Bone Marrow Transplant Registry.3476204Decker RW, Ho WG, Champlin RECancer treatment reportsPhase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia. Cancer Treat Rep. 1987 Sep; 71(9):881-2.Cancer Treat Rep1987-09-01T00:00:001987Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.3536545Mitsuyasu RT, Li SN, Champlin RE, Gale RPExperimental hematologyAbnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation. Exp Hematol. 1986 Dec; 14(11):1049-55.Exp Hematol1986-12-01T00:00:001986Abnormal T-lymphocyte colonies (CFU-TL) following bone marrow transplantation.6336819Champlin R, Ho W, Gale RPThe New England journal of medicineAntithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med. 1983 Jan 20; 308(3):113-8.N Engl J Med1983-01-20T00:00:001983Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.6587178Boccia R, Zighelboim J, Champlin RE, Kim CC, Gale RPMedical and pediatric oncologyAMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia. Med Pediatr Oncol. 1984; 12(3):178-9.Med Pediatr Oncol1984-01-01T00:00:001984AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.7565363Bayouth JE, Macey DJ, Boyer AL, Champlin REMedical physicsRadiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation. Med Phys. 1995 Jun; 22(6):743-53.Med Phys1995-06-01T00:00:001995Radiation dose distribution within the bone marrow of patients receiving holmium-166-labeled-phosphonate for marrow ablation.7620177Korbling M, Przepiorka D, Gajewski J, Champlin RE, Chan KWBloodWith first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood. 1995 Aug 01; 86(3):1235.Blood1995-08-01T00:00:001995With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially?7700921Przepiorka D, Huh YO, Khouri I, Reading C, Hester J, Marshall M, Champlin REProgress in clinical and biological researchGraft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets. Prog Clin Biol Res. 1994; 389:557-63.Prog Clin Biol Res1994-01-01T00:00:001994Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets.7711143Deisseroth AB, Kavanagh J, Champlin RHuman gene therapyUse of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther. 1994 Dec; 5(12):1507-22.Hum Gene Ther1994-12-01T00:00:001994Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial.7875244Champlin RExperimental hematologyTechnology of blood and marrow transplantation. Exp Hematol. 1995 Mar; 23(3):273-6.Exp Hematol1995-03-01T00:00:001995Technology of blood and marrow transplantation.7921993Champlin RJournal of hematotherapyBone marrow transplantation from HLA-matched unrelated donors as treatment for leukemia. J Hematother. 1993; 2(3):323-7.J Hematother1993-01-01T00:00:001993Bone marrow transplantation from HLA-matched unrelated donors as treatment for leukemia.7986714Dimopoulos MA, Hester J, Huh Y, Champlin R, Alexanian RBritish journal of haematologyIntensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haematol. 1994 Aug; 87(4):730-4.Br J Haematol1994-08-01T00:00:001994Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.8048400Seymour JF, Khouri IF, Champlin RE, Keating MJAmerican journal of clinical oncologyRefractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. Am J Clin Oncol. 1994 Aug; 17(4):360-8.Am J Clin Oncol1994-08-01T00:00:001994Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review.8124226Champlin RLeukemia & lymphomaAllogeneic bone marrow transplantation using unrelated donors. Leuk Lymphoma. 1993; 11 Suppl 2:149-52.Leuk Lymphoma1993-01-01T00:00:001993Allogeneic bone marrow transplantation using unrelated donors.8204887Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RBBloodBCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood. 1994 Jun 15; 83(12):3629-37.Blood1994-06-15T00:00:001994BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.8448545Champlin R, Coppo P, Howe CBone marrow transplantationNational Marrow Donor Program: progress and challenges. Bone Marrow Transplant. 1993; 11 Suppl 1:41-4.Bone Marrow Transplant1993-01-01T00:00:001993National Marrow Donor Program: progress and challenges.8627436Chan KW, Gajewski JL, Supkis D, Pentz R, Champlin R, Bleyer WAThe Journal of pediatricsUse of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers. J Pediatr. 1996 May; 128(5 Pt 1):644-8.J Pediatr1996-05-01T00:00:001996Use of minors as bone marrow donors: current attitude and management. A survey of 56 pediatric transplantation centers.8918502van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin RJournal of clinical oncology : official journal of the American Society of Clinical OncologyImpact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42.J Clin Oncol1996-11-01T00:00:001996Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies.9053492Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin RJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73.J Clin Oncol1997-02-01T00:00:001997Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue.9166550Champlin RThe cancer journal from Scientific AmericanImproving the results of bone marrow transplants. Cancer J Sci Am. 1996 Nov-Dec; 2(6):309-13.Cancer J Sci Am1996-11-01T00:00:001996Improving the results of bone marrow transplants.9226187Passweg JR, Soci? G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Pasquini R, Rowlings PA, Speck B, Tichelli A, Zhang MJ, Horowitz MM, Bortin MMBloodBone marrow transplantation for severe aplastic anemia: has outcome improved? Blood. 1997 Jul 15; 90(2):858-64.Blood1997-07-15T00:00:001997Bone marrow transplantation for severe aplastic anemia: has outcome improved?9359497Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, Horowitz MMBritish journal of haematologySurvival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. Br J Haematol. 1997 Oct; 99(1):23-9.Br J Haematol1997-10-01T00:00:001997Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy.9363865Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski JJournal of clinical oncology : official journal of the American Society of Clinical OncologyUse of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. J Clin Oncol. 1997 Nov; 15(11):3350-4.J Clin Oncol1997-11-01T00:00:001997Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.10232739Margolin KA, Van Besien K, Wright C, Niland J, Champlin R, Fung HC, Kashyap A, Molina A, Nademanee AP, O'Donnell MR, Parker P, Smith E, Spielberger R, Somlo G, Snyder D, Stein A, Woo D, Thomas M, Sniecinski I, Forman SJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationInterleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma. Biol Blood Marrow Transplant. 1999; 5(1):36-45.Biol Blood Marrow Transplant1999-01-01T00:00:001999Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma.10561238Adkins D, Brown R, Goodnough L, Khoury H, DiPersio JJournal of clinical oncology : official journal of the American Society of Clinical OncologyPurine analog regimens for allogeneic transplant? J Clin Oncol. 1999 Jun; 17(6):1958-60.J Clin Oncol1999-06-01T00:00:001999Purine analog regimens for allogeneic transplant?10607689Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light SBloodDaclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000 Jan 01; 95(1):83-9.Blood2000-01-01T00:00:002000Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.10784623Seong CM, Giralt S, Kantarjian H, Xu J, Swantkowski J, Hayes K, Glassman AB, Khouri I, Korbling M, Thall P, Siciliano MJ, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyEarly detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6.J Clin Oncol2000-05-01T00:00:002000Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia.10809275Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Signes-Costa J, Velarde H, Champlin RECritical care medicineOutcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med. 2000 Apr; 28(4):1014-7.Crit Care Med2000-04-01T00:00:002000Outcome of bone marrow transplantation patients requiring mechanical ventilation.10845900Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringd?n O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl ABloodBlood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000 Jun 15; 95(12):3702-9.Blood2000-06-15T00:00:002000Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).11085458Couriel DR, Hicks K, Giralt S, Champlin RECurrent opinion in oncologyRole of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000 Nov; 12(6):582-7.Curr Opin Oncol2000-11-01T00:00:002000Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.11122842Champlin R, Giralt S, Khouri ICurrent oncology reportsAllogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens. Curr Oncol Rep. 2000 Mar; 2(2):182-91.Curr Oncol Rep2000-03-01T00:00:002000Allogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: potential for nonablative preparative regimens.11908196Khouri I, Giralt S, Champlin RCancer treatment and researchNon-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. Cancer Treat Res. 2002; 110:137-47.Cancer Treat Res2002-01-01T00:00:002002Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy.12358917Ueno NT, Anagnostopoulos A, Rond?n G, Champlin RE, Mikhailova N, Pankratova OS, Zoubarovskaya LS, Semenova EV, Afanasyev BV, O'Brien S, Andreeff M, Zaritskey AYBritish journal of haematologySuccessful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002 Oct; 119(1):131-4.Br J Haematol2002-10-01T00:00:002002Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome.12587104Thall PF, Wathen JK, Bekele BN, Champlin RE, Baker LH, Benjamin RSStatistics in medicineHierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes. Stat Med. 2003 Mar 15; 22(5):763-80.Stat Med2003-03-15T00:00:002003Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.12665841Apisarnthanarax N, Donato M, K?rbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini PBone marrow transplantationExtracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003 Mar; 31(6):459-65.Bone Marrow Transplant2003-03-01T00:00:002003Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.12796796Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NTBone marrow transplantationIdiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant. 2003 Jun; 31(12):1157-63.Bone Marrow Transplant2003-06-01T00:00:002003Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.15133487Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, Champlin R, Atkinson K, Soiffer RJBone marrow transplantationCD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2004 Jul; 34(2):123-8.Bone Marrow Transplant2004-07-01T00:00:002004CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study.15148492Van Besien K, Mehra R, Wadehra N, Stock W, Khouri I, Giralt S, Devine S, Wickrema A, Peace D, Sosman J, Gajewski J, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2004 Jun; 10(6):386-94.Biol Blood Marrow Transplant2004-06-01T00:00:002004Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.15205664Gajewski JL, Foote M, Tietjen J, Melson B, Simmons A, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationBlood and marrow transplantation compensation: perspective in payer and provider relations. Biol Blood Marrow Transplant. 2004 Jul; 10(7):427-32.Biol Blood Marrow Transplant2004-07-01T00:00:002004Blood and marrow transplantation compensation: perspective in payer and provider relations.15570257Anderlini P, Sheth S, Hicks K, Ippoliti C, Giralt S, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationRe: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant. 2004 Dec; 10(12):883-4.Biol Blood Marrow Transplant2004-12-01T00:00:002004Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.16042691Couriel DR, Saliba R, Escal?n MP, Hsu Y, Ghosh S, Ippoliti C, Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima MJ, Andersson B, Neumann J, Champlin RBritish journal of haematologySirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol. 2005 Aug; 130(3):409-17.Br J Haematol2005-08-01T00:00:002005Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.16737932Anderlini P, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand? Biol Blood Marrow Transplant. 2006 Jun; 12(6):599-602.Biol Blood Marrow Transplant2006-06-01T00:00:002006Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?17085316Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAbstracts and summary of the 4th Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 19-20, 2006. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1206-27.Biol Blood Marrow Transplant2006-11-01T00:00:002006Abstracts and summary of the 4th Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 19-20, 2006.17272503Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MMBloodBone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007 May 15; 109(10):4582-5.Blood2007-02-01T00:00:002007Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens.17577932Kornblau SM, Aycox PG, Stephens C, McCue LD, Champlin RE, Marini FCExperimental hematologyControl of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes. Exp Hematol. 2007 May; 35(5):842-53.Exp Hematol2007-05-01T00:00:002007Control of graft-versus-host disease with maintenance of the graft-versus-leukemia effect in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.17611563Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima MLeukemiaTreatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia. 2007 Dec; 21(12):2540-4.Leukemia2007-07-05T00:00:002007Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.17950924Wagner J, Champlin R, Petz LDBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationFifth Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 11-12, 2007. Biol Blood Marrow Transplant. 2007 Nov; 13(11):1380-92.Biol Blood Marrow Transplant2007-11-01T00:00:002007Fifth Annual International Umbilical Cord Blood Transplantation Symposium, Los Angeles, California, May 11-12, 2007.18057230Anderlini P, Champlin REBloodBiologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008 Feb 15; 111(4):1767-72.Blood2007-12-05T00:00:002007Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges.18084340Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser DBone marrow transplantationAllogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008 Mar; 41(6):537-45.Bone Marrow Transplant2007-12-17T00:00:002007Allogeneic hematopoietic cell transplantation for metastatic breast cancer.18223284Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, Hosing C, Khouri IF, Couriel D, de Lima M, Qazilbash MH, Pro B, Romaguera J, Fayad L, Hagemeister F, Younes A, Munsell MF, Champlin REHaematologicaFludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008 Feb; 93(2):257-64.Haematologica2008-01-26T00:00:002008Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.18235440Nakayama K, Milbourne A, Schover LR, Champlin RE, Ueno NTNature clinical practice. OncologyGonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. Nat Clin Pract Oncol. 2008 Feb; 5(2):78-89.Nat Clin Pract Oncol2008-02-01T00:00:002008Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers.18300773Koca E, Champlin RECurrent opinion in oncologyPeripheral blood progenitor cell or bone marrow transplantation: controversy remains. Curr Opin Oncol. 2008 Mar; 20(2):220-6.Curr Opin Oncol2008-03-01T00:00:002008Peripheral blood progenitor cell or bone marrow transplantation: controversy remains.18378566Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza FR, Soiffer RJ, Eapen MJournal of clinical oncology : official journal of the American Society of Clinical OncologyIndividual physician practice variation in hematopoietic cell transplantation. J Clin Oncol. 2008 May 01; 26(13):2162-70.J Clin Oncol2008-03-31T00:00:002008Individual physician practice variation in hematopoietic cell transplantation.18566326Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek SBloodThe natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008 Sep 01; 112(5):1628-37.Blood2008-06-19T00:00:002008The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.19041063Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationArsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7.Biol Blood Marrow Transplant2008-12-01T00:00:002008Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.19361747van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PNBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationUnrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant. 2009 May; 15(5):554-63.Biol Blood Marrow Transplant2009-03-09T00:00:002009Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.19747634Qazilbash MH, Amjad AI, Qureshi S, Qureshi SR, Saliba RM, Khan ZU, Hosing C, Giralt SA, De Lima MJ, Popat UR, Yusuf SW, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction. Biol Blood Marrow Transplant. 2009 Oct; 15(10):1265-70.Biol Blood Marrow Transplant2009-08-03T00:00:002009Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction.19822307Nakayama K, Liu P, Detry M, Schover LR, Milbourne A, Neumann J, Rondon G, Thewes B, Champlin RE, Ueno NTBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReceiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1465-74.Biol Blood Marrow Transplant2009-11-01T00:00:002009Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time.20410183Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima MHaematologicaHemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010 Jul; 95(7):1183-90.Haematologica2010-04-21T00:00:002010Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type.20581887Kazmi SM, Saliba RM, Donato M, Wang M, Hosing C, Qureshi S, Anderlini P, Popat U, Champlin RE, Giralt SA, Qazilbash MHBone marrow transplantationPhase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5.Bone Marrow Transplant2010-06-28T00:00:002010Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma.21699878Ciurea SO, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of patients treated and one human leukocyte antigen-mismatched related compared with matched unrelated donors. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1261.Biol Blood Marrow Transplant2011-06-21T00:00:002011Outcomes of patients treated and one human leukocyte antigen-mismatched related compared with matched unrelated donors.21982422Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, Koegler G, Laughlin MJ, Michel G, Nabhan SK, Smith FO, Horowitz MM, Gluckman E, Rocha V, Eurocord-European Group for Blood and Marrow Transplantation, Netcord, Center for International Blood and Marrow Transplant ResearchThe Lancet. OncologyEffect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011 Dec; 12(13):1214-21.Lancet Oncol2011-10-06T00:00:002011Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.21988645Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima MLeukemia & lymphomaFludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6.Leuk Lymphoma2012-01-03T00:00:002012Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.22242817Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MHLeukemia & lymphomaDurable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. Leuk Lymphoma. 2012 Aug; 53(8):1525-9.Leuk Lymphoma2012-03-01T00:00:002012Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.23330820Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat UBritish journal of haematologyIncidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013 Mar; 160(6):798-805.Br J Haematol2013-01-18T00:00:002013Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation.23384030Jones D, Vichaya EG, Wang XS, Williams LA, Shah ND, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TRJournal of hematology & oncologyValidation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013 Feb 05; 6:13.J Hematol Oncol2013-02-05T00:00:002013Validation of the M. D. Anderson Symptom Inventory multiple myeloma module.23741305Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJPloS oneManufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 2013; 8(5):e64138.PLoS One2013-05-31T00:00:002013Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.23836561Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HMBloodDetection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013 Aug 15; 122(7):1214-21.Blood2013-07-08T00:00:002013Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.25778529Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJBloodEnforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.Blood2015-03-16T00:00:002015Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.Authorship 2727607Authorship 2728899Authorship 27312510Authorship 2731916Authorship 2733724Authorship 27337610Authorship 27348411Authorship 27370913Authorship 2737136Authorship 2749476Authorship 2753978Authorship 2756412Authorship 2756711Authorship 2757761Authorship 2757771Authorship 2758947Authorship 2759024Authorship 2759463Authorship 275984Authorship 2759959Authorship 2760467Authorship 2761062Authorship 276156Authorship 2762835Authorship 2763973Authorship 2764295Authorship 276453Authorship 27660923Authorship 2766962Authorship 2767258Authorship 2771722Authorship 2772936Authorship 2772961Authorship 27747112Authorship 27748813Authorship 2775596Authorship 2775612Authorship 277783141976348Nimer SD, Champlin RECancer treatment and researchTherapeutic use of hematopoietic growth factors in bone marrow transplantation. Cancer Treat Res. 1990; 50:141-64.Cancer Treat Res1990-01-01T00:00:001990Therapeutic use of hematopoietic growth factors in bone marrow transplantation.2095240Champlin RCurrent opinion in oncologyBone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol. 1990 Apr; 2(2):258-62.Curr Opin Oncol1990-04-01T00:00:001990Bone marrow transplantation for chronic myelogenous leukemia.2644980Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman CBloodGraft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989 Feb; 73(2):606-13.Blood1989-02-01T00:00:001989Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results.2645650Champlin RE, Gajewski JL, Golde DWSeminars in oncologyTreatment of acute myelogenous leukemia in the elderly. Semin Oncol. 1989 Feb; 16(1):51-6.Semin Oncol1989-02-01T00:00:001989Treatment of acute myelogenous leukemia in the elderly.2809680Gajewski JL, Ho WG, Nimer SD, Hirji KF, Gekelman L, Jacobs AD, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyEfficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol. 1989 Nov; 7(11):1637-45.J Clin Oncol1989-11-01T00:00:001989Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.2892290Cain G, Stitzel K, Gale R, Champlin RTransplantationTransplantation of DLA-compatible and incompatible fetal liver hematopoietic cells in dogs. Transplantation. 1987 Dec; 44(6):742-7.Transplantation1987-12-01T00:00:001987Transplantation of DLA-compatible and incompatible fetal liver hematopoietic cells in dogs.3000923Winston DJ, Ho WG, Lin GH, Bartoni K, Budinger MD, Gale RP, Champlin REImmunitat und Infektion[Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation]. Immun Infekt. 1985 Nov; 13(6):296-301.Immun Infekt1985-11-01T00:00:001985[Use of a polyvalent intravenous immunoglobulin or specific cytomegalovirus hyperimmunoglobulin for modification of cytomegalovirus infections and prevention of interstitial pneumonias following bone marrow transplantation].6145942Gale RP, Champlin RELancet (London, England)How does bone-marrow transplantation cure leukaemia? Lancet. 1984 Jul 07; 2(8393):28-30.Lancet1984-07-07T00:00:001984How does bone-marrow transplantation cure leukaemia?7994271Przepiorka D, Ippoliti C, Giralt S, van Beisen K, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee MBone marrow transplantationA phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):449-53.Bone Marrow Transplant1994-09-01T00:00:001994A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.8019472Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, van Besien K, Mehra R, Deisseroth AB, Andersson B, Luna MBone marrow transplantationGanciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplant. 1994 Apr; 13(4):461-4.Bone Marrow Transplant1994-04-01T00:00:001994Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.8083714Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, Dimopoulos M, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri IJournal of clinical oncology : official journal of the American Society of Clinical OncologyEtoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30.J Clin Oncol1994-09-01T00:00:001994Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies.8123178de Witte T, Schattenberg TThe New England journal of medicineTreatment of leukemia in relapse after bone marrow transplantation. N Engl J Med. 1994 Mar 03; 330(9):645; author reply 645-6.N Engl J Med1994-03-03T00:00:001994Treatment of leukemia in relapse after bone marrow transplantation.8243487Whimbey E, Vartivarian SE, Champlin RE, Elting LS, Luna M, Bodey GPEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical MicrobiologyParainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis. 1993 Sep; 12(9):699-701.Eur J Clin Microbiol Infect Dis1993-09-01T00:00:001993Parainfluenza virus infection in adult bone marrow transplant recipients.8340287Guo JQ, Hirsch-Ginsberg CF, Xian YM, Stass SA, Champlin RE, Giralt SA, McCredie KB, Campbell ML, Arlinghaus RBHematologic pathologyAcute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia. Hematol Pathol. 1993; 7(2):91-106.Hematol Pathol1993-01-01T00:00:001993Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.8703830Anderlini P, Przepiorka D, Huh Y, Lauppe J, Miller P, Sundberg J, Seong D, Champlin R, K?rbling MBritish journal of haematologyDuration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol. 1996 Jun; 93(4):940-2.Br J Haematol1996-06-01T00:00:001996Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation.8727299Gajewski J, Champlin RCurrent opinion in oncologyBone marrow transplantation from unrelated donors. Curr Opin Oncol. 1996 Mar; 8(2):84-8.Curr Opin Oncol1996-03-01T00:00:001996Bone marrow transplantation from unrelated donors.9012929Nicholson VA, Whimbey E, Champlin R, Abi-Said D, Przepiorka D, Tarrand J, Chan K, Bodey GP, Goodrich JMBone marrow transplantationComparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis. Bone Marrow Transplant. 1997 Jan; 19(1):37-41.Bone Marrow Transplant1997-01-01T00:00:001997Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.9250816Rond?n G, Giralt S, Pereira M, Van Besien K, Mehra R, Champlin R, Andreeff MLeukemia & lymphomaAnalysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization. Leuk Lymphoma. 1997 May; 25(5-6):463-7.Leuk Lymphoma1997-05-01T00:00:001997Analysis of chimerism following allogeneic bone marrow transplantation by fluorescent-in-situ hybridization.9267667Gajewski J, Gjertson D, Cecka M, Tonai R, Przepiorka D, Hunt L, Giralt S, Chan KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationThe impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82.Biol Blood Marrow Transplant1997-06-01T00:00:001997The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation.10973322Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MMNature medicineEvidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000 Sep; 6(9):1018-23.Nat Med2000-09-01T00:00:002000Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.10975509Donato M, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGranulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000; 6(4A):419-21.Biol Blood Marrow Transplant2000-01-01T00:00:002000Granulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease.11882729K?rbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov ZThe New England journal of medicineHepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002 Mar 07; 346(10):738-46.N Engl J Med2002-03-07T00:00:002002Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells.11896552Champlin R, Hesdorffer C, Lowenberg B, Martelli MF, Mertelsmann RH, Reisner Y, Schmitz NLeukemiaHaploidentical 'megadose' stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia. 2002 Mar; 16(3):427-8.Leukemia2002-03-01T00:00:002002Haploidentical 'megadose' stem cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings.12479596Anderlini P, Champlin RDrugsUse of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy. Drugs. 2002; 62 Suppl 1:79-88.Drugs2002-01-01T00:00:002002Use of filgrastim for stem cell mobilisation and transplantation in high-dose cancer chemotherapy.14682302Andersson BS, Kashyap A, Couriel D, Madden T, de Lima M, Thall PF, Fernandez H, Vaughan WP, Jones R, Wingard JR, Blume KG, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIntravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. Biol Blood Marrow Transplant. 2003 Nov; 9(11):722-4.Biol Blood Marrow Transplant2003-11-01T00:00:002003Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.15073038de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BSBloodOnce-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64.Blood2004-04-08T00:00:002004Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.16138357Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin RAmerican journal of hematologyRituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol. 2005 Sep; 80(1):43-5.Am J Hematol2005-09-01T00:00:002005Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia.16601247Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R, Giles F, Andersson BS, Champlin R, de Lima MBloodAllogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006 Aug 15; 108(4):1421-3.Blood2006-04-06T00:00:002006Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.16785065Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, Loberiza FR, Porter DLBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Jul; 12(7):758-69.Biol Blood Marrow Transplant2006-07-01T00:00:002006Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation.16892072Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima MBone marrow transplantationPhase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.Bone Marrow Transplant2006-08-07T00:00:002006Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies.16923559Hosing C, Saliba RM, K?rbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato MLLeukemia & lymphomaHigh-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Jul; 47(7):1290-4.Leuk Lymphoma2006-07-01T00:00:002006High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.16979517Johnson MR, Del Carpio-Jayo D, Lin P, Giralt S, Anderlini P, Champlin RE, Khouri IF, Vadhan-Raj S, Medeiros LJ, Bueso-Ramos CEAnnals of diagnostic pathologyPrimary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006 Oct; 10(5):263-8.Ann Diagn Pathol2006-10-01T00:00:002006Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.17652620Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima MBloodLong-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007 Nov 01; 110(9):3456-62.Blood2007-07-25T00:00:002007Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.18564354Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IFBritish journal of haematologyDisease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008 Sep; 142(5):786-92.Br J Haematol2008-06-17T00:00:002008Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation.19561406Andersson BS, de Lima M, Thall PF, Madden T, Russell JA, Champlin RECurrent opinion in oncologyReduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia. Curr Opin Oncol. 2009 Jun; 21 Suppl 1:S11-5.Curr Opin Oncol2009-06-01T00:00:002009Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.20674757Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIntravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011 Mar; 17(3):412-20.Biol Blood Marrow Transplant2010-07-30T00:00:002010Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.23469246Jena B, Maiti S, Huls H, Singh H, Lee DA, Champlin RE, Cooper LJPloS oneChimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS One. 2013; 8(3):e57838.PLoS One2013-03-01T00:00:002013Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials.25267759Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik LJournal of clinical oncology : official journal of the American Society of Clinical OncologyMulti-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505.J Clin Oncol2014-09-29T00:00:002014Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.Authorship 2780667Authorship 2780795Authorship 2786205Authorship 2786476Authorship 2792127Authorship 2793957Authorship 27954120Authorship 27957523Authorship 27978357940725Przepiorka D, Ippoliti C, Koberda J, Chan KW, Khouri IF, Fischer HE, Huh YO, Escudier SM, Seong D, Davis MTransplantationInterleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation. Transplantation. 1994 Oct 15; 58(7):858-60.Transplantation1994-10-15T00:00:001994Interleukin-2 for prevention of graft-versus-host disease after haploidentical marrow transplantation.8110925Anaissie EJ, Kontoyiannis DP, Vartivarian S, Kantarjian HM, O'Brien S, Giralt SA, Andersson BS, Karl C, Champlin RE, Bodey GPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaEffectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis. 1993 Dec; 17(6):1022-31.Clin Infect Dis1993-12-01T00:00:001993Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304.8535312Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, Przepiorka D, Luna MA, Morice RC, Neumann JLBone marrow transplantationCombination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 1995 Sep; 16(3):393-9.Bone Marrow Transplant1995-09-01T00:00:001995Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients.9053463Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis JJournal of clinical oncology : official journal of the American Society of Clinical OncologyDonor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb; 15(2):433-44.J Clin Oncol1997-02-01T00:00:001997Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.9163617Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, K?rbling M, Keating MJ, Champlin REBritish journal of haematologyAllogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.Br J Haematol1997-05-01T00:00:001997Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease.9636873Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ, Whimbey EClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaCommon emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 1998 Jun; 26(6):1418-24.Clin Infect Dis1998-06-01T00:00:001998Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults.9283913Kim SW, Rice L, Champlin R, Udden MMHaematologiaAplastic anemia in eosinophilic fasciitis: responses to immunosuppression and marrow transplantation. Haematologia (Budap). 1997; 28(3):131-7.Haematologia (Budap)1997-01-01T00:00:001997Aplastic anemia in eosinophilic fasciitis: responses to immunosuppression and marrow transplantation.9704734Khouri IF, Keating M, K?rbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin RJournal of clinical oncology : official journal of the American Society of Clinical OncologyTransplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24.J Clin Oncol1998-08-01T00:00:001998Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.10557066Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE, Xie Z, Okcu MF, Sanchez-Williams G, Dong J, Estey EH, Champlin RC, Kornblau SM, Reed JC, Zhao SLeukemiaExpression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia. 1999 Nov; 13(11):1881-92.Leukemia1999-11-01T00:00:001999Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid.10738997Hanna H, Raad I, Gonzalez V, Umphrey J, Tarrand J, Neumann J, Champlin RInfection control and hospital epidemiologyControl of nosocomial Clostridium difficile transmission in bone marrow transplant patients. Infect Control Hosp Epidemiol. 2000 Mar; 21(3):226-8.Infect Control Hosp Epidemiol2000-03-01T00:00:002000Control of nosocomial Clostridium difficile transmission in bone marrow transplant patients.Authorship 28547815Authorship 2877264Authorship 28821610Authorship 28831910Authorship 28863317Authorship 2892249Authorship 28936015Authorship 2894455Authorship 28975618Authorship 2898447Authorship 28991813Authorship 28993513Authorship 2899486Authorship 2900269Authorship 29009415Authorship 2902163Authorship 29041110Authorship 29115918Authorship 29138013Authorship 2933179Authorship 29334610Authorship 2937487Authorship 29375312Authorship 2943403Authorship 2945057Authorship 2945938Authorship 29507113Authorship 29519220Authorship 2953737Authorship 29540615Authorship 2957025Authorship 2960244Authorship 29627719Authorship 29631011Authorship 29666115Authorship 29677324Authorship 29701114Authorship 29721610Authorship 2972684Authorship 29751814Authorship 29759912Authorship 29786123Authorship 29797013Authorship 29863419Authorship 29908216Authorship 2991819Authorship 2994158Authorship 2994827Authorship 29976613Authorship 3004497Authorship 30111511Authorship 3013287Authorship 3014159Authorship 30233123Authorship 30253618Authorship 30330312Authorship 30343114Authorship 3035612Authorship 30356313Authorship 30516112Authorship 30544121Authorship 30580322Authorship 3061553Authorship 3061584Authorship 3085313Authorship 3145451163574Morrell RE, Marks MI, Champlin R, Spence LAmerican journal of epidemiologyAn outbreak of severe pneumonia due to respiratory syncytial virus in isolated Arctic populations. Am J Epidemiol. 1975 Mar; 101(3):231-7.Am J Epidemiol1975-03-01T00:00:001975An outbreak of severe pneumonia due to respiratory syncytial virus in isolated Arctic populations.167920Jackson WB, Davis PL, Groh V, Champlin RCanadian journal of ophthalmology. Journal canadien d'ophtalmologieAdenovirus type 19 keratoconjunctivitis in Canada. Can J Ophthalmol. 1975 Jul; 10(3):326-33.Can J Ophthalmol1975-07-01T00:00:001975Adenovirus type 19 keratoconjunctivitis in Canada.7000320Elazhary MA, Roy RS, Champlin R, Higgins R, Marsolais GCanadian journal of comparative medicine : Revue canadienne de medecine compareeBovine respiratory syncytial virus in Quebec: antibody prevalence and disease outbreak. Can J Comp Med. 1980 Jul; 44(3):299-303.Can J Comp Med1980-07-01T00:00:001980Bovine respiratory syncytial virus in Quebec: antibody prevalence and disease outbreak.16258420Champlin RE, Kantarjian HClinical advances in hematology & oncology : H&OCurrent evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol. 2003 Jul; 1(7):398-400.Clin Adv Hematol Oncol2003-07-01T00:00:002003Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.22282683Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, K?rbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri IJournal of blood medicineA randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med. 2010; 1:49-55.J Blood Med2010-04-14T00:00:002010A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.23997988Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SOAmerican journal of blood researchRomiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. Am J Blood Res. 2013; 3(3):260-4.Am J Blood Res2013-08-19T00:00:002013Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation.24332214Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JEClinical lymphoma, myeloma & leukemiaTyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.Clin Lymphoma Myeloma Leuk2013-12-09T00:00:002013Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.24419515Patel K, Nusrat M, Shah N, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MHBone marrow transplantationDurable responses with autologous hematopoietic SCT in patients with POEMS syndrome. Bone Marrow Transplant. 2014 Mar; 49(3):465-6.Bone Marrow Transplant2014-01-13T00:00:002014Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.24548609Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei PClinical lymphoma, myeloma & leukemiaThe effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26.Clin Lymphoma Myeloma Leuk2014-01-15T00:00:002014The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.24727332Tang X, Alatrash G, Ning J, Jakher H, Stafford P, Zope M, Shpall EJ, Jones RB, Champlin RE, Thall PF, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIncreasing chimerism after allogeneic stem cell transplantation is associated with longer survival time. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1139-44.Biol Blood Marrow Transplant2014-04-13T00:00:002014Increasing chimerism after allogeneic stem cell transplantation is associated with longer survival time.24777193Ma Q, Li D, Carre?o R, Patenia R, Tsai KY, Xydes-Smith M, Alousi AM, Champlin RE, Sale GE, Afshar-Kharghan VBone marrow transplantationComplement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):972-6.Bone Marrow Transplant2014-04-28T00:00:002014Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD.24797184Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin RBone marrow transplantationIs there an expiration date for a cord blood unit in storage? Bone Marrow Transplant. 2014 Aug; 49(8):1109-12.Bone Marrow Transplant2014-04-23T00:00:002014Is there an expiration date for a cord blood unit in storage?24816581Duong HK, Savani BN, Copelan E, Devine S, Costa LJ, Wingard JR, Shaughnessy P, Majhail N, Perales MA, Cutler CS, Bensinger W, Litzow MR, Mohty M, Champlin RE, Leather H, Giralt S, Carpenter PABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPeripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1262-73.Biol Blood Marrow Transplant2014-05-09T00:00:002014Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation.24833662Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJClinical cancer research : an official journal of the American Association for Cancer ResearchActivating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014 Nov 15; 20(22):5708-19.Clin Cancer Res2014-05-15T00:00:002014Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.24835889Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, Mohile SGJournal of geriatric oncologyOptimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. 2014 Oct 01; 5(4):422-30.J Geriatr Oncol2014-05-14T00:00:002014Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates.24844357Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MHLeukemia & lymphomaChromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma. 2015 Mar; 56(3):602-7.Leuk Lymphoma2014-08-18T00:00:002014Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.24882259Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MHLeukemia & lymphomaShort-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma. 2015 Feb; 56(2):533-5.Leuk Lymphoma2014-07-15T00:00:002014Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.24887378Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MHBone marrow transplantationAuto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41.Bone Marrow Transplant2014-06-02T00:00:002014Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.24913509Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IFLeukemia & lymphomaAllogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma. 2015 Mar; 56(3):711-5.Leuk Lymphoma2014-08-04T00:00:002014Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.24953017Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25.Biol Blood Marrow Transplant2014-06-20T00:00:002014Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation.25017763Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, Ram R, Dabaja B, Rondon G, Champlin R, Sandmaier BM, Doney K, Bar M, Kebriaei PBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCentral nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1767-71.Biol Blood Marrow Transplant2014-07-10T00:00:002014Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.25107338Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonz?lez GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MHClinical lymphoma, myeloma & leukemiaCharacteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.Clin Lymphoma Myeloma Leuk2014-07-15T00:00:002014Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.25255165Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant. 2015 Jan; 21(1):55-9.Biol Blood Marrow Transplant2014-09-22T00:00:002014Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.25534391Eapen M, Logan BR, Horowitz MM, Zhong X, Perales MA, Lee SJ, Rocha V, Soiffer RJ, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyBone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 01; 33(4):364-9.J Clin Oncol2014-12-22T00:00:002014Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.25540936Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCan a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? Biol Blood Marrow Transplant. 2015 Apr; 21(4):713-9.Biol Blood Marrow Transplant2014-12-23T00:00:002014Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?25621795Hamdi A, Cao K, Poon LM, Aung F, Kornblau S, Fernandez Vina MA, Champlin RE, Ciurea SOBone marrow transplantationAre changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT? Bone Marrow Transplant. 2015 Mar; 50(3):411-3.Bone Marrow Transplant2015-01-26T00:00:002015Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?25621808Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei PBone marrow transplantationComparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant. 2015 Apr; 50(4):493-8.Bone Marrow Transplant2015-01-26T00:00:002015Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.25667989Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.Biol Blood Marrow Transplant2015-02-07T00:00:002015Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.25669675Wang Y, Zhang LL, Champlin RE, Wang MLClinical pharmacology and therapeuticsTargeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015 May; 97(5):455-68.Clin Pharmacol Ther2015-04-03T00:00:002015Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.25704054Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, Champlin RE, Andersson BSExperimental hematologyComparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Exp Hematol. 2015 Jun; 43(6):448-61.e2.Exp Hematol2015-02-19T00:00:002015Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.25712454Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, Champlin RE, Wang MLAnnals of oncology : official journal of the European Society for Medical OncologyPatients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.Ann Oncol2015-02-23T00:00:002015Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.25721897Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MHLeukemiaPhase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia. 2015 Sep; 29(9):1945-8.Leukemia2015-02-27T00:00:002015Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.25730192Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar SBone marrow transplantationHigh-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72.Bone Marrow Transplant2015-03-02T00:00:002015High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.25779562Pundole XN, Barbo AG, Lin H, Champlin RE, Lu HJournal of clinical oncology : official journal of the American Society of Clinical OncologyIncreased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol. 2015 Apr 20; 33(12):1364-70.J Clin Oncol2015-03-16T00:00:002015Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation.25840338Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson B, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAge and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1405-1412.Biol Blood Marrow Transplant2015-03-31T00:00:002015Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation.25842049Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1413-7.Biol Blood Marrow Transplant2015-04-02T00:00:002015Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.25847930Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov ZJournal of clinical oncology : official journal of the American Society of Clinical OncologyOutcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol. 2015 May 10; 33(14):1557-63.J Clin Oncol2015-04-06T00:00:002015Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.25867648Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin RBone marrow transplantationLeukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946.Bone Marrow Transplant2015-04-13T00:00:002015Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.25937397Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat UBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1529-1531.Biol Blood Marrow Transplant2015-04-30T00:00:002015Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment.25963284El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir QClinical lymphoma, myeloma & leukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):472-6.Clin Lymphoma Myeloma Leuk2015-03-27T00:00:002015Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.25985053Pingali SR, Champlin REBone marrow transplantationPushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2015 Sep; 50(9):1157-67.Bone Marrow Transplant2015-05-18T00:00:002015Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.25985919Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, L?pez AA, Yap DY, Popat U, Rondon G, Lichtiger B, Aung F, Afshar-Kharghan V, Ma Q, Fern?ndez-Vi?a M, Champlin RE, Cao KBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationComplement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1392-8.Biol Blood Marrow Transplant2015-05-15T00:00:002015Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.26030772Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJPloS oneSleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One. 2015; 10(6):e0128151.PLoS One2015-06-01T00:00:002015Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.26071868Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationVorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.Biol Blood Marrow Transplant2015-06-11T00:00:002015Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.26130705Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringd?n OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, Horowitz MM, Fuchs EJ, Eapen MBloodHaploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20; 126(8):1033-40.Blood2015-06-30T00:00:002015Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.26172479Kongtim P, Lee DA, Cooper LJ, Kebriaei P, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1714-20.Biol Blood Marrow Transplant2015-07-11T00:00:002015Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.26183077Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationMixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1948-54.Biol Blood Marrow Transplant2015-07-14T00:00:002015Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes.26199392Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro LAnnals of oncology : official journal of the European Society for Medical OncologyBevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Oct; 26(10):2125-32.Ann Oncol2015-07-21T00:00:002015Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.26250579Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fern?ndez-Vi?a M, Champlin RE, Shpall EJHaematologicaBetter allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.Haematologica2015-08-06T00:00:002015Better allele-level matching improves transplant-related mortality after double cord blood transplantation.26253006Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHigher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.Biol Blood Marrow Transplant2015-08-05T00:00:002015Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.26256941Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CFBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIndications for Autologous and Allogeneic Hematopoietic Cell?Transplantation: Guidelines from the American Society for?Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1863-1869.Biol Blood Marrow Transplant2015-08-07T00:00:002015Indications for Autologous and Allogeneic Hematopoietic Cell?Transplantation: Guidelines from the American Society for?Blood and Marrow Transplantation.26299958Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JEAmerican journal of hematologyImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70.Am J Hematol2015-09-10T00:00:002015Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.26308885Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HMCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64.Cancer2015-08-26T00:00:002015Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.26330164Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJCancer researchTuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 2015 Sep 01; 75(17):3505-18.Cancer Res2015-09-01T00:00:002015Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.26343946Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationTreatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.Biol Blood Marrow Transplant2015-09-04T00:00:002015Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia.26361647Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir QClinical lymphoma, myeloma & leukemiaOutcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2015 Nov; 15(11):687-93.Clin Lymphoma Myeloma Leuk2015-08-05T00:00:002015Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.26416896Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic MAnnals of oncology : official journal of the European Society for Medical OncologyAllogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec; 26(12):2490-5.Ann Oncol2015-09-28T00:00:002015Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.26431162Carter BZ, Mak PY, Mak DH, Ruvolo VR, Schober W, McQueen T, Cortes J, Kantarjian HM, Champlin RE, Konopleva M, Andreeff MOncotargetSynergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 2015 Oct 13; 6(31):30487-99.Oncotarget2015-10-13T00:00:002015Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.26473529Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BSBlood cancer journalRomidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015 Oct 16; 5:e357.Blood Cancer J2015-10-16T00:00:002015Romidepsin targets multiple survival signaling pathways in malignant T cells.26484782Kumaresan P, Figliola M, Moyes JS, Huls MH, Tewari P, Shpall EJ, Champlin R, Cooper LJJournal of visualized experiments : JoVEAutomated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System. J Vis Exp. 2015 Oct 05; (104).J Vis Exp2015-10-05T00:00:002015Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System.26487577Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro LAnnals of oncology : official journal of the European Society for Medical OncologyBevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015 Dec; 26(12):2507-8.Ann Oncol2015-10-20T00:00:002015Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.26527675Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Vi?a M, Hartzman RJ, Horowitz MM, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen MBloodThe effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016 Jan 14; 127(2):260-7.Blood2015-11-02T00:00:002015The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.26527780Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EPJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75.J Clin Oncol2015-11-02T00:00:002015Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.26582244Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang MLJournal of the National Cancer InstituteMaintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108(3).J Natl Cancer Inst2015-11-18T00:00:002015Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.26640039Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang LThe Lancet. OncologyIbrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.Lancet Oncol2015-11-28T00:00:002015Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.26702475Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MHClinical lymphoma, myeloma & leukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2016 Jan; 16(1):36-42.Clin Lymphoma Myeloma Leuk2015-12-01T00:00:002015Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.11247710La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, Raad I, Jacobson K, Kontoyiannis D, Elting L, Whimbey EClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaAdenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001 Mar 15; 32(6):871-6.Clin Infect Dis2001-03-09T00:00:002001Adenovirus infections in adult recipients of blood and marrow transplants.12042047Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, K?rbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka DCytotherapyHigh CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy. 2000; 2(2):105-10.Cytotherapy2000-01-01T00:00:002000High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.10745261Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, Jacobson K, Neumann J, Ippoliti C, Mallik S, Whimbey EBone marrow transplantationRespiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant. 2000 Apr; 25(7):751-5.Bone Marrow Transplant2000-04-01T00:00:002000Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin.12123420De La Rosa GR, Champlin RE, Kontoyiannis DPTransplant infectious disease : an official journal of the Transplantation SocietyRisk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transpl Infect Dis. 2002 Mar; 4(1):3-9.Transpl Infect Dis2002-03-01T00:00:002002Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients.10800066Huaringa AJ, Leyva FJ, Signes-Costa J, Morice RC, Raad I, Darwish AA, Champlin REBone marrow transplantationBronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients. Bone Marrow Transplant. 2000 May; 25(9):975-9.Bone Marrow Transplant2000-05-01T00:00:002000Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients.12872348Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad IICancerEfficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003 Jul 15; 98(2):292-9.Cancer2003-07-15T00:00:002003Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies.14523768Hong DS, Jacobson KL, Raad II, de Lima M, Anderlini P, Fuller GN, Ippoliti C, Cool RM, Leeds NE, Narvios A, Han XY, Padula A, Champlin RE, Hosing CClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaWest Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review. Clin Infect Dis. 2003 Oct 15; 37(8):1044-9.Clin Infect Dis2003-09-18T00:00:002003West Nile encephalitis in 2 hematopoietic stem cell transplant recipients: case series and literature review.10378833Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ, Champlin RE, K?rbling MTransfusionAllogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999 Jun; 39(6):555-60.Transfusion1999-06-01T00:00:001999Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience.27247137Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani KBloodSpecific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.Blood2016-05-31T00:00:002016Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation.74Professor14Associate Professor15641032Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, Champlin RECancerThe safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer. 2005 Feb 15; 103(4):731-9.Cancer2005-02-15T00:00:002005The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation.12220244Shaikh ZH, Torres HA, Walsh GL, Champlin RE, Kontoyiannis DPTransplant infectious disease : an official journal of the Transplantation SocietyOpen lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis. Transpl Infect Dis. 2002 Jun; 4(2):80-4.Transpl Infect Dis2002-06-01T00:00:002002Open lung biopsy in bone marrow transplant recipients has a poor diagnostic yield for a specific diagnosis.12730103Giralt S, Bensinger W, Goodman M, Podoloff D, Eary J, Wendt R, Alexanian R, Weber D, Maloney D, Holmberg L, Rajandran J, Breitz H, Ghalie R, Champlin RBlood166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood. 2003 Oct 01; 102(7):2684-91.Blood2003-05-01T00:00:002003166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials.26492205Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HMBritish journal of haematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016 Feb; 172(3):392-400.Br J Haematol2015-10-22T00:00:002015Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia.26493563Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta VBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.Biol Blood Marrow Transplant2015-10-19T00:00:002015Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.26608093Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani KAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant SurgeonsSymptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant. 2016 05; 16(5):1492-502.Am J Transplant2016-03-02T00:00:002016Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients.26902653Torikai H, Mi T, Gragert L, Maiers M, Najjar A, Ang S, Maiti S, Dai J, Switzer KC, Huls H, Dulay GP, Reik A, Rebar EJ, Holmes MC, Gregory PD, Champlin RE, Shpall EJ, Cooper LJScientific reportsGenetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep. 2016 Feb 23; 6:21757.Sci Rep2016-02-23T00:00:002016Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application.27064056Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma. Biol Blood Marrow Transplant. 2016 07; 22(7):1333-1337.Biol Blood Marrow Transplant2016-04-06T00:00:002016Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell?Transplantation for Relapsed and Refractory Hodgkin?Lymphoma.27163741Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJJournal of immunotherapy (Hagerstown, Md. : 1997)Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor. J Immunother. 2016 06; 39(5):205-17.J Immunother2016-06-01T00:00:002016Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.26950376Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat UBone marrow transplantationOutcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant. 2016 07; 51(7):999-1001.Bone Marrow Transplant2016-03-07T00:00:002016Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation.14700414Chatzinikolaou I, Hanna H, Graviss L, Chaiban G, Perego C, Arbuckle R, Champlin R, Darouiche R, Samonis G, Raad IInfection control and hospital epidemiologyClinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003 Dec; 24(12):961-3.Infect Control Hosp Epidemiol2003-12-01T00:00:002003Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance.17589530Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger BBone marrow transplantationEfficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Sep; 40(5):461-4.Bone Marrow Transplant2007-06-25T00:00:002007Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.19561648Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF, Champlin RE, Khouri IBone marrow transplantationInfections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant. 2010 Feb; 45(2):339-47.Bone Marrow Transplant2009-06-29T00:00:002009Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention.19684637Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DPBone marrow transplantationUtility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Apr; 45(4):647-55.Bone Marrow Transplant2009-08-17T00:00:002009Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation.19732952Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BSLeukemia research5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res. 2010 Mar; 34(3):364-72.Leuk Res2009-09-03T00:00:0020095-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.19822306Fenske TS, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JMBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.Biol Blood Marrow Transplant2009-11-01T00:00:002009Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.20056165Ramos CA, Saliba RM, de P?dua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationResolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):686-94.Biol Blood Marrow Transplant2010-01-06T00:00:002010Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation.15776383Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad IIThe Journal of infectious diseasesZygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005 Apr 15; 191(8):1350-60.J Infect Dis2005-03-16T00:00:002005Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.27420405Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MHAmerican journal of hematologyOutcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016 10; 91(10):E442-7.Am J Hematol2016-09-03T00:00:002016Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.22023523Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BSLeukemia & lymphomaSynergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines. Leuk Lymphoma. 2012 May; 53(5):973-81.Leuk Lymphoma2011-12-06T00:00:002011Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines.22246027Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A, Vigil K, Adachi JA, Khoury AM, Tarrand J, Hosing C, Champlin RBloodThe characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012 Mar 22; 119(12):2738-45; quiz 2969.Blood2012-01-12T00:00:002012The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation.16974212Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad IIMedicineRespiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006 Sep; 85(5):278-287.Medicine (Baltimore)2006-09-01T00:00:002006Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center.22643322Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RBBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHigh-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.Biol Blood Marrow Transplant2012-05-27T00:00:002012High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.23078785Denzen EM, Majhail NS, Stickney Ferguson S, Anasetti C, Bracey A, Burns L, Champlin R, Chell J, Leather H, Lill M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Snyder EL, Wiggins L, Yolin Raley DS, Murphy EABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative. Biol Blood Marrow Transplant. 2013 Jan; 19(1):4-11.Biol Blood Marrow Transplant2012-10-15T00:00:002012Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.17245424Safdar A, Rodriguez G, Rolston KV, O'Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DPBone marrow transplantationHigh-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Feb; 39(3):157-64.Bone Marrow Transplant2007-02-01T00:00:002007High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation.17435587Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar AMedicineStreptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005. Medicine (Baltimore). 2007 Mar; 86(2):69-77.Medicine (Baltimore)2007-03-01T00:00:002007Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005.16698688Parmar S, Robinson SN, Komanduri K, St John L, Decker W, Xing D, Yang H, McMannis J, Champlin R, de Lima M, Molldrem J, Rieber A, Bonyhadi M, Berenson R, Shpall EJCytotherapyEx vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.Cytotherapy2006-01-01T00:00:002006Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity.18041885Chou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DPPharmacotherapyCaspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007 Dec; 27(12):1644-50.Pharmacotherapy2007-12-01T00:00:002007Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.17448913Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt SBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationResults of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant. 2007 May; 13(5):543-9.Biol Blood Marrow Transplant2007-02-26T00:00:002007Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.18339423Valdez BC, Murray D, Ramdas L, de Lima M, Jones R, Kornblau S, Betancourt D, Li Y, Champlin RE, Andersson BSLeukemia researchAltered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res. 2008 Nov; 32(11):1684-97.Leuk Res2008-03-12T00:00:002008Altered gene expression in busulfan-resistant human myeloid leukemia.18004177Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, Shpall EJ, Rolston KVI, Raad II, Chan KW, Champlin REMedicineInfections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005. Medicine (Baltimore). 2007 Nov; 86(6):324-333.Medicine (Baltimore)2007-11-01T00:00:002007Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996-2005.18209724de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJBone marrow transplantationTransplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May; 41(9):771-8.Bone Marrow Transplant2008-01-21T00:00:002008Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.18830258Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJLeukemiaPET imaging of T cells derived from umbilical cord blood. Leukemia. 2009 Mar; 23(3):620-2.Leukemia2008-10-02T00:00:002008PET imaging of T cells derived from umbilical cord blood.19144658Ramos CA, Saliba RM, de P?dua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima MHaematologicaImpact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica. 2009 Feb; 94(2):249-57.Haematologica2009-01-14T00:00:002009Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.19361751Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, Gee AP, Wagner JE, Horowitz MM, Eapen MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationRapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant. 2009 May; 15(5):589-96.Biol Blood Marrow Transplant2009-05-01T00:00:002009Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.19661041Ueno NT, de Souza JA, Booser D, Nakayama K, Madewell J, Wendt RE, Hortobagyi GN, Podoloff D, Champlin REClinical breast cancerPilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. Clin Breast Cancer. 2009 Aug; 9(3):173-7.Clin Breast Cancer2009-08-01T00:00:002009Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.27638366Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2159-2164.Biol Blood Marrow Transplant2016-09-13T00:00:002016Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.27862330Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MHEuropean journal of haematologyPredictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017 Mar; 98(3):263-268.Eur J Haematol2016-12-01T00:00:002016Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.28063964Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, Shah N, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Apr; 23(4):581-587.Biol Blood Marrow Transplant2017-01-04T00:00:002017Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.19822219Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationThe effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transplant. 2010 Feb; 16(2):253-62.Biol Blood Marrow Transplant2009-10-12T00:00:002009The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes.19838220Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, Shah N, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJBone marrow transplantationCD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. Bone Marrow Transplant. 2010 Jun; 45(6):1000-7.Bone Marrow Transplant2009-10-19T00:00:002009CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields.19905893Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJHuman gene therapypiggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010 Apr; 21(4):427-37.Hum Gene Ther2010-04-01T00:00:002010piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.20304082Kassis C, Champlin RE, Hachem RY, Hosing C, Tarrand JJ, Perego CA, Neumann JL, Raad II, Chemaly RFBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDetection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1265-71.Biol Blood Marrow Transplant2010-03-18T00:00:002010Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.20664358Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CMJournal of immunotherapy (Hagerstown, Md. : 1997)Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother. 2010 Sep; 33(7):684-96.J Immunother2010-09-01T00:00:002010Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.21126598Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1169-75.Biol Blood Marrow Transplant2010-11-30T00:00:002010Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation.20558104Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood CenterThe Lancet. OncologyEffect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul; 11(7):653-60.Lancet Oncol2010-07-01T00:00:002010Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.20616663Safdar A, Ma J, Saliba F, Dupont B, Wingard JR, Hachem RY, Mattiuzzi GN, Chandrasekar PH, Kontoyiannis DP, Rolston KV, Walsh TJ, Champlin RE, Raad IIMedicineDrug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. Medicine (Baltimore). 2010 Jul; 89(4):236-244.Medicine (Baltimore)2010-07-01T00:00:002010Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis.20933509Valdez BC, Li Y, Murray D, Champlin RE, Andersson BSBiochemical pharmacologyThe synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochem Pharmacol. 2011 Jan 15; 81(2):222-32.Biochem Pharmacol2010-10-08T00:00:002010The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.20948439Li D, Li Y, Hernandez JA, Patenia R, Kim TK, Khalili J, Dougherty MC, Hanley PJ, Bollard CM, Komanduri KV, Hwu P, Champlin RE, Radvanyi LG, Molldrem JJ, Ma QJournal of immunotherapy (Hagerstown, Md. : 1997)Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J Immunother. 2010 Nov-Dec; 33(9):975-82.J Immunother2010-11-01T00:00:002010Lovastatin inhibits T-cell proliferation while preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs.21323890Samuelson S, Sandmaier BM, Heslop HE, Popat U, Carrum G, Champlin RE, Storb R, Prchal JT, Gooley TA, Deeg HJBritish journal of haematologyAllogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. Br J Haematol. 2011 Apr; 153(1):76-82.Br J Haematol2011-02-17T00:00:002011Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.22635244Georgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE, Kontoyiannis DPBone marrow transplantationThe impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplant. 2013 Jan; 48(1):141-3.Bone Marrow Transplant2012-05-28T00:00:002012The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis.22664751Ma Q, Li D, Nurieva R, Patenia R, Bassett R, Cao W, Alekseev AM, He H, Molldrem JJ, Kroll MH, Champlin RE, Sale GE, Afshar-Kharghan VBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1174-81.Biol Blood Marrow Transplant2012-06-01T00:00:002012Reduced graft-versus-host disease in C3-deficient mice is associated with decreased donor Th1/Th17 differentiation.27856368Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHaploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2017 Feb; 23(2):318-324.Biol Blood Marrow Transplant2016-11-14T00:00:002016Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.22927454Chemaly RF, Torres HA, Munsell MF, Shah DP, Rathod DB, Bodey GP, Hosing C, Saifan C, Raad II, Champlin REThe Journal of infectious diseasesAn adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012 Nov; 206(9):1367-71.J Infect Dis2012-08-22T00:00:002012An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection.23128322Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RBBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAutologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.Biol Blood Marrow Transplant2012-11-02T00:00:002012Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.21771571Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, Gee AP, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationDonor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1869-73.Biol Blood Marrow Transplant2011-07-20T00:00:002011Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.22306295Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim JS, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard CM, Miller L, Champlin RE, Shpall EJ, Zweidler-McKay PAExperimental hematologyEx?vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R?(null) mice. Exp Hematol. 2012 Jun; 40(6):445-56.Exp Hematol2012-02-02T00:00:002012Ex?vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R?(null) mice.Authorship 841170Authorship 841400Authorship 841424Authorship 841592Authorship 841684Authorship 841986Authorship 842455Authorship 842480Authorship 842696Authorship 842763Authorship 842809Authorship 842903Authorship 842949Authorship 843023Authorship 843122Authorship 843129Authorship 843178Authorship 843294Authorship 843382Authorship 843735Authorship 843753Authorship 844016Authorship 844548Authorship 844753Authorship 844977Authorship 844986Authorship 845032Authorship 845039Authorship 845060Authorship 845093Authorship 845531Authorship 845605Authorship 845622Authorship 845766Authorship 846117Authorship 846335Authorship 846644Authorship 846688Authorship 846960Authorship 847211Authorship 847254Authorship 847614Authorship 847872Authorship 848961Authorship 849386Authorship 849465Authorship 850266Authorship 850391Authorship 85046022432070Mulanovich VE, Jiang Y, de Lima M, Shpall EJ, Champlin RE, Ciurea SOAmerican journal of blood researchInfectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res. 2011; 1(1):98-105.Am J Blood Res2011-06-07T00:00:002011Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation.Authorship 851417Authorship 851527Authorship 851644Authorship 852152Authorship 852357Authorship 852399Authorship 852466Authorship 852519Authorship 852554Authorship 852890Authorship 853020Authorship 853521Authorship 854221Authorship 854510Authorship 854841Authorship 854968Authorship 855080Authorship 855251Authorship 855414Authorship 855514Authorship 855688Authorship 856003Authorship 856048Authorship 856101Authorship 856193Authorship 856413Authorship 856467Authorship 856589Authorship 856838Authorship 856842Authorship 857080Authorship 857677Authorship 857921Authorship 858047Authorship 858179Authorship 858795Authorship 858887Authorship 858928Authorship 859136Authorship 859405Authorship 859633Authorship 859671Authorship 859842Authorship 859929Authorship 860125Authorship 860418Authorship 860481Authorship 860894Authorship 860923Authorship 860936Authorship 861331Authorship 861486Authorship 861951Authorship 861983Authorship 862037Authorship 862072Authorship 862115Authorship 862188Authorship 862250Authorship 862270Authorship 862512Authorship 862540Authorship 862595Authorship 862943Authorship 862957Authorship 863984Authorship 864057Authorship 864500Authorship 864610Authorship 864913Authorship 864939Authorship 865358Authorship 865612Authorship 865615Authorship 865815Authorship 865846Authorship 866173Authorship 866294Authorship 866334Authorship 866428Authorship 866459Authorship 866472Authorship 866980Authorship 867087Authorship 867181Authorship 867289Authorship 867323Authorship 867511Authorship 867663Authorship 867821Authorship 867943Authorship 868130Biology of Blood and Marrow TransplantationGraft Biology. Biology of Blood and Marrow Transplantation. 13:76.Graft BiologyLarge scale generation of genetically modified T-cells using micro-electroporators for cancer treatments. 2226-2229.Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatmentsProceedings of the National Academy of Sciences of the United States of AmericaTethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America. 113:E7788-E7797.Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cellsBone Marrow TransplantationPreface. Bone Marrow Transplantation. 10.PrefaceBlood Cancer JournalSynergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer Journal. 4.Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell linesBiology of Blood and Marrow TransplantationTreatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forPatients with Chronic Myelomonocytic LeukemiaBiology of Blood and Marrow TransplantationHaploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:318-324.Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic LeukemiaClinical Lymphoma, Myeloma and LeukemiaAutologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia. 15:472-476.Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma PatientsBiology of Blood and Marrow TransplantationHepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. Biology of Blood and Marrow Transplantation. 22:717-722.Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral AgentsBone Marrow TransplantationPushing the envelope - Nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplantation. 50:1157-1167.Pushing the envelope - Nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantationClinical Lymphoma, Myeloma and LeukemiaOutcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell TransplantationCancer BulletinPotential of gene therapy for allogeneic bone marrow transplantation. Cancer Bulletin. 45:159-163.Potential of gene therapy for allogeneic bone marrow transplantationAnnals of OncologyBevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doi. Annals of Oncology. 26:2507-2508.Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors [Ann Oncol, 26, (2015), 2125-2132] doiBiology of Blood and Marrow TransplantationAge and Modified European LeukemiaNet Classification to Predict Transplant Outcomes. Biology of Blood and Marrow Transplantation. Age and Modified European LeukemiaNet Classification to Predict Transplant OutcomesBloodGeneration and clinical useofleuimiaderived dendritic cell activated lymphocytes in patients with chronic myelogenous leukemia (CML). Blood. 96.Generation and clinical useofleuimiaderived dendritic cell activated lymphocytes in patients with chronic myelogenous leukemia (CML)Cancer Biology and TherapyUsing mesenchymal stem cells to hone in and deliver anti-tumor therapy with interferon-beta. Cancer Biology and Therapy. 3:1192.Using mesenchymal stem cells to hone in and deliver anti-tumor therapy with interferon-betaHematologieReduction de l'alloreactivite des cellules mononucleees. Hematologie. 5:104-107.Reduction de l'alloreactivite des cellules mononucleeesTransplantation ProceedingsAntithymocyte globulin treatment for aplastic anemia. Transplantation Proceedings. 15:595-598.Antithymocyte globulin treatment for aplastic anemiaBiology of Blood and Marrow TransplantationPure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biology of Blood and Marrow Transplantation. 22:961-965.Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaBiology of Blood and Marrow TransplantationMixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation. 21:1948-1954.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic SyndromesBritish Journal of HaematologyMinimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaBloodAre 2 cords better than 1?. Blood. 110:2789-2790.Are 2 cords better than 1?Bone Marrow TransplantationErratum. Bone Marrow Transplantation. 25:463.ErratumBreast DiseasesAutologous hematopoietic stem cell transplantation in breast cancer. Breast Diseases. 15:113-117.Autologous hematopoietic stem cell transplantation in breast cancerCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myelomaLeukemia and LymphomaThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia and Lymphoma. 55:1625-1634.The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfanScientific ReportsGenetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Scientific Reports. 6.Genetic editing of HLA expression in hematopoietic stem cells to broaden their human applicationBiology of Blood and Marrow TransplantationHigher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of Blood and Marrow Transplantation. 22:226-231.Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and AmyloidosisBloodAllogeneic transplantation with nonmyeloablative or reduced intensity conditioning. Blood. 96.Allogeneic transplantation with nonmyeloablative or reduced intensity conditioningAnnals of OncologyBevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Annals of Oncology. 26:2125-2132.Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumorsJAMA - Journal of the American Medical AssociationIn Reply. JAMA - Journal of the American Medical Association. 261:2332.In ReplyExperimental HematologyCladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas. Experimental Hematology. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomasBloodComparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL). Blood. 96.Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL)Bone Marrow TransplantationTotal body irradiation and the therapeutic ratio of bone marrow transplantation. Bone Marrow Transplantation. 15.Total body irradiation and the therapeutic ratio of bone marrow transplantationManagement of acute leukemias. Management of acute leukemiasCancerLong-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaBiology of Blood and Marrow TransplantationVorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biology of Blood and Marrow Transplantation. 21:1914-1920.Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory LymphomasBone Marrow TransplantationAutologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplantation. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvementPLoS OneSleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populations. PLoS One. 10.Sleeping Beauty transposition of chimeric antigen receptors targeting receptor tyrosine kinase-like orphan receptor-1 (ROR1) into diverse memory T-cell populationsCytotherapyStem-cell transplantation for lymphoma. Cytotherapy. 4:203.Stem-cell transplantation for lymphomaEstablishing a GMP manufacturing site for nanoparticles. 413-416.Establishing a GMP manufacturing site for nanoparticlesTransplant Infectious DiseasePoor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transplant Infectious Disease. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipientsExperimental HematologyInduction of graft-vs-malignancy as a primary therapeutic modality. Experimental Hematology. 26:816.Induction of graft-vs-malignancy as a primary therapeutic modalityMolecular Imaging and BiologyImaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Molecular Imaging and Biology. 1-11.Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission TomographyTransfusion and Apheresis ScienceIntegration of Biological, Procedural, Apheresis Principles of Peripheral Blood Stem Cell Transplantation Programs. Transfusion and Apheresis Science. 17:585-590.Integration of Biological, Procedural, Apheresis Principles of Peripheral Blood Stem Cell Transplantation ProgramsBiology of Blood and Marrow TransplantationGemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin LymphomaCancer BulletinDose-intensive therapy with autologous bone marrow transplantation for treatment of breast cancer. Cancer Bulletin. 45:532-537.Dose-intensive therapy with autologous bone marrow transplantation for treatment of breast cancerBone Marrow TransplantationTransplantation of blood-derived hematopoietic stem cells. Bone Marrow Transplantation. 15.Transplantation of blood-derived hematopoietic stem cellsBloodFilgrastim alone versus chemotherapy plis filgrastim for peripheral blood stem cell mobilization in multiple myeloma. Blood. 96.Filgrastim alone versus chemotherapy plis filgrastim for peripheral blood stem cell mobilization in multiple myelomaBiology of Blood and Marrow TransplantationOptimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation. Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow TransplantationOncotargetSynergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34<sup>+</sup> proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget. 6:30487-30499.Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34<sup>+</sup> proliferating and quiescent chronic myeloid leukemia blast crisis cellsRelapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation. 836-844.Relapse of Hematologic Malignancy After Allogeneic Hematopoietic TransplantationBone Marrow TransplantationAre changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?. Bone Marrow Transplantation. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?Journal of Visualized ExperimentsAutomated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. Journal of Visualized Experiments. 2015.Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture systemBone Marrow TransplantationT-cell depletion for allogeneic marrow transplantation. Bone Marrow Transplantation. 15.T-cell depletion for allogeneic marrow transplantationLeukemia and LymphomaAllogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion. Leukemia and Lymphoma. 56:711-715.Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletionExperimental HematologyInduction of graft-versus-leukemia using flu-darabine-based allogeneic mini-transplants as treatment for lymphoid malignancies. Experimental Hematology. 25:735.Induction of graft-versus-leukemia using flu-darabine-based allogeneic mini-transplants as treatment for lymphoid malignanciesComparative Haematology InternationalEffects of administration of recombinant human interleukin-2 in dogs. Comparative Haematology International. 2:201-207.Effects of administration of recombinant human interleukin-2 in dogs22687754Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BSExperimental hematologyEpigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol. 2012 Oct; 40(10):800-10.Exp Hematol2012-06-09T00:00:002012Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.HaematologicaBetter allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 100:1361-1370.Better allele-level matching improves transplant-related mortality after double cord blood transplantationCurrent Opinion in Organ TransplantationNonmyeloablative hematopoietic transplantation for treatment of malignant diseases. Current Opinion in Organ Transplantation. 7:275-278.Nonmyeloablative hematopoietic transplantation for treatment of malignant diseasesThe Lancet OncologyIbrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma. The Lancet Oncology. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphomaPLoS OneRedirecting specificity of t cells using the Sleeping Beauty system to express chimeric antigen receptors by mix-and-matching of V<sub>L</sub> and V<sub>H</sub> domains targeting CD123<sup>+</sup> tumors. PLoS One. 11.Redirecting specificity of t cells using the Sleeping Beauty system to express chimeric antigen receptors by mix-and-matching of V<sub>L</sub> and V<sub>H</sub> domains targeting CD123<sup>+</sup> tumorsLeukemia and LymphomaDouble umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leukemia and Lymphoma. 1-9.Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphomaClinical Infectious DiseasesCMV pneumonia in adult autologous blood and marrow transplant recipients. Clinical Infectious Diseases. 25:374.CMV pneumonia in adult autologous blood and marrow transplant recipientsBiology of Blood and Marrow TransplantationAllogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous LeukemiaBone Marrow TransplantationFludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplantation. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patientsBiology of Blood and Marrow TransplantationProceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biology of Blood and Marrow Transplantation. 22:594-604.Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014Leukemia and LymphomaStem cell transplantation outcomes in lymphoblastic lymphoma. Leukemia and Lymphoma. 1-6.Stem cell transplantation outcomes in lymphoblastic lymphomaThe LancetBONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA. The Lancet. 326:1295.BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIAJournal of ImmunotherapyRedirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptor. Journal of Immunotherapy. 39:205-217.Redirecting T-cell specificity to EGFR using mRNA to self-limit expression of chimeric antigen receptorBiology of Blood and Marrow TransplantationComplement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1392-1398.Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell TransplantationExperimental HematologyRecombinant human thrombopoietin (RHTPO) for moblization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer. Experimental Hematology. 26:780.Recombinant human thrombopoietin (RHTPO) for moblization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancerAnnals of OncologyAllogeneic stem-cell transplantation in patients with cutaneous lymphoma. Annals of Oncology. 26:2490-2495.Allogeneic stem-cell transplantation in patients with cutaneous lymphomaTransplantation ProceedingsProspective randomized controlled trial of ex vivo treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for prevention of graft-versus-host disease. Transplantation Proceedings. 17:482-485.Prospective randomized controlled trial of ex vivo treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for prevention of graft-versus-host diseaseAmerican Journal of TransplantationSymptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. American Journal of Transplantation. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell RecipientsClinical Infectious DiseasesInfluenza B in hospitalized immunocompromised adults. Clinical Infectious Diseases. 25:376.Influenza B in hospitalized immunocompromised adultsCancerPrognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemiaBloodSpecific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 128:297-312.Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationCancerDifferential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaBone Marrow TransplantationMulti-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplantation. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomesHematologic cancer survivorship management. 167-186.Hematologic cancer survivorship managementLeukemia and LymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference. Leukemia and Lymphoma. 1-5.Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies ConferenceBone Marrow TransplantationOutcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplantation. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantationLeukemia and LymphomaChromosome 8q24.1/c-MYC abnormality. Leukemia and Lymphoma. 56:602-607.Chromosome 8q24.1/c-MYC abnormalityBiology of Blood and Marrow TransplantationOutcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 22:2159-2164.Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell TransplantationCancer BulletinOutpatient autologous bone marrow transplantation. Cancer Bulletin. 47:298-300.Outpatient autologous bone marrow transplantationHospital FormularyControlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Hospital Formulary. 24:20-31.Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patientsBiology of Blood and Marrow TransplantationIndications for Autologous and Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1863-1869.Indications for Autologous and Allogeneic Hematopoietic Cell TransplantationJournal of Clinical OncologyEpstein-Barr virus and B cells in the pathogenesis of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation. Journal of Clinical Oncology. 34:2201-2202.Epstein-Barr virus and B cells in the pathogenesis of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantationBiology of Blood and Marrow TransplantationOutcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biology of Blood and Marrow Transplantation. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based ConditioningUnknown JournalForeword. Unknown Journal. ForewordBloodGeneration of immunologically active dendritic cells from chronic myelomonocytic leukemia (CMML). Blood. 96.Generation of immunologically active dendritic cells from chronic myelomonocytic leukemia (CMML)Experimental HematologyReply to Sackstein. Experimental Hematology. 40:519-520.Reply to SacksteinClinical Lymphoma, Myeloma and LeukemiaOutcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation. Clinical Lymphoma, Myeloma and Leukemia. 15:687-693.Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantationTransplantation ProceedingsSuccessful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemia. Transplantation Proceedings. 17:496-499.Successful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemiaIndications for hematopoietic transplantation for aml. 777-797.Indications for hematopoietic transplantation for amlBiology of Blood and Marrow TransplantationClofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 23:285-292.Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic LeukemiaOncologyNonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Oncology. 17:94-100.Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantationExpert Opinion on Orphan Drugs5-Azacitidine for treating acute myelogenous leukemia. Expert Opinion on Orphan Drugs. 3:1197-1207.5-Azacitidine for treating acute myelogenous leukemiaHematopoietic Stem Cell Transplantation. 485-492.e2.Hematopoietic Stem Cell TransplantationBone Marrow TransplantationLeukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplantation. 50:939-946.Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationLeukemia and LymphomaSynergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leukemia and Lymphoma. 1-9.Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cellsLeukemia and LymphomaShort-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Leukemia and Lymphoma. 56:533-535.Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myelomaCancerResults of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 122:3316-3326.Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantationBiology of Blood and Marrow TransplantationHaploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies. Biology of Blood and Marrow Transplantation. 22:1290-1298.Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid MalignanciesJournal of Investigative MedicineThe human multiple drug resistance gene (mdr-1) is used to confer chemoprotection upon hematopoietic progenitor cells in a clinical gene therapy trial setting for ovarian and breast cancer treatment. Journal of Investigative Medicine. 44.The human multiple drug resistance gene (mdr-1) is used to confer chemoprotection upon hematopoietic progenitor cells in a clinical gene therapy trial setting for ovarian and breast cancer treatmentExperimental HematologyInduction of graft-vs-leukemin as a therapeutic modality. Experimental Hematology. 24:1155.Induction of graft-vs-leukemin as a therapeutic modalityBiology of Blood and Marrow TransplantationOutcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 21:1413-1417.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, andSoft Tissue Involvement after Autologous Hematopoietic Stem Cell TransplantationExperimental HematologyStem cell selection. Experimental Hematology. 24:1155.Stem cell selectionSeminars in Breast DiseaseAllogeneic transplantation in metastatic breast cancer. Seminars in Breast Disease. 3:176-184.Allogeneic transplantation in metastatic breast cancerHematologia - Citocinas, Inmunoterapia y Terapia CelularBases biológicas e indicaciones de los trasplantes no mieloablativos. Hematologia - Citocinas, Inmunoterapia y Terapia Celular. 5:182-192.Bases biológicas e indicaciones de los trasplantes no mieloablativosBloodPhase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 127:1656-1665.Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failureExperimental HematologyHigh-dose chemo-radiotherapy with autologous bone marrow transplantation (ABMT) in patients with cancer. Experimental Hematology. 9:142.High-dose chemo-radiotherapy with autologous bone marrow transplantation (ABMT) in patients with cancerBloodAllogeneic hematopoietic transplantation for indolent lymphomas. Blood. 96.Allogeneic hematopoietic transplantation for indolent lymphomasBiology of Blood and Marrow TransplantationHaploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. Biology of Blood and Marrow Transplantation. 21:1714-1720.Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular TherapyAmerican Journal of HematologyImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeHaematologicaPre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 102:110-117.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaLeukemiaPR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignanciesLeukemia ResearchRomidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leukemia Research. 47:100-108.Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cellsClinical Infectious DiseasesCMV pneumonia in adult allogeneic blood and marrow transplant recipients. Clinical Infectious Diseases. 25:355.CMV pneumonia in adult allogeneic blood and marrow transplant recipients22796535Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImproved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.Biol Blood Marrow Transplant2012-07-11T00:00:002012Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.Journal of Clinical InvestigationPhase i trials using sleeping beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. 126:3363-3376.Phase i trials using sleeping beauty to generate CD19-specific CAR T cellsSeminars in HematologyErratum. Seminars in Hematology. 39:141.ErratumBritish Journal of HaematologyPost-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. British Journal of Haematology. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantationSeminars in OncologyThe University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Seminars in Oncology. 24.The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancerBiology of Blood and Marrow TransplantationHematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30<sup>+</sup> Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biology of Blood and Marrow Transplantation. 21:1529-1531.Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30<sup>+</sup> Lymphoma Patients Who Received Multiple Prior Lines of TreatmentBloodThe effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 127:260-267.The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyExperimental HematologyAn analysis of factors correlated with the collection of peripheral blood progenitor cells (pbpcs) from normal donors. Experimental Hematology. 24:1046.An analysis of factors correlated with the collection of peripheral blood progenitor cells (pbpcs) from normal donorsBiology of Blood and Marrow TransplantationBiology of Blood and Marrow Transplantation. 22:1792-1800.Biology of Blood and Marrow TransplantationOncotargetDifferential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 7:63829-63838.Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapyBloodMHC class I chain-related gene a (MICA) in unrelated donor transplantation. Blood. 114:4754-4756.MHC class I chain-related gene a (MICA) in unrelated donor transplantationArchives of Internal MedicinePneumococcal Vaccination of Recipients of Bone Marrow Transplants. Archives of Internal Medicine. 143:1735-1737.Pneumococcal Vaccination of Recipients of Bone Marrow TransplantsFrontiers in Bioscience - ScholarCARs. Frontiers in Bioscience - Scholar. 4 S:520-531.CARsProceedings of the National Academy of Sciences of the United States of AmericaResults of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351)). Proceedings of the National Academy of Sciences of the United States of America. 94:5495.Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy (Proceedings of the National Academy of Sciences (December 24, 1996) 93 (15346-15351))Bone marrow transplantation for chronic myelogenous leukemia (CML) in chronic phase. Bone marrow transplantation for chronic myelogenous leukemia (CML) in chronic phaseBone Marrow TransplantationGenetic therapy of human disease. Bone Marrow Transplantation. 15.Genetic therapy of human diseaseBiology of Blood and Marrow TransplantationErratum. Biology of Blood and Marrow Transplantation. 10:884.ErratumJournal of Clinical OncologyPhase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen. Journal of Clinical Oncology. 33:4167-4175.Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimenCancer BulletinTherapeutic use of hematopoietic growth factors for patients receiving high-dose chemotherapy and bone marrow transplantation. Cancer Bulletin. 43:197-207.Therapeutic use of hematopoietic growth factors for patients receiving high-dose chemotherapy and bone marrow transplantationLeukemia and LymphomaNew directions in the biology and therapy of chronic myeloid leukemia. Leukemia and Lymphoma. 6:89-95.New directions in the biology and therapy of chronic myeloid leukemiaCancerPrognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseInfusionstherapie und TransfusionsmedizinAllogeneic blood stem cell transplantation. Infusionstherapie und Transfusionsmedizin. 24:244.Allogeneic blood stem cell transplantation28295190Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJBritish journal of haematologyPhase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.Br J Haematol2017-03-14T00:00:002017Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.28389254Pingali SR, Saliba RM, Anderlini P, Hosing C, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat URBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAge over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2017 Jul; 23(7):1059-1063.Biol Blood Marrow Transplant2017-04-04T00:00:002017Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma.7688862Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork AThe New England journal of medicinePreliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med. 1993 Sep 09; 329(11):757-61.N Engl J Med1993-09-09T00:00:001993Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.8722930Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, Przepiorka D, Lewis VA, Mirza N, Yousuf H, Tarrand JJ, Bodey GPClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaCommunity respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996 May; 22(5):778-82.Clin Infect Dis1996-05-01T00:00:001996Community respiratory virus infections among hospitalized adult bone marrow transplant recipients.8922798Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K, Przepiorka D, Mirza NQ, Yousuf HM, Luna M, Bodey GP, Whimbey EClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRespiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996 Nov; 23(5):1033-7.Clin Infect Dis1996-11-01T00:00:001996Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients.9181397Garcia R, Raad I, Abi-Said D, Bodey G, Champlin R, Tarrand J, Hill LA, Umphrey J, Neumann J, Englund J, Whimbey EInfection control and hospital epidemiologyNosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients. Infect Control Hosp Epidemiol. 1997 Jun; 18(6):412-6.Infect Control Hosp Epidemiol1997-06-01T00:00:001997Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients.28485023Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing CBritish journal of haematologyA randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017 08; 178(4):561-570.Br J Haematol2017-05-09T00:00:002017A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.28522110Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash MThe Lancet. HaematologyHigh-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol. 2017 Jun; 4(6):e283-e292.Lancet Haematol2017-05-15T00:00:002017High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.10194088Nguyen Q, Champlin R, Giralt S, Rolston K, Raad I, Jacobson K, Ippoliti C, Hecht D, Tarrand J, Luna M, Whimbey EClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaLate cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis. 1999 Mar; 28(3):618-23.Clin Infect Dis1999-03-01T00:00:001999Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.10530441Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey EClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis. 1999 Sep; 29(3):528-32.Clin Infect Dis1999-09-01T00:00:001999Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients.10706456Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MALeukemia & lymphomaIntensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.Leuk Lymphoma1999-10-01T00:00:001999Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.11071260Andersson BS, Madden T, Tran HT, Hu WW, Blume KG, Chow DS, Champlin RE, Vaughan WPBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAcute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant. 2000; 6(5A):548-54.Biol Blood Marrow Transplant2000-01-01T00:00:002000Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.28160352Maher OM, Silva JG, Wu J, Liu D, Cooper LJ, Tarek N, Worth L, Lee DA, Petropoulos D, Franklin AR, Zweidler-Mckay P, Wells RJ, Rondon G, Champlin RE, Tewari PPediatric transplantationOutcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatr Transplant. 2017 May; 21(3).Pediatr Transplant2017-02-03T00:00:002017Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.11477447Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, Rolston K, Jacobson K, Tarrand J, Luna M, Nguyen Q, Whimbey EBone marrow transplantationCytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant. 2001 Apr; 27(8):877-81.Bone Marrow Transplant2001-04-01T00:00:002001Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients.27862740Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani KTransplant infectious disease : an official journal of the Transplantation SocietyPoor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017 Feb; 19(1).Transpl Infect Dis2016-12-28T00:00:002016Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.26479980Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MHBone marrow transplantationAutologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant. 2016 Feb; 51(2):307-9.Bone Marrow Transplant2015-10-19T00:00:002015Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement.28725044Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani KLeukemiaCord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531.Leukemia2017-07-20T00:00:002017Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.28766962Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BSExpert opinion on drug metabolism & toxicologyClarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017 Sep; 13(9):901-923.Expert Opin Drug Metab Toxicol2017-08-17T00:00:002017Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.15069017Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin RBloodTumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54.Blood2004-04-06T00:00:002004Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.16400333Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, Kaur I, Fu P, Del Angel M, Messinger R, Flagge F, de Lima M, Decker W, Xing D, Champlin R, Shpall EJBone marrow transplantationSuperior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant. 2006 Feb; 37(4):359-66.Bone Marrow Transplant2006-02-01T00:00:002006Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells.16435011Yang H, Eaves C, de Lima M, Lee MS, Champlin RE, McMannis JD, Robinson SN, Niu T, Decker WK, Xing D, Ng J, Li S, Yao X, Eaves AC, Jones R, Andersson BS, Shpall EJBone marrow transplantationA novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant. 2006 Mar; 37(6):575-82.Bone Marrow Transplant2006-03-01T00:00:002006A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.16480795Decker WK, Xing D, Li S, Robinson SN, Yang H, Yao X, Segall H, McMannis JD, Komanduri KV, Champlin RE, Shpall EJVaccineDouble loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine. 2006 Apr 12; 24(16):3203-16.Vaccine2006-01-23T00:00:002006Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help.16691620Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, Shpall EJ, Raad II, Kantarjian HM, Champlin RECancerRecombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006 Jun 15; 106(12):2664-71.Cancer2006-06-15T00:00:002006Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.16698683Xing D, Decker WK, Li S, Robinson SN, Yang H, Segal H, O'Connor S, Yao X, Komanduri KV, McMannis JD, Jones RB, de Lima M, Champlin RE, Shpall EJCytotherapyAML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy. 2006; 8(2):95-104.Cytotherapy2006-01-01T00:00:002006AML-loaded DC generate Th1-type cellular immune responses in vitro.16845427Qazilbash MH, Ueno NT, Hosing C, De Lima M, Cortes J, Massaro A, Rivera Z, Deavers M, Adachi JA, Champlin REBone marrow transplantationStrongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 2006 Sep; 38(5):393-4.Bone Marrow Transplant2006-07-17T00:00:002006Strongyloidiasis after unrelated nonmyeloablative allogeneic stem cell transplantation.17530009Ozdemir E, Saliba RM, Champlin RE, Couriel DR, Giralt SA, de Lima M, Khouri IF, Hosing C, Kornblau SM, Anderlini P, Shpall EJ, Qazilbash MH, Molldrem JJ, Chemaly RF, Komanduri KVBone marrow transplantationRisk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.Bone Marrow Transplant2007-05-28T00:00:002007Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.17605730Sims CR, Thompson K, Chemaly RF, Shpall EJ, Champlin RE, Safdar ATransplant infectious disease : an official journal of the Transplantation SocietyOral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection. Transpl Infect Dis. 2007 Sep; 9(3):256-9.Transpl Infect Dis2007-07-01T00:00:002007Oral topical cidofovir: novel route of drug delivery in a severely immunosuppressed patient with refractory multidrug-resistant herpes simplex virus infection.19746587Przepiorka D, Lu JG, Anderlini P, K?rbling M, Donato M, Champlin R, Gee AP, van Vlasselaer PCytotherapyDebulking blood stem cell collections by density gradient centrifugation in a closed-vessel system. Cytotherapy. 1999; 1(2):111-7.Cytotherapy1999-01-01T00:00:001999Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system.20946966Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationClofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900.Biol Blood Marrow Transplant2010-10-11T00:00:002010Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.21396475Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationReversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1551-5.Biol Blood Marrow Transplant2011-03-09T00:00:002011Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement.21451576Jin Z, Maiti S, Huls H, Singh H, Olivares S, M?t?s L, Izsv?k Z, Ivics Z, Lee DA, Champlin RE, Cooper LJGene therapyThe hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. 2011 Sep; 18(9):849-56.Gene Ther2011-03-31T00:00:002011The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor.21646477Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJCancer researchEx vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9.Cancer Res2011-06-06T00:00:002011Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.22178961Majhail NS, Murphy EA, Denzen EM, Ferguson SS, Ferguson SS, Anasetti C, Bracey A, Burns L, Champlin R, Hubbard N, Markowitz M, Maziarz RT, Medoff E, Neumann J, Schmit-Pokorny K, Weisdorf DJ, Yolin Raley DS, Chell J, Snyder ELBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationThe National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment. Biol Blood Marrow Transplant. 2012 Feb; 18(2):172-82.Biol Blood Marrow Transplant2011-12-14T00:00:002011The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.23234514de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJThe New England journal of medicineCord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.N Engl J Med2012-12-13T00:00:002012Cord-blood engraftment with ex vivo mesenchymal-cell coculture.28986189Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPrevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 02; 24(2):353-358.Biol Blood Marrow Transplant2017-10-03T00:00:002017Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation.28834808Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AMThe American journal of surgical pathologyHistologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol. 2017 Nov; 41(11):1483-1490.Am J Surg Pathol2017-11-01T00:00:002017Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease.Authorship 88708423Authorship 88725019Authorship 88757917Authorship 88786923Authorship 88798914Authorship 88802819Authorship 88805718Authorship 88813513Authorship 88817114Authorship 88825212Authorship 88826418Authorship 8885853Authorship 88865122Authorship 88886130Authorship 88893115Authorship 88904713Authorship 88918410Authorship 8892309Authorship 88933221Authorship 88959616Authorship 88962418Authorship 88964621Authorship 8898869Authorship 8900987D018380Procedures56065190.273632Hematopoietic Stem Cell TransplantationD016026Procedures33215800.664377Bone Marrow TransplantationD019172Procedures21822240.514993Transplantation ConditioningAuthorship 8952264Authorship 90438721Authorship 9045347Authorship 90464112Authorship 9046462Authorship 90487414Authorship 90497037Authorship 9050178Authorship 90512416Authorship 90537710Authorship 90652920Authorship 90661613Authorship 90683819Authorship 90715421Authorship 9080668Authorship 9083369Authorship 90891231Authorship 90902620Authorship 90956017Authorship 90970516Authorship 9098559Authorship 9099315Authorship 9102748Authorship 91031521Authorship 91064616Authorship 9106739Authorship 91073614Authorship 9107869Authorship 9109077Authorship 91106618Authorship 9112936Authorship 91161418Authorship 9117628Authorship 91226524Authorship 91229618Authorship 9126279Authorship 9127619Authorship 91293717Authorship 9132625Authorship 91491921Authorship 91499012Authorship 9150415Authorship 91530218Authorship 91537022Authorship 91541913Authorship 91551425Authorship 9155626Authorship 91634325Authorship 91652020Authorship 91718712Authorship 91735825Authorship 9174332Authorship 91749615Authorship 9175858Authorship 91785013Authorship 91798314Authorship 91842311Authorship 91865416Authorship 9190657Authorship 91942917Authorship 91958612Authorship 91996111Authorship 92007313Authorship 92023215Authorship 9222045Authorship 92239216Authorship 92252621Authorship 92312111Authorship 92339916Authorship 92345215Authorship 9236817Authorship 92385212Authorship 9239259Authorship 92396316Authorship 92461112Authorship 92553914Authorship 92563321Authorship 92574219Authorship 92599627Authorship 9270416Authorship 92705117Authorship 9271499Authorship 9275537Authorship 9276028Authorship 92768512Authorship 92977719Authorship 92999521Authorship 9305707Authorship 9321624Authorship 93231312Authorship 93279011Authorship 93286811Authorship 9330453Authorship 93331417Authorship 93471418Authorship 93480712Authorship 9350508Authorship 9351165Authorship 93517616Authorship 93557417Authorship 93570516Authorship 93600319Authorship 93687015Authorship 93748028Authorship 93757110Authorship 93766913Authorship 93793317Authorship 93851914Authorship 93904621Authorship 93997111Authorship 9403422511701541Cabanillas F, Horning S, Kaminski M, Champlin RHematology. American Society of Hematology. Education ProgramManaging Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. Hematology Am Soc Hematol Educ Program. 2000; 166-179.Hematology Am Soc Hematol Educ Program2000-01-01T00:00:002000Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options.25356072Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt SThe Internet journal of hematologyThe Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol. 2009; 7(1).Internet J Hematol2009-01-01T00:00:002009The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes.26472485Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CMLeukemia & lymphomaDouble umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.Leuk Lymphoma2015-12-23T00:00:002015Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma.26773409Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MHEuropean journal of haematologyOutcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. Eur J Haematol. 2016 Oct; 97(4):342-7.Eur J Haematol2016-02-15T00:00:002016Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.26825712Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D'Agostino RB, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJBloodPhase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65.Blood2016-01-29T00:00:002016Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.26887657Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CSLeukemia & lymphomaAsia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma. 2016 07; 57(7):1534-8.Leuk Lymphoma2016-02-17T00:00:002016Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China.26947769Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, Qazilbash M, Bashir Q, Ahmed S, Popat U, Hosing C, Khouri I, Shpall EJ, Champlin RE, Ciurea SOBritish journal of haematologyPost-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.Br J Haematol2016-03-07T00:00:002016Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.26524730Bayraktar UD, Milton DR, Guindani M, Rondon G, Chen J, Al-Atrash G, Rezvani K, Champlin R, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOptimal Threshold and Time of Absolute Lymphocyte Count?Assessment for Outcome Prediction after Bone Marrow?Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):505-13.Biol Blood Marrow Transplant2015-10-31T00:00:002015Optimal Threshold and Time of Absolute Lymphocyte Count?Assessment for Outcome Prediction after Bone Marrow?Transplantation.26806585Al Malki MM, Horowitz M, Handgretinger R, Leung W, Roy DC, Huang XJ, Fuchs E, Locatelli F, Blaise D, Mineishi S, Martelli M, Miller J, June C, Ai HS, Luznik L, Mavilio D, Lugli E, van den Brink MRM, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationProceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr; 22(4):594-604.Biol Blood Marrow Transplant2016-01-13T00:00:002016Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.26871714Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZBlood cancer journalSiltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J. 2016 Feb 12; 6:e396.Blood Cancer J2016-02-12T00:00:002016Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.26497906Brammer JE, Khouri I, Gaballa S, Anderlini P, Tomuleasa C, Ahmed S, Ledesma C, Hosing C, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016 Mar; 22(3):493-8.Biol Blood Marrow Transplant2015-10-20T00:00:002015Outcomes of Haploidentical Stem Cell Transplantation for?Lymphoma with Melphalan-Based Conditioning.26712592Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, Torres HABiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. Biol Blood Marrow Transplant. 2016 Apr; 22(4):717-722.Biol Blood Marrow Transplant2015-12-19T00:00:002015Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents.26921820Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat UBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.Biol Blood Marrow Transplant2016-02-26T00:00:002016Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.26976752Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BSExperimental hematologyCladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol. 2016 06; 44(6):458-65.Exp Hematol2016-03-11T00:00:002016Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.27090958Lee DA, Denman CJ, Rondon G, Woodworth G, Chen J, Fisher T, Kaur I, Fernandez-Vina M, Cao K, Ciurea S, Shpall EJ, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHaploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant. 2016 07; 22(7):1290-1298.Biol Blood Marrow Transplant2016-04-16T00:00:002016Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.27091710Rezvani K, Champlin REJournal of clinical oncology : official journal of the American Society of Clinical OncologyEpstein-Barr Virus and B Cells in the Pathogenesis of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2016 07 01; 34(19):2201-2.J Clin Oncol2016-04-18T00:00:002016Epstein-Barr Virus and B Cells in the Pathogenesis of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation.27377901Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationLong-Term Outcomes after Treatment with Clofarabine???Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2016 10; 22(10):1792-1800.Biol Blood Marrow Transplant2016-07-01T00:00:002016Long-Term Outcomes after Treatment with Clofarabine???Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.27294334Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BSLeukemia researchRomidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res. 2016 08; 47:100-8.Leuk Res2016-05-27T00:00:002016Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.27439912Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson A, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani KBloodIL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood. 2016 09 08; 128(10):1346-61.Blood2016-07-20T00:00:002016IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation.27508525Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour ECancerPrognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.Cancer2016-08-10T00:00:002016Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.27654852Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, Kanodia S, Ruisaard KE, Giralt SA, Estey EH, Cortes J, Komanduri KV, Clise-Dwyer K, Alatrash G, Ma Q, Champlin RE, Molldrem JJLeukemiaPR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia. 2017 03; 31(3):697-704.Leukemia2016-09-22T00:00:002016PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.27058617Oran B, Cortes J, Beitinjaneh A, Chen HC, de Lima M, Patel K, Ravandi F, Wang X, Brandt M, Andersson BS, Ciurea S, Santos FP, de Padua Silva L, Shpall EJ, Champlin RE, Kantarjian H, Borthakur GBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226.Biol Blood Marrow Transplant2016-04-04T00:00:002016Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.27203405Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BSCancerDouble epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer. 2016 09 01; 122(17):2680-8.Cancer2016-05-20T00:00:002016Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.27348707Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei PLeukemia & lymphomaStem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma. 2017 02; 58(2):366-371.Leuk Lymphoma2016-06-27T00:00:002016Stem cell transplantation outcomes in lymphoblastic lymphoma.27482888Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJThe Journal of clinical investigationPhase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.J Clin Invest2016-08-02T00:00:002016Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.27564097Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BSOncotargetDifferential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget. 2016 Sep 27; 7(39):63829-63838.Oncotarget2016-09-27T00:00:002016Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.26980288Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BSLeukemia & lymphomaSynergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma. 2016 11; 57(11):2644-52.Leuk Lymphoma2016-03-16T00:00:002016Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.27246312Najjar AM, Manuri PR, Olivares S, Flores L, Mi T, Huls H, Shpall EJ, Champlin RE, Turkman N, Paolillo V, Roszik J, Rabinovich B, Lee DA, Alauddin M, Gelovani J, Cooper LJMolecular imaging and biologyImaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography. Mol Imaging Biol. 2016 12; 18(6):838-848.Mol Imaging Biol2016-12-01T00:00:002016Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.27404668Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SOCancerResults of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.Cancer2016-07-12T00:00:002016Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.27816651Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationClofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292.Biol Blood Marrow Transplant2016-11-02T00:00:002016Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.27821506Alsuliman A, Muftuoglu M, Khoder A, Ahn YO, Basar R, Verneris MR, Muranski P, Barrett AJ, Liu E, Li L, Stringaris K, Armstrong-James D, Shaim H, Kondo K, Imahashi N, Andersson B, Marin D, Champlin RE, Shpall EJ, Rezvani KBloodA subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood. 2017 02 09; 129(6):740-758.Blood2016-11-07T00:00:002016A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.27991894Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin REBone marrow transplantationFludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant. 2017 Apr; 52(4):580-587.Bone Marrow Transplant2016-12-19T00:00:002016Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.27941772El Boghdadly Z, Oran B, Jiang Y, Rondon G, Champlin R, Kontoyiannis DPBone marrow transplantationPretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2017 03; 52(3):476-479.Bone Marrow Transplant2016-12-12T00:00:002016Pretransplant chest computed tomography screening in asymptomatic patients with leukemia and myelodysplastic syndrome.28052408Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SOAmerican journal of hematologyRelapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.Am J Hematol2017-02-13T00:00:002017Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.28263919Bayraktar UD, Milton DR, Shpall EJ, Rondon G, Price KJ, Champlin RE, Nates JLBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPrognostic Index for Critically Ill Allogeneic Transplantation Patients. Biol Blood Marrow Transplant. 2017 Jun; 23(6):991-996.Biol Blood Marrow Transplant2017-03-03T00:00:002017Prognostic Index for Critically Ill Allogeneic Transplantation Patients.27618682Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei PBone marrow transplantationMulti-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant. 2017 Jan; 52(1):20-27.Bone Marrow Transplant2016-09-12T00:00:002016Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes.27696391Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour ECancerPrognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.Cancer2016-10-03T00:00:002016Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.27849617Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJProceedings of the National Academy of Sciences of the United States of AmericaTethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A. 2016 11 29; 113(48):E7788-E7797.Proc Natl Acad Sci U S A2016-11-14T00:00:002016Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells.28018583Lu H, Champlin RE, Popat U, Pundole X, Escalante CP, Wang X, Qiao W, Murphy WA, Gagel RFBoneKEy reportsIbandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial. Bonekey Rep. 2016; 5:843.Bonekey Rep2016-10-19T00:00:002016Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial.28117884Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen MCancerAllogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017 06 01; 123(11):2025-2034.Cancer2017-01-24T00:00:002017Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.28185276Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing CTransfusionPatient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion. 2017 04; 57(4):1052-1057.Transfusion2017-02-10T00:00:002017Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.27540139Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin REHaematologicaPre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017 01; 102(1):110-117.Haematologica2016-08-18T00:00:002016Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.27548616Thokala R, Olivares S, Mi T, Maiti S, Deniger D, Huls H, Torikai H, Singh H, Champlin RE, Laskowski T, McNamara G, Cooper LJPloS oneRedirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. PLoS One. 2016; 11(8):e0159477.PLoS One2016-08-22T00:00:002016Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.27602508Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HMCancerDifferential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.Cancer2016-09-07T00:00:002016Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.27680710Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerProlonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2016 Dec 15; 122(24):3831-3837.Cancer2016-09-28T00:00:002016Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.27760759Stringaris K, Marin D, Barrett AJ, Hills R, Sobieski C, Cao K, Saltarrelli JG, Daher M, Shaim H, Smith N, Linch D, Gale R, Allen C, Sekine T, Mehta R, Champlin R, Shpall EJ, Kantarjian H, Garcia-Manero G, Rezvani KBloodKIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823.Blood2016-10-19T00:00:002016KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.28096091de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kr?ger NBloodAllogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. 2017 03 30; 129(13):1753-1762.Blood2017-01-17T00:00:002017Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.28295181Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CMBritish journal of haematologyLong-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.Br J Haematol2017-03-14T00:00:002017Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival.28324640Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran BCancerCytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670.Cancer2017-03-21T00:00:002017Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.28351938Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SOBloodPredictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.Blood2017-03-28T00:00:002017Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.28400618Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SOLeukemiaDonor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2017 07; 31(7):1654-1657.Leukemia2017-04-12T00:00:002017Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.28404929Huang XJ, Liu K, Ritchie D, Andersson B, Lu J, Hou J, Burguera AF, Wang J, Yeoh A, Yan C, Zhou D, Tan D, Kim DW, Wu D, Shpall E, Kornblau S, Neelapu S, Hongeng S, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Hagemeister F, Westin J, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Orlowski RZ, Chim CS, Mulligan S, Sanz M, Ozawa K, Parmar S, Issaragrisil SOncotargetHematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget. 2017 Jun 20; 8(25):41620-41630.Oncotarget2017-06-20T00:00:002017Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China.28394191Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BSLeukemia & lymphomaThe PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma. 2017 11; 58(11):2705-2716.Leuk Lymphoma2017-04-10T00:00:002017The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.28506845Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran BBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEx Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366.Biol Blood Marrow Transplant2017-05-12T00:00:002017Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery.28513828Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir QCancerOutcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.Cancer2017-05-17T00:00:002017Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.28673185Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MHLeukemia & lymphomaA case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leuk Lymphoma. 2018 02; 59(2):515-518.Leuk Lymphoma2017-07-03T00:00:002017A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.28859185Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian HJAMA oncologySalvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234.JAMA Oncol2018-02-01T00:00:002018Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.28860112Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJBMJ supportive & palliative careRisk factors for falls in older patients with cancer. BMJ Support Palliat Care. 2018 Mar; 8(1):34-37.BMJ Support Palliat Care2017-08-31T00:00:002017Risk factors for falls in older patients with cancer.28844850Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJJournal of geriatric oncologyMalnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol. 2018 01; 9(1):81-83.J Geriatr Oncol2017-08-24T00:00:002017Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index.28844946Rond?n G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2166-2171.Biol Blood Marrow Transplant2017-08-24T00:00:002017Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.28850699Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia TAmerican journal of hematologyClinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.Am J Hematol2017-09-25T00:00:002017Clinical outcomes in adult patients with aplastic anemia: A single institution experience.28918304Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationHaploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.Biol Blood Marrow Transplant2017-09-14T00:00:002017Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.28835441Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin REBloodPhase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 10 19; 130(16):1857-1868.Blood2017-08-23T00:00:002017Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.28895206Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash MEuropean journal of haematologyInpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol. 2017 Dec; 99(6):532-535.Eur J Haematol2017-10-08T00:00:002017Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.28692030Bachegowda LS, Shah MV, Veltri LW, Tanase A, Popat U, Anderlini P, Chen J, Rondon G, Champlin RE, Ciurea SOBone marrow transplantationHLA-mismatched bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2017 09; 52(9):1347-1348.Bone Marrow Transplant2017-07-10T00:00:002017HLA-mismatched bone marrow transplantation in severe aplastic anemia.29197676Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, Acute Leukemia Committee of the CIBMTRBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIntravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 04; 24(4):726-733.Biol Blood Marrow Transplant2017-12-25T00:00:002017Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.29197959Edwards BJ, Sun M, Zhang X, Holmes HM, Song J, Khalil P, Karuturi M, Shah JB, Dinney CP, Gagel RF, Valero V, Champlin RE, Tripathy D, Murphy WASupportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience. Support Care Cancer. 2018 May; 26(5):1561-1568.Support Care Cancer2017-12-02T00:00:002017Fractures frequently occur in older cancer patients: the MD Anderson Cancer Center experience.29260444Shah N, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XSQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationUtility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Qual Life Res. 2018 Apr; 27(4):979-985.Qual Life Res2017-12-19T00:00:002017Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.29325829Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina HBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 05; 24(5):1079-1087.Biol Blood Marrow Transplant2018-01-08T00:00:002018Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.29464765Ariza-Heredia EJ, Chemaly RF, Shahani LR, Jang Y, Champlin RE, Mulanovich VETransplant international : official journal of the European Society for Organ TransplantationDelay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study. Transpl Int. 2018 06; 31(6):639-648.Transpl Int2018-03-13T00:00:002018Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.29469961Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler ACancerRelapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018 05 15; 124(10):2134-2141.Cancer2018-02-22T00:00:002018Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.29619576Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu HArchives of osteoporosisFracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos. 2018 Apr 04; 13(1):38.Arch Osteoporos2018-04-04T00:00:002018Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation.29375566Khoder A, Alsuliman A, Basar R, Sobieski C, Kondo K, Alousi AM, Szydlo R, Muftuoglu M, Shaim H, Apperley JF, Gokdemir E, Cooper N, Mehta RS, Marin D, Champlin R, Shpall E, Rezvani KFrontiers in immunologyEvidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease. Front Immunol. 2017; 8:1937.Front Immunol2018-01-12T00:00:002018Evidence for B Cell Exhaustion in Chronic Graft-versus-Host Disease.29386198Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao KBloodEffect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.Blood2018-01-31T00:00:002018Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion.29448058Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran BBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEarly Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.Biol Blood Marrow Transplant2018-02-12T00:00:002018Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.29530493Edwards BJ, Zhang X, Sun M, Holmes HM, Ketonen L, Guha N, Khalil P, Song J, Kesler S, Shah JB, Tripathy D, Valero V, Champlin REJournal of geriatric oncologyNeurocognitive deficits in older patients with cancer. J Geriatr Oncol. 2018 09; 9(5):482-487.J Geriatr Oncol2018-03-09T00:00:002018Neurocognitive deficits in older patients with cancer.29295650Malek E, Gupta V, Creger R, Caimi P, Vatsayan A, Covut F, Bashir Q, Champlin R, Delgado R, Rondon G, Cooper B, de Lima M, Lazarus HM, Qazilbash MLeukemia & lymphomaAmifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma. Leuk Lymphoma. 2018 08; 59(8):1905-1912.Leuk Lymphoma2018-01-02T00:00:002018Amifostine reduces gastro-intestinal toxicity after autologous transplantation for multiple myeloma.29501779Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPhase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.Biol Blood Marrow Transplant2018-03-02T00:00:002018Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.29265180Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat URBritish journal of haematologySensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol. 2018 12; 183(5):831-835.Br J Haematol2017-12-19T00:00:002017Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.29269797Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AMBone marrow transplantationPentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant. 2018 03; 53(3):315-325.Bone Marrow Transplant2017-12-21T00:00:002017Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.29277360Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki YClinical lymphoma, myeloma & leukemiaManagement of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e41-e50.Clin Lymphoma Myeloma Leuk2017-10-12T00:00:002017Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.29339270Al Malki MM, Jones R, Ma Q, Lee D, Reisner Y, Miller JS, Lang P, Hongeng S, Hari P, Strober S, Yu J, Maziarz R, Mavilio D, Roy DC, Bonini C, Champlin RE, Fuchs EJ, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationProceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016. Biol Blood Marrow Transplant. 2018 05; 24(5):895-908.Biol Blood Marrow Transplant2018-01-12T00:00:002018Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.29419530Zeng D, Desai A, Yan F, Gong T, Ye H, Ahmed M, Nomie K, Romaguera J, Champlin R, Li S, Wang MAmerican journal of clinical oncologyChallenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). Am J Clin Oncol. 2019 03; 42(3):304-316.Am J Clin Oncol2019-03-01T00:00:002019Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma).29423093Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BSOncotargetCombination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget. 2018 Jan 09; 9(3):3908-3921.Oncotarget2017-12-17T00:00:002017Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.29645075Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O'Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJCancerResults of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.Cancer2018-04-12T00:00:002018Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.29933073de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock CBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationCC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018 10; 24(10):2017-2024.Biol Blood Marrow Transplant2018-06-20T00:00:002018CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.30005678Ye H, Desai A, Huang S, Jung D, Champlin R, Zeng D, Yan F, Nomie K, Romaguera J, Ahmed M, Wang MLJournal of experimental & clinical cancer research : CRParamount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy. J Exp Clin Cancer Res. 2018 Jul 13; 37(1):150.J Exp Clin Cancer Res2018-07-13T00:00:002018Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.30206098Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin REBlood advancesIs a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.Blood Adv2018-09-11T00:00:002018Is a matched unrelated donor search needed for all allogeneic transplant candidates?30258129Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SOBone marrow transplantationImpact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2019 06; 54(6):839-848.Bone Marrow Transplant2018-09-26T00:00:002018Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.30337700Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SOBone marrow transplantationPilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 04; 54(4):601-606.Bone Marrow Transplant2018-10-18T00:00:002018Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.30405633Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani KFrontiers in immunologyDonor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol. 2018; 9:2444.Front Immunol2018-10-23T00:00:002018Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation.30102945Valdez BC, Tang X, Li Y, Murray D, Liu Y, Popat U, Champlin RE, Andersson BSExperimental hematologyEpigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells. Exp Hematol. 2018 11; 67:49-59.e1.Exp Hematol2018-08-10T00:00:002018Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells.30175400Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang MLBritish journal of haematologyLong-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018 11; 183(4):578-587.Br J Haematol2018-09-02T00:00:002018Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.30244203Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy DBMJ supportive & palliative careOverall survival in older patients with cancer. BMJ Support Palliat Care. 2020 Mar; 10(1):25-35.BMJ Support Palliat Care2018-09-22T00:00:002018Overall survival in older patients with cancer.30308325Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin DBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2019 03; 25(3):505-514.Biol Blood Marrow Transplant2018-10-09T00:00:002018Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.29769208Davies JK, Brennan LL, Wingard JR, Cogle CR, Kapoor N, Shah AJ, Dey BR, Spitzer TR, de Lima M, Cooper LJ, Thall PF, Champlin RE, Nadler LM, Guinan ECClinical cancer research : an official journal of the American Association for Cancer ResearchInfusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. Clin Cancer Res. 2018 09 01; 24(17):4098-4109.Clin Cancer Res2018-05-16T00:00:002018Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.29769261Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin REBloodPrognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.Blood2018-05-16T00:00:002018Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.30016656Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, Shah ND, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2197-2203.Biol Blood Marrow Transplant2018-08-09T00:00:002018Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation.30032678Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MHLeukemia & lymphomaHigh-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma. 2019 02; 60(2):442-452.Leuk Lymphoma2018-07-22T00:00:002018High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.30521974Sheshadri A, Chemaly RF, Alousi AM, Shah PK, Rondon G, Bashoura L, Kmeid J, Azzi J, Blanco DW, Kaous M, Dickey BF, Champlin RE, Shah DPBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationPulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant. 2019 04; 25(4):800-809.Biol Blood Marrow Transplant2018-12-03T00:00:002018Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.30479692Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar SOncotargetThird party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget. 2018 Nov 02; 9(86):35611-35622.Oncotarget2018-11-02T00:00:002018Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.30709875Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CDCold Spring Harbor molecular case studiesHematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1).Cold Spring Harb Mol Case Stud2019-02-01T00:00:002019Hematologic malignancies and Li-Fraumeni syndrome.30389035Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BSThe Lancet. HaematologyFludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.Lancet Haematol2018-11-01T00:00:002018Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.30300461Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHAmerican journal of hematologyMelphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2019 01; 94(1):E2-E5.Am J Hematol2018-10-31T00:00:002018Melphalan-based autologous transplant in octogenarian multiple myeloma patients.30304652Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani KThe New England journal of medicineAllogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2018 10 11; 379(15):1443-1451.N Engl J Med2018-10-11T00:00:002018Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy.30446740Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MHBone marrow transplantationPrimary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant. 2019 07; 54(7):1089-1093.Bone Marrow Transplant2018-11-16T00:00:002018Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.30532055Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BSBone marrow transplantationReduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. Bone Marrow Transplant. 2019 08; 54(8):1245-1253.Bone Marrow Transplant2018-12-10T00:00:002018Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.30545798Uckun FM, Qazi S, Demirer T, Champlin REEBioMedicineContemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine. 2019 Jan; 39:612-620.EBioMedicine2018-12-10T00:00:002018Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma.30548467Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KKAmerican journal of hematologyLong-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol. 2019 03; 94(3):E72-E74.Am J Hematol2018-12-21T00:00:002018Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome.30683577Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir QCurrent research in translational medicineHLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019 05; 67(2):51-55.Curr Res Transl Med2019-01-23T00:00:002019HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.30763728Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationImpact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.Biol Blood Marrow Transplant2019-02-11T00:00:002019Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma.D006086Disorders28926200.452482Graft vs Host DiseaseD014184Procedures41228460.618953Transplantation, HomologousAuthorship 94157614Authorship 9426791530826465Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IFBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAllogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant. 2019 07; 25(7):1347-1354.Biol Blood Marrow Transplant2019-03-01T00:00:002019Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.30639822Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationComparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.Biol Blood Marrow Transplant2019-01-11T00:00:002019Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.Authorship 9430929Authorship 9432132530900768Ciurea SO, Hansrivijit P, Ciurea AM, Hymes S, Chen J, Rondon G, Hosing C, Popat U, Champlin REAmerican journal of hematologyCurative potential of hematopoietic stem cell transplantation for advanced psoriasis. Am J Hematol. 2019 06; 94(6):E176-E180.Am J Hematol2019-04-03T00:00:002019Curative potential of hematopoietic stem cell transplantation for advanced psoriasis.30910541Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MHThe Lancet. HaematologyConditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol. 2019 May; 6(5):e266-e275.Lancet Haematol2019-03-22T00:00:002019Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Authorship 9449072430948491Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat URHaematologicaMyeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.Haematologica2019-04-04T00:00:002019Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.12842990Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima MBloodReduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003 Oct 15; 102(8):3052-9.Blood2003-07-03T00:00:002003Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years.19654407Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina MBloodDonor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood. 2009 Oct 01; 114(14):2884-7.Blood2009-08-04T00:00:002009Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.19668237Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski JBone marrow transplantationReduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.Bone Marrow Transplant2009-08-10T00:00:002009Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.19855248Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina MTransplantationHigh risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27; 88(8):1019-24.Transplantation2009-10-27T00:00:002009High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.20351328Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing CJournal of clinical oncology : official journal of the American Society of Clinical OncologyTotal skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010 May 10; 28(14):2365-72.J Clin Oncol2010-03-29T00:00:002010Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.20658954Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing CLeukemia & lymphomaHematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma. 2010 Aug; 51(8):1478-84.Leuk Lymphoma2010-08-01T00:00:002010Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.20969970Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci. Biol Blood Marrow Transplant. 2011 Jun; 17(6):923-9.Biol Blood Marrow Transplant2010-10-20T00:00:002010Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 loci.21087679Bashir Q, Andersson BS, Fernandez-Vina M, de Padua Silva L, Giralt S, Chiattone A, Wei W, Sharma M, Anderlini P, Shpall EJ, Popat U, Rodrigues M, Champlin RE, de Lima MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationUnrelated donor transplantation for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Jul; 17(7):1067-71.Biol Blood Marrow Transplant2010-11-16T00:00:002010Unrelated donor transplantation for acute myelogenous leukemia in first remission.21149654Parmar S, Andersson BS, Couriel D, Munsell MF, Fernandez-Vina M, Jones RB, Shpall EJ, Popat U, Anderlini P, Giralt S, Alousi A, Cano P, Bosque D, Hosing C, Silva Lde P, Westmoreland M, Wathen JK, Berry D, Champlin RE, de Lima MJJournal of clinical oncology : official journal of the American Society of Clinical OncologyProphylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.J Clin Oncol2010-12-13T00:00:002010Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study.21780997Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHLeukemia & lymphomaFeasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.Leuk Lymphoma2011-08-24T00:00:002011Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma.21967975Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina MBloodDonor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.Blood2011-10-03T00:00:002011Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation.22231283Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MHAmerican journal of hematologyPredictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.Am J Hematol2012-01-09T00:00:002012Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.22279576Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DAPloS oneMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012; 7(1):e30264.PLoS One2012-01-18T00:00:002012Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.23503529Yilmaz M, Chemaly RF, Han XY, Thall PF, Fox PS, Tarrand JJ, De Lima MJ, Hosing CM, Popat UR, Shpall E, Champlin RE, Qazilbash MHBone marrow transplantationAdenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant. 2013 Sep; 48(9):1218-23.Bone Marrow Transplant2013-03-18T00:00:002013Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.23545991Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad LLeukemiaOral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.Leukemia2013-04-02T00:00:002013Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.23572228Shah DP, Ghantoji SS, Shah JN, El Taoum KK, Jiang Y, Popat U, Hosing C, Rondon G, Tarrand JJ, Champlin RE, Chemaly RFThe Journal of antimicrobial chemotherapyImpact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013 Aug; 68(8):1872-80.J Antimicrob Chemother2013-04-09T00:00:002013Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections.23596045Fern?ndez-Vi?a MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, Horowitz MM, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima MBloodMultiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013 May 30; 121(22):4603-10.Blood2013-04-17T00:00:002013Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.23648290Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BSExperimental hematologyMechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol. 2013 Aug; 41(8):719-30.Exp Hematol2013-05-03T00:00:002013Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.Authorship 9474021031112940Zeng Z, Liu W, Benton CB, Konoplev S, Lu H, Wang RY, Chen J, Shpall E, Baggerly KA, Champlin R, Konopleva MActa haematologicaProteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. Acta Haematol. 2019; 142(3):176-184.Acta Haematol2019-05-21T00:00:002019Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.Authorship 949573331217161van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SOBlood advancesHaploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867.Blood Adv2019-06-25T00:00:002019Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.Authorship 9506681731243571Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KKAnnals of hematologyOutcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.Ann Hematol2019-06-26T00:00:002019Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia.Authorship 95172313Authorship 9518271731282244Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MHLeukemia & lymphomaOutcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma. 2019 12; 60(14):3536-3543.Leuk Lymphoma2019-07-08T00:00:002019Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years.31296578Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat URHaematologicaMixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.Haematologica2021-07-01T00:00:002021Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.Authorship 9544331031448830El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R, Chemaly RFJournal of medical virologyClinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020 01; 92(1):86-95.J Med Virol2019-09-03T00:00:002019Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.Authorship 9548802631481508Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHClinical cancer research : an official journal of the American Association for Cancer ResearchImpact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res. 2019 11 15; 25(22):6781-6787.Clin Cancer Res2019-09-03T00:00:002019Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.Authorship 9563961031582392Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bola?os Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen MBlood advancesMyeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019 10 08; 3(19):2836-2844.Blood Adv2019-10-08T00:00:002019Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.Authorship 9568922331595538Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SOAmerican journal of hematologyHaploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.Am J Hematol2019-10-21T00:00:002019Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation.Authorship 9619491831786242Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationAge Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 06; 26(6):1077-1083.Biol Blood Marrow Transplant2019-11-29T00:00:002019Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.Authorship 96237526Authorship 96243316Authorship 962492731830234Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JDJAMA oncologyComparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2020 04 01; 6(4):486-493.JAMA Oncol2020-04-01T00:00:002020Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.31821460Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani KBlood advancesA novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv. 2019 12 10; 3(23):4117-4130.Blood Adv2019-12-10T00:00:002019A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation.31826244Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin REBloodIs there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020 02 06; 135(6):449-452.Blood2020-02-06T00:00:002020Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Authorship 9747542931881283Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MHBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOutcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.Biol Blood Marrow Transplant2019-12-24T00:00:002019Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis.Authorship 9761402031961918Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei PBloodLong-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.Blood2020-03-12T00:00:002020Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.Authorship 976832132005652Champlin RHaematologicaIs unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission? Haematologica. 2020; 105(2):252-254.Haematologica2020-01-31T00:00:002020Is unrelated donor or haploidentical hematopoietic transplantation preferred for patients with acute myeloid leukemia in remission?Authorship 9774067Authorship 9774322532019857Ciurea SO, Kongtim P, Hasan O, Ramos Perez JM, Torres J, Rondon G, Champlin REClinical cancer research : an official journal of the American Association for Cancer ResearchValidation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies. Clin Cancer Res. 2020 05 15; 26(10):2404-2410.Clin Cancer Res2020-02-04T00:00:002020Validation of a Hematopoietic Cell Transplant-Composite Risk (HCT-CR) Model for Post-Transplant Survival Prediction in Patients with Hematologic Malignancies.32023374Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani KThe New England journal of medicineUse of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553.N Engl J Med2020-02-06T00:00:002020Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.Authorship 977823632045652Varma A, Rondon G, Srour SA, Chen J, Ledesma C, Champlin RE, Ciurea SO, Saliba RMBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEndothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1013-1020.Biol Blood Marrow Transplant2020-02-09T00:00:002020Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation.Authorship 97854612Authorship 9786031632107328Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SOHaematologicaImpact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. 2021 01 01; 106(1):269-274.Haematologica2021-01-01T00:00:002021Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation.32101640Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran BCancerSignificance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.Cancer2020-02-26T00:00:002020Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.Authorship 9791295Authorship 97941128Authorship 9796901832191807Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang MLBlood advancesGenomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.Blood Adv2020-03-24T00:00:002020Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.32165328Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, Giralt SA, LeMaistre CF, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Veys PA, Carpenter PA, Hamadani MBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationIndications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020 07; 26(7):1247-1256.Biol Blood Marrow Transplant2020-03-09T00:00:002020Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy.32125707Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver NCancerPosttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.Cancer2020-03-03T00:00:002020Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors.Authorship 9862612532236526Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat URBlood advancesIdiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.Blood Adv2020-04-14T00:00:002020Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.Authorship 9893222032396617Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, Soci? G, Karduss-Urueta A, Helbig G, Bornhauser M, Niittyvuopio R, Ganser A, Ciceri F, Brecht A, Koc Y, Bejanyan N, Ferraro F, Kebriaei P, Mokhtari S, Ghobadi A, Nakamura R, Forman SJ, Champlin R, Mohty M, Ciurea SO, Nagler ABlood advancesComparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv. 2020 05 12; 4(9):2073-2083.Blood Adv2020-05-12T00:00:002020Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.Authorship 9899282232438043Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin REBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationOptimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445.Biol Blood Marrow Transplant2020-05-11T00:00:002020Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.Authorship 9909251832492706Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei PBloodImpact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.Blood2020-10-08T00:00:002020Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL.Authorship 99215214Authorship 9927322532557828Ohanian M, Kantarjian HM, Shoukier M, Dellasala S, Musaelyan A, Nogueras Gonzalez GM, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Tamamyan G, Champlin R, Pierce S, Ferrajoli A, Kadia T, Cortes JEAmerican journal of hematologyThe clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020 Oct; 95(10):1127-1134.Am J Hematol2020-07-23T00:00:002020The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia.32589978Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian HThe Lancet. HaematologyHyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.Lancet Haematol2020-07-01T00:00:002020Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.Authorship 99297314Authorship 99299715Authorship 99304522Authorship 99314424Authorship 9932171132602112Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SOAmerican journal of hematologyHaploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. 2020 Oct; 95(10):E267-E269.Am J Hematol2020-07-21T00:00:002020Haploidentical transplants for patients with graft failure after the first allograft.32602954Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani KTransplant infectious disease : an official journal of the Transplantation SocietyDevelopment and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2020 Oct; 22(5):e13395.Transpl Infect Dis2020-07-14T00:00:002020Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients.32604096Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat URActa haematologicaCytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.Acta Haematol2020-06-30T00:00:002020Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.32614241Sheshadri A, Alousi A, Bashoura L, Stolar K, Baghaie S, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Peterson SK, Langhals R, Taylor M, Stenzler A, Mehta RS, Popat UR, Hosing C, Rondon G, Shen F, Li L, Cheng GS, Ost DE, Champlin RE, Dickey BFAnnals of the American Thoracic SocietyFeasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients. Ann Am Thorac Soc. 2020 10; 17(10):1329-1333.Ann Am Thorac Soc2020-10-01T00:00:002020Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients.32619033Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SOAmerican journal of hematologyHaploidentical transplants for patients with relapse after the first allograft. Am J Hematol. 2020 Oct; 95(10):1187-1192.Am J Hematol2020-08-01T00:00:002020Haploidentical transplants for patients with relapse after the first allograft.Authorship 9937891132636464Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita ABone marrow transplantationCan we cure refractory Hodgkin's lymphoma with transplantation? Bone Marrow Transplant. 2021 01; 56(1):278-281.Bone Marrow Transplant2020-07-07T00:00:002020Can we cure refractory Hodgkin's lymphoma with transplantation?Authorship 99433438Authorship 994634532662346Hu B, Lin X, Lee HC, Huang X, Tidwell RSS, Ahn KW, Hu ZH, Jabbour E, Verstovsek S, Ravandi F, Garcia-Manero G, Kharfan-Dabaja MA, Hossain NM, Marks DI, Kamble RT, Inamoto Y, Kindwall-Keller T, Saad A, Litzow MR, Savani BN, Hale GA, Bacher U, Gerds AT, Liesveld JL, Ustun C, Olsson RF, Daly A, Grunwald MR, Solh M, DeFilipp Z, Aljurf M, Wirk B, Akpek G, Nishihori T, Cerny J, Seo S, Hsu JW, Champlin R, de Lima M, Alyea E, Popat U, Sobecks R, Scott BL, Kantarjian H, Cortes J, Saber WLeukemia & lymphomaTiming of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820.Leuk Lymphoma2020-07-14T00:00:002020Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients.32681739Abaza Y, Kantarjian H, Alwash Y, Borthakur G, Champlin R, Kadia T, Garcia-Manero G, Daver N, Ravandi F, Verstovsek S, Burger J, Estrov Z, Ohanian M, Lim M, Pemmaraju N, Jabbour E, Cortes JAmerican journal of hematologyPhase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.Am J Hematol2020-08-12T00:00:002020Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia.Authorship 99548936Authorship 995623932726398Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, Srour S, Partlow D, Champlin RE, Cao KBlood advancesMolecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020 08 11; 4(15):3474-3485.Blood Adv2020-08-11T00:00:002020Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.32717029Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani KBlood advancesLarge-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv. 2020 07 28; 4(14):3357-3367.Blood Adv2020-07-28T00:00:002020Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells.Authorship 9961401132755333Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes JLeukemia & lymphomaSurvivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma. 2020 12; 61(13):3120-3127.Leuk Lymphoma2020-08-05T00:00:002020Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years.Authorship 9992005332902645Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani KBloodTargeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.Blood2021-02-04T00:00:002021Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells.Authorship 100085913Authorship 10010913133009515Sheshadri A, Saliba R, Patel B, Ahmed T, Bueno LC, Arain MH, Mehta RS, Popat UR, Hosing CM, Rondon G, Bashoura L, Dickey BF, Champlin RE, Alousi AMBone marrow transplantationAzithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients. Bone Marrow Transplant. 2021 03; 56(3):745-748.Bone Marrow Transplant2020-10-02T00:00:002020Azithromycin may increase hematologic relapse rates in matched unrelated donor hematopoietic cell transplant recipients who receive anti-thymocyte globulin, but not in most other recipients.32995792Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Mendt M, Silva FR, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee P, Li Y, Li S, Garcia LM, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin R, Shpall EJ, Rezvani KbioRxiv : the preprint server for biologyGeneration of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy. bioRxiv. 2020 Sep 15.bioRxiv2020-09-15T00:00:002020Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy.Authorship 10022551933027527Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MHBlood advancesBusulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020 10 13; 4(19):4834-4837.Blood Adv2020-10-13T00:00:002020Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM.Authorship 10048051133170934Oran B, de Lima M, Garcia-Manero G, Thall PF, Lin R, Popat U, Alousi AM, Hosing C, Giralt S, Rondon G, Woodworth G, Champlin REBlood advancesA phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020 11 10; 4(21):5580-5588.Blood Adv2020-11-10T00:00:002020A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients.Authorship 1006167633258192Ragoonanan D, Tambaro FP, Khazal SJ, Tewari P, Petropoulos D, Champlin R, Mahadeo KMPediatric blood & cancerCytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. Pediatr Blood Cancer. 2021 05; 68(5):e28839.Pediatr Blood Cancer2020-11-30T00:00:002020Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy.Authorship 1006688133301030Puerta-Alcalde P, Champlin RE, Kontoyiannis DPBloodHow I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease. Blood. 2020 12 10; 136(24):2741-2753.Blood2020-12-10T00:00:002020How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease.Authorship 10082031933398094Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AMBone marrow transplantationRandomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.Bone Marrow Transplant2021-01-04T00:00:002021Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD.Authorship 10095861433471943Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat URCancerFractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605.Cancer2021-01-20T00:00:002021Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome.Authorship 101151620Authorship 101209128Authorship 10124102733585199Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CDFrontiers in oncologyNext-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.Front Oncol2021-01-28T00:00:002021Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.33637601Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus S, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash GJournal for immunotherapy of cancerPost-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021 02; 9(2).J Immunother Cancer2021-02-01T00:00:002021Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.33614514Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KMFrontiers in oncologyCase Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. Front Oncol. 2021; 11:625707.Front Oncol2021-02-04T00:00:002021Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2.Authorship 10137622433717142Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani KFrontiers in immunologyGMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol. 2021; 12:626098.Front Immunol2021-02-26T00:00:002021GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.Authorship 101445217Authorship 10145532033758890Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJmedRxiv : the preprint server for health sciencesHigh levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. medRxiv. 2021 Mar 10.medRxiv2021-03-10T00:00:002021High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients.33767403Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei PBone marrow transplantationOutcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.Bone Marrow Transplant2021-03-25T00:00:002021Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.Authorship 101505716Authorship 10152098Authorship 101543617Authorship 101545420Authorship 10156641733821472Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat URBritish journal of haematologyAllogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol. 2021 06; 193(5):1004-1008.Br J Haematol2021-04-06T00:00:002021Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.33830182Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RFClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaRefractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era. Clin Infect Dis. 2021 10 20; 73(8):1346-1354.Clin Infect Dis2021-10-20T00:00:002021Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.33781521Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto YTransplantation and cellular therapyInfluence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther. 2021 03; 27(3):243.e1-243.e6.Transplant Cell Ther2020-12-20T00:00:002020Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma.33781539Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi ATransplantation and cellular therapyVedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther. 2021 03; 27(3):272.e1-272.e5.Transplant Cell Ther2020-12-16T00:00:002020Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.33793964Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour ECancerPrognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.Cancer2021-04-01T00:00:002021Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.Authorship 10162181333846563Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat UBone marrow transplantationAcute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant. 2021 08; 56(8):2005-2012.Bone Marrow Transplant2021-04-12T00:00:002021Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality.Authorship 10173754133929874Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani KJournal of clinical oncology : official journal of the American Society of Clinical OncologyThird-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol. 2021 08 20; 39(24):2710-2719.J Clin Oncol2021-04-30T00:00:002021Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.Authorship 10177383133951890Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BSHaematologicaImproved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2022 04 01; 107(4):899-908.Haematologica2022-04-01T00:00:002022Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.Authorship 101810219Authorship 101811823Authorship 10183843533965178Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed STransplantation and cellular therapyImpact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2021 05; 27(5):404.e1-404.e5.Transplant Cell Ther2021-02-12T00:00:002021Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.33965187Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat UTransplantation and cellular therapyEltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.Transplant Cell Ther2021-02-06T00:00:002021Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial.33986022Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak M, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani KClinical cancer research : an official journal of the American Association for Cancer ResearchCombining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.Clin Cancer Res2021-05-13T00:00:002021Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.Authorship 101872117Authorship 10190314334017325Mendt M, Daher M, Basar R, Shanley M, Kumar B, Wei Inng FL, Acharya S, Shaim H, Fowlkes N, Tran JP, Gokdemir E, Uprety N, Nunez-Cortes AK, Ensley E, Mai T, Kerbauy LN, Melo-Garcia L, Lin P, Shen Y, Mohanty V, Lu J, Li S, Nandivada V, Wang J, Banerjee P, Reyes-Silva F, Liu E, Ang S, Gilbert A, Li Y, Wan X, Gu J, Zhao M, Baran N, Muniz-Feliciano L, Wilson J, Kaur I, Gagea M, Konopleva M, Marin D, Tang G, Chen K, Champlin R, Rezvani K, Shpall EJFrontiers in immunologyMetabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol. 2021; 12:631353.Front Immunol2021-05-04T00:00:002021Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD.33995420Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJFrontiers in immunologyHigh Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol. 2021; 12:675679.Front Immunol2021-04-28T00:00:002021High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.Authorship 10192202034023569Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei PTransplantation and cellular therapyOutcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther. 2021 08; 27(8):689-695.Transplant Cell Ther2021-05-21T00:00:002021Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia.Authorship 10205897Authorship 10208601934096089S Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic MAmerican journal of hematologyPost-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol. 2021 09 01; 96(9):E350-E353.Am J Hematol2021-06-28T00:00:002021Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.34115096Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi KBloodClonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739.Blood2021-11-04T00:00:002021Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.Authorship 10212971Authorship 102133412Authorship 10213444334135465Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi KLeukemiaDonor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262.Leukemia2021-06-16T00:00:002021Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.34138471Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJCancerHyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.Cancer2021-06-17T00:00:002021Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.34138753Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani KThe Journal of clinical investigationTargeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest. 2021 07 15; 131(14).J Clin Invest2021-07-15T00:00:002021Targeting the av integrin/TGF-? axis improves natural killer cell function against glioblastoma stem cells.Authorship 10245001234224914Saber W, Steinert P, Zhang MJ, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales MA, Forman S, Champlin R, Langston A, Rudebeck M, Horowitz MTransplantation and cellular therapyA Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. Transplant Cell Ther. 2021 10; 27(10):837.e1-837.e10.Transplant Cell Ther2021-07-02T00:00:002021A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies.Authorship 10248556Authorship 102512827Authorship 10252523234247985Hare J, DeLeon PG, Pool K, Reioux D, Fontenot M, Champlin RE, Eaton EN, Marin D, Rezvani K, Shpall EJ, Wilson JM, Hosing CCytotherapyOptimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy. 2021 11; 23(11):1029-1035.Cytotherapy2021-07-08T00:00:002021Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking.34264268Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed SBlood advancesCRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021 07 27; 5(14):2799-2806.Blood Adv2021-07-27T00:00:002021CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity.34270918Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Nunez Cortes AK, Mendt M, Reyes Silva F, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee PP, Li Y, Li S, Melo Garcia L, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin RE, Shpall EJ, Rezvani KCell reportsGeneration of glucocorticoid-resistant SARS-CoV-2 T?cells for adoptive cell therapy. Cell Rep. 2021 07 20; 36(3):109432.Cell Rep2021-07-07T00:00:002021Generation of glucocorticoid-resistant SARS-CoV-2 T?cells for adoptive cell therapy.Authorship 102616314Authorship 102625220Authorship 10265492634304802Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, Burroughs LM, Majhail N, Al-Homsi AS, Al-Kadhimi ZS, Bar M, Bertaina A, Boelens JJ, Champlin R, Chaudhury S, DeFilipp Z, Dholaria B, El-Jawahri A, Fanning S, Fraint E, Gergis U, Giralt S, Hamilton BK, Hashmi SK, Horn B, Inamoto Y, Jacobsohn DA, Jain T, Johnston L, Kanate AS, Kansagra A, Kassim A, Kean LS, Kitko CL, Knight-Perry J, Kurtzberg J, Liu H, MacMillan ML, Mahmoudjafari Z, Mielcarek M, Mohty M, Nagler A, Nemecek E, Olson TS, Oran B, Perales MA, Prockop SE, Pulsipher MA, Pusic I, Riches ML, Rodriguez C, Romee R, Rondon G, Saad A, Shah N, Shaw PJ, Shenoy S, Sierra J, Talano J, Verneris MR, Veys P, Wagner JE, Savani BN, Hamadani M, Carpenter PATransplantation and cellular therapyStandardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021 08; 27(8):642-649.Transplant Cell Ther2021-08-01T00:00:002021Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.34312462Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RELeukemiaDecrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 01; 36(1):155-164.Leukemia2021-07-26T00:00:002021Decrease post-transplant relapse using donor-derived expanded NK-cells.34329753Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat URTransplantation and cellular therapyMyeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12.Transplant Cell Ther2021-07-28T00:00:002021Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial.Authorship 10275412034380640Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin REClinical cancer research : an official journal of the American Association for Cancer ResearchNine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res. 2021 11 01; 27(21):5847-5856.Clin Cancer Res2021-08-11T00:00:002021Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.Authorship 10279711934407606Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MHHaematologicaMelphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica. 2021 12 01; 106(12):3211-3214.Haematologica2021-12-01T00:00:002021Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma.Authorship 10283871534435482Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao KHaematologicaRefined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica. 2022 04 01; 107(4):844-856.Haematologica2022-04-01T00:00:002022Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation.Authorship 10289111234474478Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, Forman SJ, Champlin R, Gendzekhadze K, Cao KBlood advancesTreatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021 10 26; 5(20):4031-4043.Blood Adv2021-10-26T00:00:002021Treatment of allosensitized patients receiving allogeneic transplantation.Authorship 10292585Authorship 10292831834493481Ombres R, des Bordes JKA, Popat UR, Yennu S, Champlin RE, Mohile SG, Kebriaei P, Holmes HMJournal of geriatric oncologySerial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study. J Geriatr Oncol. 2022 03; 13(2):194-199.J Geriatr Oncol2021-09-04T00:00:002021Serial frailty assessments following allogeneic stem cell transplant in older adults: A pilot study.34495313Saliba RM, Greenbaum U, Ma Q, Srour SA, Carmazzi Y, Li L, Oran B, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Partlow D, Li D, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou JBlood advancesMismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021 09 14; 5(17):3407-3417.Blood Adv2021-09-14T00:00:002021Mismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation.Authorship 10297282634521108Qazilbash MH, Saini NY, Cha SC, Wang Z, Stadtmauer EA, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura S, Zhang T, Anderson A, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen A, Vogl DT, Dengel K, June CH, Champlin R, Kwak LWBloodA randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood. 2022 03 03; 139(9):1289-1301.Blood2022-03-03T00:00:002022A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.Authorship 103004226Authorship 103006221Authorship 10303012034537419Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AMTransplantation and cellular therapyBone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.Transplant Cell Ther2021-09-16T00:00:002021Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.34537421Szewczyk NA, Ngo-Huang A, Soones TN, Adekoya LM, Fontillas RC, Ferguson JK, Gale-Capps HE, Kurse BC, Lindsay RJ, Ombres R, Rivera ZR, Gulbis AM, Neumann JL, Braveman BH, Marin D, Shigle TL, Whited L, Wallis WD, Sullivan H, Cao L, Champlin RE, Shpall E, Popat URTransplantation and cellular therapyFeasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2021 12; 27(12):1008-1014.Transplant Cell Ther2021-09-16T00:00:002021Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation.34559916Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MHAmerican journal of hematologyBlack multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol. 2021 12 01; 96(12):E455-E457.Am J Hematol2021-10-04T00:00:002021Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis.Authorship 1030816734592759Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, Champlin R, Popat UBlood advancesCardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021 12 28; 5(24):5599-5607.Blood Adv2021-12-28T00:00:002021Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era.Authorship 10313371634629467Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju NBone marrow transplantationAllogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant. 2022 01; 57(1):51-56.Bone Marrow Transplant2021-10-11T00:00:002021Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).Authorship 10319572334686083Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHLeukemia & lymphomaReal-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2022 03; 63(3):710-721.Leuk Lymphoma2021-10-22T00:00:002021Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance.Authorship 10347441634861697Zhang X, Zhang R, Ren C, Xu Y, Wu S, Meng C, Pataer A, Song X, Zhang J, Yao Y, He H, Chen H, Ma W, Wang J, Meric-Bernstam F, Champlin RE, Heymach JV, Rooney CM, Swisher SG, Vaporciyan AA, Roth JA, You MJ, Wang M, Fang BBlood advancesEpstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022 02 08; 6(3):891-901.Blood Adv2022-02-08T00:00:002022Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.Authorship 1035071134876697Oran B, Champlin RE, Wang F, Tanaka T, Saliba RM, Al-Atrash G, Garcia-Manero G, Kantarjian H, Cao K, Shpall EJ, Alousi AM, Mehta RS, Popat U, Futreal A, Takahashi KLeukemiaCorrection to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298.Leukemia2022-01-01T00:00:002022Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.Authorship 10356262534914826Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei PBloodBlinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood. 2022 03 24; 139(12):1908-1919.Blood2022-03-24T00:00:002022Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.Authorship 10370842335008100Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SABlood advancesAutologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022 04 12; 6(7):2267-2274.Blood Adv2022-04-12T00:00:002022Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement.Authorship 10378171235266218Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez CAmerican journal of hematologyExternal validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol. 2022 06 01; 97(6):740-748.Am J Hematol2022-03-24T00:00:002022External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant.Authorship 103883321Authorship 103911113Authorship 103951020Authorship 10406868Authorship 10412031235129455Sheshadri A, Makhnoon S, Alousi AM, Bashoura L, Andrade R, Miller CJ, Stolar KR, Arain MH, Noor L, Balagani A, Jain A, Blanco D, Ortiz A, Taylor MS, Stenzler A, Mehta R, Popat UR, Hosing C, Ost DE, Champlin RE, Dickey BF, Peterson SKJMIR formative researchHome-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability. JMIR Form Res. 2022 Feb 07; 6(2):e29393.JMIR Form Res2022-02-07T00:00:002022Home-Based Spirometry Telemonitoring After Allogeneic Hematopoietic Cell Transplantation: Mixed Methods Evaluation of Acceptability and Usability.35225133Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IFLeukemia & lymphomaClinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma. 2022 04; 63(4):885-893.Leuk Lymphoma2022-02-27T00:00:002022Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.35093134Short NJ, Venugopal S, Qiao W, Kadia TM, Ravandi F, Macaron W, Dinardo CD, Daver N, Konopleva M, Borthakur G, Shpall EJ, Popat U, Champlin RE, Mehta R, Al-Atrash G, Oran B, Jabbour E, Garcia-Manero G, Issa GC, Montalban-Bravo G, Yilmaz M, Maiti A, Kantarjian HJournal of hematology & oncologyImpact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.J Hematol Oncol2022-01-29T00:00:002022Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.35176751Kawedia JD, Ramchandran S, Liu X, Gulbis AM, Titus M, Bashir Q, Qazilbash MH, Champlin RE, Ciurea SOAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsStability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. Am J Health Syst Pharm. 2022 06 07; 79(12):1011-1018.Am J Health Syst Pharm2022-06-07T00:00:002022Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration.35331973Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyImpact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2022 06; 28(6):307.e1-307.e8.Transplant Cell Ther2022-03-22T00:00:002022Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.Authorship 104519522Authorship 10452682535513252Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJTransplantation and cellular therapyHaploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2022 07; 28(7):395.e1-395.e11.Transplant Cell Ther2022-05-02T00:00:002022Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.35523847Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MHBone marrow transplantationKRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant. 2022 07; 57(7):1142-1149.Bone Marrow Transplant2022-05-06T00:00:002022KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma.24094497Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, Shah N, Mart?n-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJCytotherapyFucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9.Cytotherapy2013-10-01T00:00:002013Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment.24204673Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJPloS oneAntigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.PLoS One2013-10-18T00:00:002013Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.22677155Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera JThe Lancet. OncologyLenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.Lancet Oncol2012-06-06T00:00:002012Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.Authorship 10456562935533245Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi KBlood cancer discoveryClonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov. 2022 09 06; 3(5):385-393.Blood Cancer Discov2022-09-06T00:00:002022Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.Authorship 104645922Authorship 104651725Authorship 10466272335605883Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir QTransplantation and cellular therapyLong-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther. 2023 04; 29(4):264.e1-264.e9.Transplant Cell Ther2022-05-20T00:00:002022Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.35610308Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin REBone marrow transplantationA randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.Bone Marrow Transplant2022-05-24T00:00:002022A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation.35618218Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei PTransplantation and cellular therapyVorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplant Cell Ther. 2022 08; 28(8):501.e1-501.e7.Transplant Cell Ther2022-05-23T00:00:002022Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.Authorship 10475432135662592Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AMTransplantation and cellular therapyMycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors? Transplant Cell Ther. 2022 08; 28(8):500.e1-500.e10.Transplant Cell Ther2022-05-31T00:00:002022Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?Authorship 10490631935770531Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RSHaematologicaA myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica. 2022 10 01; 107(10):2496-2500.Haematologica2022-10-01T00:00:002022A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study.Authorship 10509083535853610Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringd?n O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SOTransplantation and cellular therapyCharacteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther. 2022 10; 28(10):681-693.Transplant Cell Ther2022-07-16T00:00:002022Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.Authorship 105136517Authorship 105133615Authorship 10512531835877996Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei PBloodThe role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 11 17; 140(20):2101-2112.Blood2022-11-17T00:00:002022The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.35874659Saliba RM, Srour SA, Greenbaum U, Ma Q, Carmazzi Y, Moller M, Wood J, Ciurea SO, Kongtim P, Rondon G, Li D, Saengboon S, Alousi AM, Rezvani K, Shpall EJ, Cao K, Champlin RE, Zou JFrontiers in immunologySIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.Front Immunol2022-07-07T00:00:002022SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies.35902049Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AMTransplantation and cellular therapyPost-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther. 2022 10; 28(10):695.e1-695.e10.Transplant Cell Ther2022-07-25T00:00:002022Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation.Authorship 105949720Authorship 106216019Authorship 106074613Authorship 105461612Authorship 105745122Authorship 105743554Authorship 106027712Authorship 105780621Authorship 105993729Authorship 105994435Authorship 106090720Authorship 106004815Authorship 106078315Authorship 10597415Authorship 10589088Authorship 105650719Authorship 10626541436383683Schwabkey ZI, Wiesnoski DH, Chang CC, Tsai WB, Pham D, Ahmed SS, Hayase T, Ortega Turrubiates MR, El-Himri RK, Sanchez CA, Hayase E, Frenk Oquendo AC, Miyama T, Halsey TM, Heckel BE, Brown AN, Jin Y, Raybaud M, Prasad R, Flores I, McDaniel L, Chapa V, Lorenzi PL, Warmoes MO, Tan L, Swennes AG, Fowler S, Conner M, McHugh K, Graf T, Jensen VB, Peterson CB, Do KA, Zhang L, Shi Y, Wang Y, Galloway-Pena JR, Okhuysen PC, Daniel-MacDougall CR, Shono Y, Burgos da Silva M, Peled JU, van den Brink MRM, Ajami N, Wargo JA, Reddy P, Valdivia RH, Davey L, Rondon G, Srour SA, Mehta RS, Alousi AM, Shpall EJ, Champlin RE, Shelburne SA, Molldrem JJ, Jamal MA, Karmouch JL, Jenq RRScience translational medicineDiet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.Sci Transl Med2022-11-16T00:00:002022Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment.36470579Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJTransplantation and cellular therapyHLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198.Transplant Cell Ther2022-12-05T00:00:002022HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection.35940528Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyLenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther. 2022 11; 28(11):752.e1-752.e6.Transplant Cell Ther2022-08-05T00:00:002022Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma.36626702Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat URJCO oncology practiceEnhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant. JCO Oncol Pract. 2023 03; 19(3):e417-e427.JCO Oncol Pract2023-01-10T00:00:002023Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant.36175679Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederst?dt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani KNature medicineKIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022 Oct; 28(10):2133-2144.Nat Med2022-09-29T00:00:002022KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.36179667Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Pe?a J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RRCellMucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 09 29; 185(20):3705-3719.e14.Cell2022-09-29T00:00:002022Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.36503180Alkhunaizi M, Patel B, Bueno L, Bhan N, Ahmed T, Arain MH, Saliba R, Rondon G, Dickey BF, Bashoura L, Ost DE, Li L, Wang S, Shpall E, Champlin RE, Mehta R, Popat UR, Hosing C, Alousi AM, Sheshadri ATransplantation and cellular therapyRisk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 03; 29(3):204.e1-204.e7.Transplant Cell Ther2022-12-09T00:00:002022Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.36683287Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian HAmerican journal of hematologyThe outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.Am J Hematol2023-01-31T00:00:002023The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.36384092Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash SCell reports. MedicineA polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med. 2022 11 15; 3(11):100720.Cell Rep Med2022-11-15T00:00:002022A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.36123927Torres HA, Angelidakis G, Jiang Y, Economides M, Mustafayev K, Yibirin M, Orlowski R, Champlin R, Verstovsek S, Raad IMedicineSerologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. Medicine (Baltimore). 2022 Sep 16; 101(37):e30608.Medicine (Baltimore)2022-09-16T00:00:002022Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies.36630564Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei PBlood advancesHaploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. Blood Adv. 2023 04 25; 7(8):1594-1603.Blood Adv2023-04-25T00:00:002023Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.36311784Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao KFrontiers in immunologyDonor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.Front Immunol2022-10-13T00:00:002022Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy.36502492Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei PAmerican journal of hematologyPrognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol. 2023 02; 98(2):E35-E37.Am J Hematol2022-12-11T00:00:002022Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission.36601982Dhakal B, Zhang MJ, Burns LJ, Tang X, Meyer C, Mau LW, Nooka AK, Stadtmauer E, Micallef IN, McGuirk J, Costa L, Juckett MB, Shah N, Champlin RE, Usmani SZ, Farag SS, Nishihori T, Roy V, Bodiford A, Barnes YJ, Drea EJ, Hari P, Hamadani MHaematologicaEfficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 08 01; 108(8):2249-2254.Haematologica2023-08-01T00:00:002023Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.36068929Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed SBritish journal of haematologyPositron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol. 2023 01; 200(1):35-44.Br J Haematol2022-09-06T00:00:002022Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.36646323Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyAutologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther. 2023 04; 29(4):260.e1-260.e6.Transplant Cell Ther2023-01-14T00:00:002023Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.36439104Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei PFrontiers in immunologySleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol. 2022; 13:1032397.Front Immunol2022-11-10T00:00:002022Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies.Authorship 106314710Authorship 10630251136738229Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao KCancerMolecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023 04 15; 129(8):1205-1216.Cancer2023-02-04T00:00:002023Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation.36734029Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RSAmerican journal of hematologyYounger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol. 2023 05; 98(5):712-719.Am J Hematol2023-02-13T00:00:002023Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.Authorship 106415116Authorship 10640323436798261Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EResearch squareCharacteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq. 2023 Feb 07.Res Sq2023-02-07T00:00:002023Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant.36778495Hayase E, Hayase T, Mukherjee A, Stinson SC, Jamal MA, Ortega MR, Sanchez CA, Ahmed SS, Karmouch JL, Chang CC, Flores II, McDaniel LK, Brown AN, El-Himri RK, Chapa VA, Tan L, Tran BQ, Pham D, Halsey TM, Jin Y, Tsai WB, Prasad R, Glover IK, Ajami NJ, Wargo JA, Shelburne S, Okhuysen PC, Liu C, Fowler SW, Conner ME, Peterson CB, Rondon G, Molldrem JJ, Champlin RE, Shpall EJ, Lorenzi PL, Mehta RS, Martens EC, Alousi AM, Jenq RRResearch squareBacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease. Res Sq. 2023 Jan 31.Res Sq2023-01-31T00:00:002023Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graft-versus-host disease.Authorship 106574240Authorship 10657511836916461Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBritish journal of haematologyImpact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol. 2023 05; 201(4):e37-e41.Br J Haematol2023-03-14T00:00:002023Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant.36914893Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, M?ller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav ENature medicineA non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023 04; 29(4):906-916.Nat Med2023-03-13T00:00:002023A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.Authorship 1067366636990221Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Kebriaei P, Weisdorf DTransplantation and cellular therapyImpact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplant Cell Ther. 2023 06; 29(6):377.e1-377.e7.Transplant Cell Ther2023-03-28T00:00:002023Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.Authorship 10681831737104058Short NJ, Ong F, Ravandi F, Nogueras-Gonzalez G, Kadia TM, Daver N, DiNardo CD, Konopleva M, Borthakur G, Oran B, Al-Atrash G, Mehta R, Jabbour EJ, Yilmaz M, Issa GC, Maiti A, Champlin RE, Kantarjian H, Shpall EJ, Popat UBlood advancesImpact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.Blood Adv2023-07-25T00:00:002023Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation.Authorship 106962512Authorship 107088322Authorship 10709151637137874Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MHBlood cancer journalImpact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J. 2023 05 03; 13(1):68.Blood Cancer J2023-05-03T00:00:002023Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.37198234Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IFBone marrow transplantationClinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant. 2023 09; 58(9):1000-1007.Bone Marrow Transplant2023-05-18T00:00:002023Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.37202544Mehta RS, Ali H, Dai Y, Yao B, Overman B, Ratanatharathorn V, Gill S, Soci? G, Anderson K, Cahn JY, Mujeebuddin A, Champlin R, Shpall E, Holtan SG, Alousi ABone marrow transplantationA prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant. 2023 09; 58(9):991-999.Bone Marrow Transplant2023-05-18T00:00:002023A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement.Authorship 107326921Authorship 107347020Authorship 107422617Authorship 10730762037334870Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia TAmerican journal of hematologyEvolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393.Am J Hematol2023-06-19T00:00:002023Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.37376789Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBritish journal of haematologyOutcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol. 2023 08; 202(4):866-873.Br J Haematol2023-06-27T00:00:002023Outcomes of young adults (aged?=?40?years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.37289498Ostrin EJ, Rider NL, Alousi AM, Irajizad E, Li L, Peng Q, Kim ST, Bashoura L, Arain MH, Noor LZ, Patel N, Mehta R, Popat UR, Hosing C, Jenq RR, Rondon G, Hanash SM, Paczesny S, Shpall EJ, Champlin RE, Dickey BF, Sheshadri AImmunoHorizonsA Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. Immunohorizons. 2023 Jun 01; 7(6):421-430.Immunohorizons2023-06-01T00:00:002023A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept.37437764Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir QTransplantation and cellular therapyCharacteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther. 2024 Feb; 30(2):205.e1-205.e12.Transplant Cell Ther2023-07-10T00:00:002023Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.Authorship 10750332037461327Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHAmerican journal of hematologySingle-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol. 2023 10; 98(10):1571-1578.Am J Hematol2023-07-17T00:00:002023Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.Authorship 10756252737494448Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani KScience advancesLoss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023 07 28; 9(30):eadd6997.Sci Adv2023-07-26T00:00:002023Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.Authorship 107773319Authorship 107895120Authorship 107935113Authorship 107871725Authorship 10778411037611156Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJBlood advancesMyeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv. 2023 Oct 24; 7(20):6196-6205.Blood Adv2023-10-24T00:00:002023Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities.37635400Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian HAmerican journal of hematologyPhase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia. Am J Hematol. 2023 11; 98(11):1711-1720.Am J Hematol2023-08-27T00:00:002023Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.37726490Marinos A, Ramdial J, Khawaja F, Saliba RM, Shigle TL, Alousi AM, Rondon G, Chen J, Ledesma C, Champlin RE, Daher M, Chen G, Marin D, Rezvani K, Shpall EJ, Chemaly RFBone marrow transplantationHematopoietic cell transplantation can be safely performed after COVID-19. Bone Marrow Transplant. 2023 12; 58(12):1410-1412.Bone Marrow Transplant2023-09-19T00:00:002023Hematopoietic cell transplantation can be safely performed after COVID-19.37607645Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto YTransplantation and cellular therapyHigh-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther. 2023 Nov; 29(11):690-694.Transplant Cell Ther2023-08-20T00:00:002023High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.37673125Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHTransplantation and cellular therapyOutcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther. 2023 Dec; 29(12):757-762.Transplant Cell Ther2023-09-04T00:00:002023Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.Authorship 107987814Authorship 1079780837753818Damron EP, Qazilbash MH, Fang PQ, Wu SY, Dabaja BS, Rondon G, Hosing C, Champlin RE, Bashir Q, Shpall EJ, Knafl MK, Lee HC, Manasanch EE, Patel K, Thomas SK, Orlowski RZ, Weber DM, Pinnix CC, Gunther JRTransplantation and cellular therapyRadiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.Transplant Cell Ther2022-10-29T00:00:002022Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.37742746Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat URTransplantation and cellular therapyTransplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther. 2023 Dec; 29(12):770.e1-770.e6.Transplant Cell Ther2023-09-23T00:00:002023Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning.Authorship 10812831237822075Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed SBritish journal of haematologyReal-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol. 2024 01; 204(1):e11-e16.Br J Haematol2023-10-11T00:00:002023Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function.Authorship 1081601637850688Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RSAmerican journal of hematologyEffect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2024 Jan; 99(1):38-47.Am J Hematol2023-10-18T00:00:002023Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age.Authorship 10827551537890590Bachar-Lustig E, Lask A, Eidelstein Y, Or-Geva N, Gidron-Budovsky R, Nathansohn-Levy B, Eyrich M, Liu WH, Dang G, Miranda KC, Ramirez A, Kaur I, Rezvani K, Shpall E, Champlin RE, Nagler A, Shimoni A, Barnees-Kagan S, Reisner YTransplantation and cellular therapyGeneration of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy. Transplant Cell Ther. 2024 Jan; 30(1):71.e1-71.e13.Transplant Cell Ther2023-10-26T00:00:002023Generation of Non-Alloreactive Antiviral Central Memory CD8 Human Veto T Cells for Cell Therapy.Authorship 10840141738042257Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani KTransplantation and cellular therapyEx Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):203.e1-203.e9.Transplant Cell Ther2023-11-30T00:00:002023Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.Authorship 108561815Authorship 10856371938124057Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto YBMC cancerCharacteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer. 2023 Dec 20; 23(1):1258.BMC Cancer2023-12-20T00:00:002023Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.38127583Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHCancerImpact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 2023 Dec 21.Cancer2023-12-21T00:00:002023Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.Authorship 10863522938182787Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederst?dt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani KNature medicineAuthor Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2024 Mar; 30(3):906.Nat Med2024-03-01T00:00:002024Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.Authorship 10865062238199987Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MHBlood cancer journalOutcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J. 2024 01 10; 14(1):4.Blood Cancer J2024-01-10T00:00:002024Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.Authorship 10870833338238616Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani KNature medicineSafety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.Nat Med2024-01-18T00:00:002024Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial.Authorship 10878632138266155Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat U, Oran B, Olson A, Bashir Q, Qazilbash M, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri I, Srour S, Champlin R, Shpall E, Kebriaei PBlood advancesIncidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv. 2024 Mar 12; 8(5):1128-1136.Blood Adv2024-03-12T00:00:002024Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.Authorship 10884732138314663Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat URAmerican journal of hematologyEltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 Apr; 99(4):562-569.Am J Hematol2024-02-05T00:00:002024Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.Authorship 10890892738355908Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed SBone marrow transplantationOutcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 Feb 14.Bone Marrow Transplant2024-02-14T00:00:002024Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis.Authorship 10893922238400519Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJAmerican journal of hematologySafety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024 Feb 23.Am J Hematol2024-02-23T00:00:002024Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.Authorship 10897349Authorship 10898141338426274Saliba RM, Lee SJ, Carpenter PA, Hill GR, Lee CJ, Alousi A, Daher M, Chen G, Champlin RE, Rezvani K, Shpall EJ, Mehta RSHaematologicaMycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation. Haematologica. 2024 Feb 29.Haematologica2024-02-29T00:00:002024Mycophenolate mofetil is associated with inferior overall survival in cytomegalovirus seropositive patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.38403505Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran BClinical lymphoma, myeloma & leukemiaAzacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 Feb 03.Clin Lymphoma Myeloma Leuk2024-02-03T00:00:002024Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.Authorship 109028820Authorship 10902701538444268Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DAAmerican journal of hematologyResults of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024 Mar 05.Am J Hematol2024-03-05T00:00:002024Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.38448009Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MHBritish journal of haematologyImpact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol. 2024 Mar 06.Br J Haematol2024-03-06T00:00:002024Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.Authorship 10908041138460821Febres-Aldana A, Khawaja F, Morado-Aramburo O, Shigle TL, Rondon G, Sassine J, Spallone A, Srinivasan K, Ramdial J, Alousi A, Champlin R, Chen G, Daher M, Rezvani K, Ariza-Heredia EJ, Shpall EJ, Chemaly RFClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious DiseasesMortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience. Clin Microbiol Infect. 2024 Mar 07.Clin Microbiol Infect2024-03-07T00:00:002024Mortality in recipients of allogeneic hematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: A single center retrospective Experience.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor24169268Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJClinical lymphoma, myeloma & leukemiaThe development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.Clin Lymphoma Myeloma Leuk2013-10-26T00:00:002013The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.24413065Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BSBlood cancer journalSynergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J. 2014 Jan 10; 4:e171.Blood Cancer J2014-01-10T00:00:002014Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines.2326879Nimer SD, Milewicz AL, Champlin RE, Busuttil RWTransplantationSuccessful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation. 1990 Apr; 49(4):819-21.Transplantation1990-04-01T00:00:001990Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation.24144307Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BSLeukemia & lymphomaThe histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. 2014 Jul; 55(7):1625-34.Leuk Lymphoma2014-02-04T00:00:002014The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.24700783Shah DP, Ghantoji SS, Ariza-Heredia EJ, Shah JN, El Taoum KK, Shah PK, Nesher L, Hosing C, Rondon G, Champlin RE, Chemaly RFBloodImmunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014 May 22; 123(21):3263-8.Blood2014-04-03T00:00:002014Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections.24806159Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornh?user M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, K?lling K, Stobernack HP, Lischka P, Zimmermann H, R?bsamen-Schaeff H, Champlin RE, Ehninger G, AIC246 Study TeamThe New England journal of medicineLetermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 08; 370(19):1781-9.N Engl J Med2014-05-08T00:00:002014Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation.24327130Chemaly RF, Ghantoji SS, Shah DP, Shah JN, El Taoum KK, Champlin RE, Nunez CA, Mulanovich V, Ariza-Heredia EJournal of pediatric hematology/oncologyRespiratory syncytial virus infections in children with cancer. J Pediatr Hematol Oncol. 2014 Aug; 36(6):e376-81.J Pediatr Hematol Oncol2014-08-01T00:00:002014Respiratory syncytial virus infections in children with cancer.25002471Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, Zhang L, Najjar AM, Huls MH, Lee DA, Champlin RE, Kontoyiannis DP, Cooper LJProceedings of the National Academy of Sciences of the United States of AmericaBioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014 Jul 22; 111(29):10660-5.Proc Natl Acad Sci U S A2014-07-07T00:00:002014Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.25051962Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani KBloodRegulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014 Sep 25; 124(13):2034-45.Blood2014-07-22T00:00:002014Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.25111583Song G, Valdez BC, Li Y, Liu Y, Champlin RE, Andersson BSBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationSynergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1687-95.Biol Blood Marrow Transplant2014-08-09T00:00:002014Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.